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Colorectal cancer (CRC) is the second most common form of cancer in the 
world and the most common cancer in Singapore. The limitations of the 
currently available methods and biomarkers for CRC management highlight 
the necessity of finding novel markers. Alterations in different metabolic 
pathways in CRC as indicated by proteomic studies, are likely to result in 
changes in metabolic profile which if identified with the aid of metabolic 
profiling can help in the identification of marker metabolites and can provide 
molecular insight in CRC. Metabolic profiling is complementary to genomics 
and proteomics as it measures the perturbed metabolic end-points due to 
environmental, pharmacological or pathological influences while in genomics 
and proteomics, more upstream biological events are typically profiled and 
studied. 
In this thesis, metabolic profiling of CRC was carried out with a non-
targeted as well as a targeted approach to identify metabolite-based markers. 
For non-targeted metabolic profiling of CRC, three different analytical 
platforms namely GC/MS, HR-MAS NMR spectroscopy and 
GC×GC/TOFMS were explored. The data generated in conjunction with 
chemometric analysis led to the identification of marker metabolites belonging 
to diverse chemical classes. Although the orthogonal partial least squares 
discriminant analysis (OPLS-DA) models generated on the basis of profiled 
data using the three analytical platforms were capable of discriminating 
normal tissues from malignant ones, no valid OPLS-DA model was obtained 
using CRC stage as the classifier. This implied that the metabolic phenotype 
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associated with CRC although distinct from that of normal tissue, it is not 
sensitive enough to discriminate the different stages of CRC. Of the three 
analytical methods used, only HR-MAS NMR spectroscopy-based metabolic 
profiling was able to produce a valid OPLS-DA model capable of 
discriminating anatomical site of tumor. The identified marker metabolites 
when linked to metabolic pathways using KEGG database, revealed 
perturbations of various biochemical processes the majority of which could be 
attributed to the higher energy demand, tissue, hypoxia and altered synthetic 
rate of cellular components of rapidly proliferating tumor cells. In addition to 
this, altered eicosanoid biosynthetic pathway as indicated by reduced 
arachidonic acid (AA) levels in CRC tissues and presence of comparatively 
higher levels of picolinic acid in CRC tissues, implied an association of 
inflammatory environment with CRC development.   
A strong evidence of association between inflammation and CRC 
exists. Moreover the significant role played by eicosanoids in inflammation, as 
well as the altered expression of key enzymes involved in eicosanoid 
biosynthesis in CRC, formed our objective to carry out targeted metabolic 
profiling of 8 biologically relevant eicosanoids and the major metabolic 
precursor AA. The main aim of this study was to record the fluctuations of 
these inflammatory metabolites and to better understand their implicated roles 
in inflammation mediated CRC carcinogenesis. An UPLC/MS/MS-based 
method was developed and validated successfully for this purpose. The results 
indicated deregulation of eicosanoid biosynthetic pathways and implied that a 
complex interaction between pro-tumorigenic and antitumorigenic eicosanoids 
is involved in inflammation-associated CRC carcinogenesis.  
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Metabolic profiling of CRC led to the identification of marker 
metabolites and revealed metabolic perturbations that may be exploited for 
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CHAPTER 1  
INTRODUCTION 
 
1.1. Overview of colorectal cancer 
 
In this section an overview of different aspects of colorectal cancer (CRC) 
such as prevalence, etiology, pathways of CRC development, diagnosis, 
staging, prognosis, treatment, relation between inflammation and CRC and 
current challenges in CRC management is presented. 
 
1.1.1. Prevalence of colorectal cancer 
 
Worldwide statistics indicate that CRC is the third most common cancer in 
men (663000 cases, 10.0% of the total) and the second in women (571000 
cases, 9.4% of the total) (Ferlay et al., 2008). Incidence rates are considerably 
prominent in men than in women [overall sex ratio of the age-standardized 
rate (ASR) is 1.4:1]. According to the World Health Organization (WHO), the 
ASR for incidence of CRC is greater than 49.4 per 100,000 per year, in 
regions such as North America, Europe, Japan, Israel, Singapore, Australia 
and New Zealand. In addition to this, CRC is relatively prevalent in some 
areas of Brazil, Argentina, Hong Kong, Southern China and Malaysia (ASR 
for incidence of CRC greater than 25.3 per 100,000 per year) 
(http://www.who.int, Rozen et al., 2006). In Singapore, CRC is the leading 
cancer in males and the second most common cancer in females, accounting 
for 17.9% of all cancers in males and 14.4% in females. When both genders 
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are combined, CRC is the most common cancer in Singapore. In the world, 
around 608000 deaths occur from CRC, constituting for 8% of all cancer 
deaths, making it the fourth most common cause of death from cancer. As 
observed for incidence, mortality rates are lower in women than in men, 
except in the Caribbean. There is less variability in mortality rates worldwide 
(6-fold in men, 5-fold in women), with the highest mortality rates in both 
sexes estimated in Central and Eastern Europe (20.1 per 100,000 for male, 
12.2 per 100,000 for female), and the lowest in Middle Africa (3.5 and 2.7 
respectively). Almost 60% of the cases occur in developed regions (Ferlay et 
al., 2008). The ASR for mortality from CRC in Singapore over the period 
from 2002 to 2006 was 18.1 per 100,000 per year in males and 12.5 in females 
(Tey et al., 2008). The ASR for CRC mortality rates in the United States and 
United Kingdom in 2002 according to the WHO were 14.8 and 17.3 per 
100,000 per year, respectively (http://www.who.int). Certainly CRC has 
emerged as a serious threat to public health both in Singapore as well as 
overseas. 
 
1.1.2. Etiology of colorectal cancer 
 
On the basis of etiology, CRC can be inheritable, inflammatory or sporadic in 
nature. Lynch syndrome is the most common hereditary syndrome that 
predisposes patients to CRC, followed by familial adenomatous polyposis coli 
(FAP). Although the terms Lynch syndrome and hereditary nonpolyposis 
colorectal cancer (HNPCC) are often used synonymously, HNPCC 
specifically refers to those disorders that have similar phenotypes but lack the 
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specific mutations involved in Lynch syndrome. Lynch syndrome and HNPCC 
together account for 2-5% of all CRC. This form of heritable CRC is 
characterized by early onset and predominantly right-sided mucinous tumor. 
Germline mutations in the mismatch repair (MMR) genes namely MLH1 and 
MSH2 characterized by replication error and hence DNA or microsatellite 
instability (MSI), comprises the major genetic defect causing HNPCC or 
Lynch syndrome. Apart from CRC, HNPCC or Lynch syndrome also 
predisposes patients to other extra-colonic cancers such as small-intestine, 
renal pelvis and endometrial cancer (Lindor et al., 2005; Lynch et al., 2009). 
FAP which is responsible for less than 1% of all CRC cases occurs due to a 
mutation in the adenomatous polyposis coli (APC) gene. Development of 
hundreds to thousands of adenomatous polyps in the colon and rectum of 
individuals starting from early adolescence, which inevitably leads to CRC if 
untreated, is the main characteristic of FAP. FAP also leads to various extra-
colonic manifestations like thyroid cancer, duodenal and fundic gland 
polyposis and desmoids (Jasperson et al., 2010). Inflammatory bowel disease 
(IBD) including Crohn’s disease (CD) and ulcerative colitis may also lead to 
CRC. However patients with IBD represent only 1-2% of CRC cases. The risk 
of CRC is much higher in individuals having prolonged (more than 30 years) 
and extensive ulcerative colitis (Lakatos and Lakatos, 2008; Kraus and Arber, 
2009). Majority of CRC (up to 80%) is sporadic in nature with no well defined 
etiology and occurs due to interaction between genetic and environmental 
factors (Cheah, 1990).  Ageing is one of the major risk factors for sporadic 
CRC as 99% of cases occur in people more than 40 years of age and 85% in 
those more than 60 years of age. Higher incidence of CRC in affluent societies 
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is related to lifestyle related factors such as high intake of fat and red meat, 
insufficient intake of fiber rich food and vegetables, obesity and low physical 
activity. High alcohol consumption, diabetes mellitus and smoking also 
increase the risk of CRC (Ballinger and Anggiansah, 2007; Cunningham et al., 
2010). 
 
1.1.3. Pathways of colorectal cancer development 
 
CRC develops because of genetic abnormalities most of which are caused by 
environmental and lifestyle related factors while some are inherited. The two 
major genetic pathways of CRC development are the chromosomal instability 
(CIN) pathway and the microsatellite instability (MSI) pathway. In most cases 
CRC develops by the CIN pathway which is characterized by aneuploidy. The 
most frequent genetic abnormality consists of mutations in the V-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS) and APC genes. 
Inherited mutations in the APC gene results in FAP whereas allelic loss of 
chromosome 5 (site of the APC gene) causes APC changes in sporadic CRC. 
Loss of function of the protein 53 (p53) is a crucial event related to the 
transformation of adenoma to carcinoma (Powell et al., 1992; Stoler et al., 
1999; Vogelstein et al., 1988). The MSI pathway is characterized by the 
dysfunction of MMR gene. Such mutations may be inherited resulting in 
HNPCC or Lynch syndrome or may result from acquired epigenetic events. 
Genes which are more susceptible to mutations in this pathway include 
transforming growth factor-beta receptor II (TGFBR2) gene, B-cell 
lymphoma-2 (bcl-2) associated X protein (BAX) gene (essential for apoptosis) 
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and Immunoglobulin G Fc Receptor II (IGFR2) gene (essential for 
differentiation) (Grady, 2004). Apart from the CIN and the MSI pathways, 
CRC can also develop through the serrated adenoma pathway. This pathway is 
characterized by the absence of MSI and widespread methylation of genes 
SLC5A8, p16 and MGMT (Dong et al., 2005; Jass, 1999). 
 
1.1.4. Diagnosis of colorectal cancer 
 
CRC if diagnosed at an early stage improves the chances of survival of 
patients and reduces treatment-related morbidity. An individual may be 
diagnosed with CRC when he or she presents certain symptoms or as a result 
of any screening program. Usually the early stage CRC does not produce any 
detectable symptoms. Moreover, most of the symptoms of CRC such as 
change in bowel habits, blood in stool, general discomfort in the abdomen, 
weight loss and tiredness, lack specificity. Therefore it is essential to carry out 
regular screening programs to detect CRC. Endoscopy using either flexible 
sigmoidoscopy or colonoscopy with tumour biopsy is the most common 
diagnostic method for CRC. However, these techniques require extensive 
bowel preparation and lacks patient compliance due to their invasive nature.  
Double contrast barium enema (DCBE) is used as an adjunct diagnostic 
technique especially to detect tumours or polyps in tortuous anatomical sites 
where endoscopic study is difficult to carry out. Although faecal occult blood 
test (FOBT) for CRC diagnosis is simple and non invasive in nature, it lacks 
specificity. Faecal DNA based test is more sensitive than FOBT but it is 
tedious to administer and expensive. Computed tomographic (CT) 
6 
 
colonography, also termed as virtual colonoscopy, is a non- invasive 
diagnostic technique that produces two- and three-dimensional images of the 
colorectal tract. It is particularly useful for imaging the colonic lumen 
proximal to a stenosing or obstructed lesion which cannot be traversed by a 
flexible endoscope.  It is also used to stage the extent of disease in patients 
with suspected distant metastasis from CRC. Magnetic resonance imaging 
(MRI) with its superior differentiation of tissue planes, is especially useful in 
assessing the local invasion of rectal tumors within the narrow confines of the 
pelvis. However, these imaging techniques do not allow for biopsies for 
histological proof and requires exposure to ionizing radiation or nephrotoxic 
contrast administration. Of the various serum-based markers for CRC that 
have been investigated, CEA has been found to be useful for preoperative 
staging and follow up. However, CEA is not recommended for diagnosis 
because of its low sensitivity and specificity. Genetic tests are required for 
screening of heritable forms of CRC (Cunningham et al., 2010; Labianca et 
al., 2010).  
 
1.1.5. Staging of colorectal cancer 
 
The Dukes classification (Dukes, 1932; Weiss, 2000) and the TNM (tumor, 
node, metastases) system (Fleming et al., 1997) are the two most common 
staging systems for CRC. The other less commonly used staging system is the 
modified Astler Coller (MAC) system (Astler and Coller, 1954; Gunderson 
and Sosin, 1974). The TNM system is mainly based on the size and degree of 
invasion of the primary tumour (T), extent of lymph node involvement (N) 
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and degree of metastasis (M). It was introduced by the AJCC and the most 
preferred system of staging of CRC. The TNM system and AJCC stage 
groupings with equivalent Dukes and MAC stages of CRC are summarized in 
Table 1.1. The TNM system encompasses both clinical and a pathological 
staging. The clinical classification is designated as cTNM and the 
histopathological classification is designated as pTNM. Usually the cTNM is 
used to select treatment regimen whereas the pTNM is used for prognosis of 
CRC. Preoperative staging involves assessment of patient’s medical history, 
physical examination for hepatomegaly, ascites, lymphadenopathy, blood 
count, CEA,  liver chemistries, examination of large intestine. Surgical staging 
of CRC involves an evaluation of extra-colonic metastases, nodal spread and 
degree of tumour invasion through the colonic wall and into surrounding 
structures (Labianca et al., 2010). 
 
1.1.6. Prognosis of colorectal cancer 
 
The extent of penetration of tumor through the colonic wall and the 
involvement of lymph nodes, are important prognostic factors of CRC. Other 
pertinent prognostic parameters include tumor grade, thymidine labelling 
index, vascular and perineural invasion and lymphoid inflammatory response. 
Grading of CRC tumors is carried out on the basis of histopathological 
parameters such as histologic type, quality of differentiation, polarity of 
nucleus, configuration of tubules, growth pattern, lymphocytic infiltration and 
extent of fibrosis. At present a three grade system is most widely used. Well 
differentiated tumors with well formed tubules and showing least nuclear 
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polymorphism and mitoses are termed as grade 1. Poorly differentiated tumors 
with rare glandular forms, multistructural cells and a high extent of mitoses 
are termed as grade 3. Tumors intermediate between grades 1 and 3 are 
considered as grade 2. Grade 1 CRC tumors are the least aggressive and the 5-
year survival rate (YSR) is 59-93%. In case of grade 2 and 3 tumors the 5-
YSR falls to 33-75% and 11-56% respectively (Jass et al., 1986; Qizilbash, 
1982). The clinical utility of various other prognostic indicators like 
expression of p53, bcl-2, TGF-α, EGF, TGFBR2, deleted in colorectal cancer 
(DCC) gene, thymidylate synthase (TS), KRAS mutations, MSI status, allelic 
loss of chromosome 18q, has been investigated. Although 18q deletion and 
MSI status have shown promise, their practical utility remains to be confirmed 
by large scale studies (Deans et al., 1992; Steinberg et al., 1987; Sternberg et 
al., 1999). Location of CRC tumor is also a good indicator of prognosis. For 
instance, the left sided lesions favour patient survival whereas right sided 
tumors, especially those causing bowel obstruction, reduce the chances of 
survival  (Wolmark et al., 1983).  Presence of perforation in the colonic tract 
indicates negative prognosis (Steinberg et al., 1987). Increased pre-treatment 
levels of serological markers like carbohydrate antigen 19-9 (CA 19-9) and 
CEA are associated with poor prognosis (Filella et al., 1992). CRC patients 
who respond to chemotherapy with drugs like 5-ﬂuorouracil (5-FU), irinotecan 
and oxaliplatin have longer median survival time than non-responders. 
Response to chemotherapy and chances of survival in cases of metastatic CRC 
are dependent on the extent of metastasis which can be evaluated by 
determining the number of sites to which metastasis has occurred, number of 
lesions in such sites and the extent to which the metastatic site is affected. 
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Table 1.1. TNM system and AJCC stage groupings with equivalent Dukes and 
MAC stages of CRC (adapted from Labianca et al., 2010). 
 
TNM system 
Primary tumour (T) 
TX: Assessment of primary tumour cannot be done 
T0: Lack of evidence of primary tumour 
Tis: Carcinoma in situ: invasion of the lamina propria or intraepithelial  
T1: Submucosa invaded by tumour  
T2: Muscularis propria invaded by tumour  
T3: Invasion of tumour through the muscularis propria into the subserosa, or into 
the nonperitonealized pericolic or perirectal tissues 
T4: Tumour directly invades other organs or structures and/or perforates the 
visceral peritoneum 
Regional lymph nodes (N) 
NX: Assessment of regional nodes cannot be done 
N0: Regional lymph node metastasis absent 
N1: Metastasis in 1 to 3 regional lymph nodes 
N2: Metastasis in 4 or more regional lymph nodes 
Distant metastasis (M) 
MX: Presence of distant metastasis cannot be assessed 
M0: No distant metastasis 









Stage 0 Tis, N0, M0 - - 
Stage I T1, N0, M0 
T2, N0, M0 
A A 
B1 
Stage IIA T3, N0, M0 B B2 
Stage IIB T4, N0, M0  B3 
Stage IIIA T1-2, N1, M0 C C1 
Stage IIIB T3-4, N1,M0  C2 
Stage IIIC Any T, N2, M0  C3 
Stage IV Any T, any N, M1 D D 
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Generally female patients have better survival time than male patients. 
Patients showing no symptoms of CRC exhibit better response to 
chemotherapy and survive longer than those showing symptoms. Prior 
chemotherapy results in resistance to second-line treatment (Buyse et al., 
2000a, 2000b; Kohne et al., 2002). 
 
1.1.7. Treatment of colorectal cancer 
 
Surgery alone is the first line of treatment particularly for stage 0 and I CRC. 
Adjuvant chemotherapy is administered especially in high risk stage II and III 
CRC in order to reduce chances of recurrence and to increase survival time. 5-
FU [with leucovorin (LV)] by infusion or capecitabine (oral prodrug of 5-FU) 
is usually used for adjuvant chemotherapy. In some cases, oxaliplatin in 
combination with 5-FU (with LV) is also used (Labianca et al., 2010). 
Unfortunately 25 to 30% of CRC patients reach stage IV at the time of 
diagnosis, implying that the optimal treatment window has already expired. In 
such cases, the standard treatment approach involves surgical removal of the 
primary tumor, treatment of extra-colonic metastases and palliative 
radiotherapy and chemotherapy. Liver is the commonest organ to be affected 
by distant metastasis from CRC followed by lung (Ridge and Daly, 1985). 
Treatment of metastases involves surgical resection if possible with or without 
additional chemotherapy. Radiotherapy and chemotherapeutic agents like 5-
FU, irinotecan and oxaliplatin are used for palliative treatment in inoperable 
metastatic cases (Metrakos, 2009). In some cases, newer drugs such as 
bevacizumab [an inhibitor of vascular endothelial growth factor (VEGF)] and 
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cetuximab (an antibody against EGF) are used in combination with 
conventional drugs to enhance response and survival of metastatic CRC 
patients (Hurwitz et al., 2004; Kabbinavar et al., 2003; Saltz et al., 2004). 
 
1.1.8. Inflammation and colorectal cancer 
 
Past evidence suggest a strong association of inflammation with different 
forms of cancer including CRC. For instance, IBD is a considerable risk factor 
for CRC development. Inflammation is also linked to both hereditary and 
sporadic forms of CRC. Inflammation promotes tumor growth, partially 
through stimulation of proliferation and angiogenesis as well as by inhibiting 
apoptosis and immune surveillance. The underlying mechanisms involved in 
the interplay of inflammation and CRC are quite complicated. Although 
various inflammatory cytokines, such as tumor necrosis factor- alpha (TNF-α) 
and interleukin-6 (IL-6), have been found to be involved in CRC 
carcinogenesis, the two major bridging factors of inflammation and CRC are 
the cyclooxygenase-2 (COX-2) enzyme and nuclear factor kappa B (NF-ĸB) 
(Mantovani et al., 2008; Kraus and Arber, 2009; Terzic et al., 2010). NF-ĸB 
consists of a family of five closely related transcription factors which are 
involved in the modulation of inflammation and apoptosis (Dolcet et al., 
2005). Activation of constitutive NF-ĸB promotes tumor growth in CRC. Of 
the different isoforms of COX, which catalyze the metabolism of arachidonic 
acid (AA) into eicosanoids, including prostaglandins (PGs) and thromboxanes 
(TXs), COX-2 is overexpressed in CRC (Kashfi and Rigas, 2005; Sano et al., 
1995; Soslow et al., 2000). Some of the lipoxygenase (LOX) enzymes which 
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convert AA to eicosanoids like hydroxy eicosatetraenoic acids (HETEs) and 
leukotrienes (LTs) are also overexpressed in CRC (Shureiqi and Lippman, 
2001; Soumaoro et al., 2006). As a consequence, perturbation of AA 
metabolic pathway, which plays a key role in inflammation mediated CRC 
carcinogenesis, occurs. Clinico-epidemiological studies have shown that 
chronic use of selective COX-2 inhibitors like coxibs and non selective non-
steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of CRC implying 
the importance of COX-2 in inflammation mediated development of CRC 
(Marnett, 1992; Smalley and DuBois, 1997). 
 
1.1.9. Challenges in the management of colorectal cancer 
 
Pre-symptomatic screening is carried out with the aim of detecting early stage 
CRC or precursor lesions in order to improve survival and reduce treatment-
related morbidity. Unfortunately, only about 37% of CRC remain localized at 
the time of diagnosis. Present diagnostic and screening methods for CRC, such 
as colonoscopy, flexible sigmoidscopy, DCBE, CT, FOBT, faecal based DNA 
test, serological markers such as CEA, have certain limitations and shortfalls 
in their own ways. For instance, endoscopic diagnostic techniques are invasive 
and may cause iatrogenic injury resulting in poor patient compliance. 
Although the use of FOBT and colonoscopy in high risk individuals, has 
improved detection, CRC detected using these methods usually are not at early 
stages, meaning the chance of curing such patients has already passed. The 
limitations of these methods become more pronounced when it comes to 
prognosis of CRC. Although CEA measurement is minimally invasive, it 
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suffers from low specificity. Faecal DNA testing while more specific, is 
cumbersome to administer leading to poor patient compliance (Brenner et al., 
2005). Although genomics and proteomics techniques have lead to the 
identification of many serum-based, tissue- based and faecal- based markers of 
CRC, the clinical utility of such markers is limited and in some cases 
controversial (de Noo et al., 2006; Locker et al., 2006).  
Patients at high risk for CRC relapse following surgical resection may 
be given adjuvant chemotherapy to improve their survival time. Although the 
5-year survival rate (YSR) for patients with stage II CRC is 75%, recurrence 
occurs in one fourth of these patients. Response of stage II or stage III CRC 
patients to 5-FU based adjuvant therapy is dependent on MSI status of 
patients. Responders usually have stable or low MSI whereas non-responders 
have high MSI. However, determination of MSI status is quite labour 
intensive and costly (Ribic et al., 2003). Therefore, some patients may not 
derive significant clinical benefits when given adjuvant chemotherapy and 
may in fact suffer from the toxic side effects of anticancer drugs. Therefore, 
there is a real need to identify new markers of CRC that demonstrate 
diagnostic and prognostic values as well as markers capable of patient 
stratification. This would enable oncologists to optimize the current clinical 
management of CRC (Crawford et al., 2003; Duffy et al., 2007). 
 
1.2. Metabolic profiling 
 
Since its inception in the late 1960’s the field of metabolic profiling has grown 
remarkably in terms of its applications and contributions to system biology 
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research. Metabolic profiling which encompasses both metabonomics and 
metabolomics, provides a powerful tool for gaining valuable insight into 
functional biology, toxicology, pharmacology and diagnosis of diseases. 
Although the terms metabonomics and metabolomics are often used 
interchangeably there exists an important difference between the two. 
Metabonomics involves determination of changes in metabolic profiles of 
living organisms in response to any diseased condition or genetic modification 
or due to effect of environment or lifestyle related factors (Nicholson et al., 
1999) whereas in metabolomics, metabolic profiling of living organisms under 
normal physiological conditions without any extraneous influence is carried 
out (Harrigan and Goodacre, 2003). Metabolic profiling is complementary to 
genomics and proteomics as it measures the perturbed metabolic end-points 
due to environmental, pharmacological or pathological influences while in 
genomics and proteomics, more upstream biological events are typically 
profiled and studied (Fiehn, 2001). It involves the analysis of various 
biological matrices such as plasma, urine and tissues using suitable analytical 
platforms. Metabolic profiling can be carried out with a global non-targeted 
approach as well as with a targeted approach. In targeted metabolic profiling, 
alterations in the levels of a specific class of metabolites or metabolites 
belonging to a specific metabolic pathway are ascertained using an appropriate 
analytical technique (Morris and Watkins, 2005; Urpi-Sarda et al., 2009). In 
global non-targeted metabolic profiling, metabolites belonging to diverse 
metabolic pathways are profiled. The metabolites that are determined in non-
targeted approach belong to various chemical classes such as organic acids, 
amino acids, fatty acids, amines, sugars, sugar alcohols, steroids, nucleic acid 
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bases and other miscellaneous substances. So, multiple complementary 
analytical techniques are often utilized for non-targeted metabolic profiling of 
biological matrices, in order to cover as much of metabolic space as possible 
(Dunn and Ellis, 2005; Lindon et al., 2007a). 
 
1.2.1. Biomatrices used for metabolic profiling 
 
Plasma, urine, tissue specimens and tissue extracts are the commonly used 
biomatrices for metabolic profiling. As plasma and urine can be obtained in 
minimally invasive manner, metabolic profiling of these biomatrices, holds the 
potential for diagnosis of diseases. On the other hand tissue-based metabolic 
profiling furnishes spatial and site specific information about metabolites and 
provides molecular insight into disease conditions (Price et al., 2008). In 
addition to these, other biomatrices utilized for metabolic profiling include 
seminal fluid, saliva, cerebrospinal fluid, lung aspirates, gastrointestinal fluids, 
bile, tears, fluids obtained from cysts and blisters, amniotic fluid, synovial 
fluid and dialysis fluid (Lindon et al., 2007b). Metabolic profiling can also be 
carried out using in vitro cell culture systems such as cancer cells (Ippolito et 
al., 2005) and tissue spheroids (Bollard et al., 2002).  
 
1.2.2. Analytical platforms used in metabolic profiling 
 
In an ideal world, an analytical platform for metabolic profiling should allow 
analysis with minimal or no sample preparation, should be high throughput, 
highly sensitive and should exhibit high degree of robustness and 
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reproducibility. Moreover for non- targeted metabolic profiling, 
comprehensive coverage of metabolic space and ease of identification of 
profiled metabolites are additional desirable properties of an analytical 
platform. Analytical platforms that are commonly used for metabolic profiling 
include nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS) based techniques like direct infusion MS, gas 
chromatography mass spectrometry (GC/MS), liquid chromatography mass 
spectrometry (LC/MS) or capillary electrophoresis mass spectrometry 
(CE/MS). In addition to these techniques other methods like Fourier transform 
infrared (FTIR) spectroscopy, LC with ultraviolet or coulometric detection and 
CE with ultraviolet detection have also been used for metabolic profiling. In 
this section a brief overview of the different analytical methods used for 
metabolic profiling is provided. 
 
1.2.2.1. Nuclear magnetic resonance (NMR) spectroscopy 
 
NMR spectroscopy possesses many attributes of an ideal platform for 
metabolic profiling such as minimal sample pretreatment, high reproducibility, 
robustness, rapid analysis time, non-selectivity (in terms of metabolic space) 
and capability of providing detailed structural information about profiled 
metabolites. Although NMR spectroscopy is comparatively less sensitive than 
MS-based techniques, the availability of cryogenic NMR probes has improved 
the sensitivity and throughput of NMR spectroscopy (Keun et al., 2002). An 
estimate of NMR sensitivity in terms of number of metabolites measured can 
be obtained from a recent study in which NMR was able to measure 49 
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metabolites in human serum as compared to 96 by LC/MS and 99 by GC/MS 
(Psychogios et al., 2011). NMR spectroscopy has been utilized extensively for 
the metabolic profiling of liquid biomatrices like body fluids and tissue 
extracts. The introduction of high resolution magic angle spinning NMR (HR-
MAS NMR) spectroscopy has extended the applicability of NMR 
spectroscopy for metabolic profiling of solid and semisolid biomatrices like 
intact tissue specimens. Proton (
1
H) NMR spectroscopy is the dominant 
technique used for metabolic profiling. Spectral assignment and metabolite 
identification in 
1
H NMR is quite complicated and dependent on chemical 
shifts, relative intensities, signal multiplicities of the 
1
H resonances and 
coupling constants. Two dimensional 1H NMR spectroscopic methods like 
correlation spectroscopy (COSY) and total correlation spectroscopy (TOCSY) 
are often utilized for spectral assignment and identification of metabolites. 
Apart from 
1






P can also be 
exploited to aid spectral assignment in certain cases.  Various NMR pulse 
sequences can be utilized to differentiate spectral contributions of 
macromolecules (such as proteins and lipoproteins) from those obtained from 
low molecular weight metabolites (Lenz and Wilson, 2007; Lindon et al., 
2007b; Nicholson et al., 1995). 
 
1.2.2.2. Mass spectrometry (MS) based techniques 
 
MS can be used alone as direct infusion MS or in conjunction with separation 
techniques for metabolic profiling. Direct infusion of liquid biomatrices or 
tissue extracts into MS has been used for metabolic profiling in some cases. 
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Although it is a high throughput technique, it suffers from the disadvantage of 
high matrix effects, as proper sample preparation steps and chromatographic 
separation are not involved. Matrix effect can be defined as the indirect or 
direct changes or interference in response due to the presence of unintended 
analytes (for analysis) or other interfering substances in the sample (FDA, 
2001). The limitations become more pronounced in the case of complex and 
variable biomatrices like urine and also in the case of isobaric analytes (Dunn 
et al., 2005). 
High resolution, high sensitivity and availability of commercial 
libraries for metabolite identification render GC/MS an excellent and robust 
platform for the global non-targeted metabolic profiling of complex 
biomatrices. However, GC/MS analysis involves tedious sample preparation 
steps as it is necessary to derivatize analytes to reduce their polarity and 
increase volatility. This shortcoming is often tolerated in metabonomic 
research where the demand for chromatographic resolution takes priority over 
the need for the assay to be high throughput. The advent of two dimensional 
gas chromatography time of flight mass spectrometry (GC×GC/TOFMS) has 
comprehensively enhanced the metabolic space coverage of conventional 
GC/MS. Moreover, the development of softwares packages with 
deconvolution feature to differentiate co-eluting chromatographic peaks has 
facilitated shorter GC/MS analysis thus improving the throughput of the 
technique (Lenz and Wilson, 2007). 
LC/MS has certain advantages over GC/MS in terms of ease of sample 
pretreatment and flexibility in throughput. The applicability of LC/MS in non-
targeted metabolic profiling is comparatively restricted due to the constraint in 
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the number of metabolites amenable to analysis (Halket et al., 2005; Want et 
al., 2010). However, developments in diverse LC column chemistries and 
chemical derivatization strategies (Groger et al., 2003; Halket et al., 2005; 
Tolstikov and Fiehn, 2002) have enhanced the metabolic space coverage of 
LC/MS. Although LC/MS is considered as a suitable analytical platform for 
both targeted and non-targeted metabolic profiling, its applicability is more 
established in the case of targeted profiling of metabolites. This is due the fact 
that LC/MS can be operated in highly selective and sensitive mode if desired 
for targeted analysis. For non-targeted profiling, LC/MS is generally operated 
in both positive and negative electrospray ionization (ESI) modes for the 
comprehensive coverage of metabolic space. The emergence of microbore 
LC/MS and ultra performance LC (UPLC) systems has improved the resolving 
capacity, sensitivity and separation speed of conventional LC/MS (Lenz and 
Wilson, 2007; Lindon et al., 2007b; Wilson et al., 2005). 
CE/MS has also been used as a platform for metabolic profiling 
especially for profiling low abundance metabolites. The separation mechanism 
of CE/MS makes it a suitable platform for analysis of polar, ionisable 
metabolites. Another advantage of CE/MS is the small sample volume needed. 
Moreover, liquid biomatrices like urine requires minimal sample preparation 
steps prior to analysis (Lee et al., 2007; Soga et al., 2003, 2007). 
 
1.2.2.3. LC/NMR/MS hybrid techniques 
 
For metabolic profiling, LC/NMR/MS hybrid platforms can also be utilized. In 
such systems the LC eluent is split into two parts and subjected to concomitant 
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analysis by both NMR and MS. The resulting NMR- and MS-based data 
provide in-depth molecular information and aids in metabolite identification 
(Lindon et al., 2000, 2004). Emergence of highly sophisticated data analysis 
techniques has further facilitated the analysis and interpretation of 
LC/NMR/MS hybrid platforms (Cloarec et al., 2007; Shen et al., 2002). 
LC/NMR/MS methods have shown promise in the discovery of metabolite 
based markers of xenobiotic induced renal toxicity (Foxall et al., 1996) and 
characterization of lipoproteins in human blood serum (Daykin et al., 2001). 
LC/NMR/MS has also been utilized for urinary metabolic profiling of 
pediatric metabolic disorders such as methylmalon aciduria (Zurek et al., 
2005). It has also been used for the metabolic profiling of human amniotic 
fluid with an aim to diagnose disorders in the mother or developing fetus 
(Graca et al., 2008).  
 
1.2.2.4. Other analytical techniques 
 
Although LC with ultraviolet (Pham-Tuan et al., 2003) or coulometric 
detection (Gamache et al., 2004; Vigneau-Callahan et al., 2001) and CE with 
ultraviolet detection (Barbas et al., 1998; Zomer et al., 2004) have been 
explored for metabolic profiling, their usage is limited by their inability to 
identify metabolites directly. However, in the case of LC with coulometric 
detection, libraries of standard compounds can be created on the basis of LC 
retention times and redox properties for metabolite identification (Gamache et 
al., 2004). Although FTIR spectroscopy has been explored for metabolic 
profiling, its applicability is very limited as it does not provide sufficient 
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information to identify metabolites. However, the short analysis time required 
per sample (about 5 to 10 s) enables its usage as an optional tool for screening 
or group classification or as an adjunct method to other commonly used 
analytical platforms (Dunn et al., 2005; Harrigan et al., 2004; Kaderbhai et al., 
2003; Leon et al., 2009). The advantages, disadvantages and applications of 
different analytical platforms used for metabolic profiling have been 
summarized in Table 1.2. 
 
1.2.3. Chemometrics in metabolic profiling 
 
Global non-targeted metabolic profiling results in the generation of huge and 
complex data sets containing a large number of variables. Multivariate 
statistical techniques or chemometric tools are indispensable for the analysis 
of such data sets. Of the different chemometric methods available such as 
hierarchical clustering, partitional clustering, artificial neural networks, 
support vector machine, evolutionary-based algorithms and regression trees, 
projection-based chemometric methods are extensively used (Goodacre et al., 
2007). Projection-based methods include both unsupervised methods like 
principal component analysis (PCA) and supervised methods such as partial 
least squares discriminant analysis (PLS-DA) and orthogonal PLS-DA (OPLS-
DA). Projection-based methods are based on the assumption that the system in 
question is controlled by a few latent variables (LVs) or principal components 
(PCs). In PCA, the variation in the data is approximated by a model plane of a 
low dimension on the basis of computed principal components. The largest 
variation in the data is defined by the first PC and the second largest variation
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Table 1.2. Advantages, disadvantages and applications of different analytical platforms used for metabolic profiling 
 
Analytical Technique Advantages Disadvantages Applications 
NMR spectroscopy Involves minimal sample 
pretreatment 
Highly reproducible and robust 
High throughput  
Non-selective (in terms of 
metabolic space)  
Provides detailed structural 
information about profiled 
metabolites 
Less sensitive than MS-based 
techniques 
Spectral assignment and 
metabolite identification is 
complicated 
Metabolic profiling for xenobiotic 
toxicity assessment, different forms of 
cancer, neurological disorders, 
metabolic disorders, aging etc (Coen et 
al., 2008). 
Intact tissue based metabolic profiling 
using solid state MAS-NMR (Keun et 
al., 2002).  
Direct infusion MS High throughput Suffers from high matrix effect 
and isobaric interference 
Microbial metabolic profiling studies 
(Dunn et al., 2005) 
GC/MS High resolution and sensitivity 
Availability of EI spectra-based 
commercial libraries for 
metabolite identification 
Not susceptible to matrix effect 
Involves tedious sample 
preparation 
Comparatively low throughput 
Profiling of volatile metabolites in lung 
cancer (Chen et al., 2007) and skin 
emissions (Gallagher et al., 2008) 
using headspace GC/MS. 
Metabolic profiling for validating 
animal models of diseases (Chang et 
al., 2011), xenobiotic toxicity 
assessment (Boudonck et al., 2009), 
different forms of cancer (Denkert et 
al., 2008), metabolic disorders (Bao et 
al., 2009), neurological disorders 




Table 1.2. Advantages, disadvantages and applications of different analytical platforms used for metabolic profiling  (Continued). 
 
Analytical Technique Advantages Disadvantages Applications 
LC/MS Ease of sample pretreatment as 
compared to GC/MS 
Allows flexibility in throughput 
Highly suitable for targeted 
profiling 
Susceptible to matrix effect 
Non-availability of EI spectra-
based commercial libraries for 
easy metabolite identification 
Metabolic profiling for xenobiotic 
metabolism and toxicity assessment (Chen 
et al., 2007), different forms of cancer (Ong 
et al., 2010), metabolic disorders (Wang et 
al., 2005), neurological disorders (Li et al., 
2010). 
CE/MS Liquid biomatrices like urine 
requires minimal sample 
preparation 
Requires small sample volume 
Metabolic space coverage 
restricted to polar, ionisable 
metabolites 
Microbial metabolic profiling and as a 
complementary platform to GC/MS or 
LC/MS for metabolic profiling of diseases 
(Lenz and Wilson, 2007; Barbas et al., 
2011) 
LC/NMR/MS Provides in-depth molecular 
information 
Combination of NMR and MS 
aids in metabolite identification 
Highly expensive 
instrumentation 
Metabolic profiling for metabolic disorders 
(Zurek et al., 2005) and human amniotic 
ﬂuid (Graca et al., 2008). 
FTIR spectroscopy High throughput  Applicability is limited as it 
does not provide sufficient 
information to identify 
metabolites 
Microbial metabolic profiling, metabolic 
profiling for cancer and other diseases 
(Dunn et al., 2005).  
CE or LC with UV or 
coulometric detection 
Comparatively inexpensive  Application limited due to 
inability to identify metabolites 
readily 
Less sensitive and less specific 
than MS-based techniques 
Evaluation of food ingredient impact 
(Pham-Tuan et al., 2003; Vigneau-Callahan 
et al., 2001), animal model of diabetes 
(Barbas et al., 2011), profiling of exogenous 
metabolites (Gamache et al., 2004). 
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by the second PC and so on. These PCA model components are mutually 
orthogonal to each other. A score plot generated by plotting the first two 
components aids in the visualization of the relation between the observations 
or samples in the data set. The score plot is useful for identifying outliers and 
inherent clustering trends. Outliers can also be detected by using the distance 
to model plot (DModX) based on residual variance of the model. The 
contribution of the variables in the model plane and their interrelation are 
depicted by the loading plot (Lindon et al., 2001). PLS is a supervised method 
that is usually used to determine whether a quantitative relationship exist 
between two data matrices for instance X matrix and Y matrix. PLS when 
used to discriminate different classes, is termed as partial least squares 
discriminant analysis (PLS-DA). In PLS-DA, class information is used to 
enhance separation of observations belonging to different classes. The class 
information is provided by generating a Y data matrix composed of discrete 
dummy variables denoting specific class belonging. However the disadvantage 
of PLS models is that they are influenced by variation in the X matrix that is 
unrelated to the Y matrix. This results in difficulty of model interpretation and 
identification of variables contributing significantly to the model for instance 
identifying marker metabolites in the case of metabonomics (Wold et al., 
1984). The orthogonal partial least squares (OPLS) method is a modified form 
of PLS where orthogonal signal correction is used to split the variation in X 
matrix into two parts, one that is unrelated or orthogonal to Y and the other 
that is related to Y. This eases model interpretation and identification of 
important variables contributing to the model. OPLS if used for class 
discrimination is termed as orthogonal partial least squares discriminant 
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analysis (OPLS-DA) (Bylesjö et al., 2006). In our global non-targeted 
metabolic profiling studies, we have used PCA to identify innate grouping 
trends and outliers (if any) and OPLS-DA to generate discriminating models 
and to identify marker metabolites. Chemometric softwares such as SIMCA-P 
and Unscrambler (CAMO software, Oslo, Norway), and mathematical 
environments such as MATLAB and R (open source GNU project) are 
typically employed for chemometric data analysis in metabonomics. 
A typical chemometric model built in a metabonomic study is 
characterized by the use of a relatively small number of observations 
compared to the number of variables (Westerhuis et al., 2008). Therefore, in 
some cases, it is possible that optimistic performance characteristics observed 
in a PLS-DA or OPLS-DA model could be due to specimen artifacts, over 
fitting of data or chance correlation (Broadhurst and Kell, 2006; Smit et al., 
2007; Trygg et al., 2007). Therefore, validation of each model should be 
performed before it can be leveraged to predict the unknown observations or 
identification of marker metabolites. Model validation can be performed in 
two stages starting with internal validation and followed by external 
validation. Internal validation of PLS-DA models can be performed using 
permutations test and receiver operating characteristic (ROC) analysis 




) of the 
original model is compared with the goodness of fit of several PLS-DA 
models built using the data matrix where the order of the Y-observations are 
randomly permuted, while the X-matrix is kept intact (Mahadevan et al., 2008; 
Wiklund et al., 2007). Subsequent to confirmation of validity of each model 
using internal validation strategies, model validity can be further confirmed 
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using external validation. To perform external validation, a subset of 
observations is randomly selected for building a training set and classification 
of the remaining samples are then predicted. The selection of training and tests 
sets should be defined prior to chemometric analysis to represent actual 
prediction of unknown samples and to avoid any bias related to data 
preprocessing and pretreatment. External validation can be performed 
iteratively by randomly selecting different combination of training and test 
sets to estimate the predictive ability of the model. Most software packages 
(SIMCA-P or MetaboAnalyst) offer in-built features to perform validation.   
 
1.2.4. Role of metabolic profiling in colorectal cancer 
 
The present challenges in the management of CRC imply that there is a dearth 
in the availability of clinically significant biomarkers of prognostic, diagnostic 
and patient stratification. Global non-targeted metabolic profiling has already 
shown potential in identifying metabolite-based markers in ovarian cancer 
(Denkert et al., 2006), prostate cancer (Cheng et al., 2005; Sreekumar et al., 
2009), kidney cancer (Kind et al., 2007), bladder cancer (Pasikanti et al., 
2009), liver cancer (Yang et al., 2004) and brain cancer (Petrik et al., 2006). 
Similar metabolic profiling of CRC may lead to the identification of marker 
metabolites which may provide greater insight into the carcinogenesis, 
diagnosis, prognosis and patient stratification. On the other hand, targeted 
metabolic profiling can help in recording the deregulation of a specific 
metabolic pathway and thereby elucidating the roles of the associated 




1.3. Study hypotheses 
 
1.3.1. Hypothesis for non-targeted metabolic profiling of CRC 
 
Previous studies indicate that changes in gene expression and consequent up 
or down regulation of metabolic enzymes may result in perturbation of 
metabolic pathways in CRC (Bi et al., 2006; Longley et al., 2006). This led to 
our hypothesis that tissue-based non-targeted metabolic profiling of CRC if 
used to determine such changes in metabolic profiles would enable 
identification of marker metabolites differentially expressed in CRC and 
normal tissue and provide greater insight into disease progression, treatment 
response and carcinogenesis in CRC.  
 
1.3.2. Hypothesis for targeted profiling of eicosanoids and arachidonic 
acid in CRC 
 
Altered expression of COX-2 and LOX enzymes in CRC causes fluctuations 
in the levels of eicosanoids such as PGs, HETEs, TXs and LTs (Kashfi and 
Rigas, 2005; Sano et al., 1995; Shureiqi and Lippman, 2001; Soslow et al., 
2000; Soumaoro et al., 2006). Therefore we hypothesized that targeted 
profiling of these eicosanoids and their major metabolic precursor AA would 
help to elucidate the deregulation of eicosanoid biosynthetic pathway as well 
as the implications of these profiled metabolites in inflammation-mediated 




1.4. Study objectives 
 
The main objectives of this study are stated below. 
 Tissue-based non-targeted metabolic profiling of CRC using three 
different analytical platforms viz. GC/MS, HR-MAS NMR 
spectroscopy and GC×GC/TOFMS followed by multivariate and 
univariate statistical analyses of generated data to identify marker 
metabolites and altered metabolic processes in CRC. 
 
 Targeted metabolic profiling of eicosanoids and their major metabolic 
precursor AA using ultra performance liquid chromatography tandem 
mass spectrometry (UPLC/MS/MS) in order to identify significantly 
altered metabolites belonging to the eicosanoid biosynthetic pathway 
and their biological relevance in inflammation-mediated CRC 
development.  
 
1.5. Significance of the study 
 
Non-targeted metabolic profiling of CRC in conjunction with chemometric 
data analysis may help in the identification of marker metabolites and related 
metabolic pathways that are altered in CRC. This in turn would help to 
elucidate the metabolic phenotype of CRC and provide molecular insight in 
CRC development. Such information is valuable from the perspective of 
future biomarker research and identification of alternative therapeutic 
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strategies in CRC. Targeted metabolic profiling of relevant eicosanoids and 
AA in CRC would help to elucidate the role of these metabolites in associating 
inflammation with CRC. As NSAIDs exert their pharmacological effect 
primarily by inhibiting COX mediated synthesis of some of these eicosanoids, 
the targeted profiling of these metabolites would also help to postulate the 
mechanistic aspect of NSAID-based adjuvant chemotherapy in improving the 




DEVELOPMENT AND VALIDATION OF A GC/MS METHOD FOR 





Tissue-based metabolic profiling differs from plasma- or urine-based 
metabolic profiling as it provides anatomical site-specific information of the 
endogenous metabolites. As these metabolites belong to diverse chemical 
classes and possess physicochemical heterogeneity, it is quite challenging to 
develop a robust and reproducible analytical method for their profiling.  
Among the various methods utilized conventionally for metabolic profiling, 
GC/MS has emerged as a potentially useful method because of its high 
sensitivity, reproducibility and peak resolution. Moreover identification of 
metabolites can be easily carried out using GC/MS electron impact (EI) 
spectral libraries. However chemical derivatization of the polar functional 
groups of analytes in order to decrease their polarity, increase their volatility 
and thermal stability, is usually required for GC/MS analysis. As a result of 
this tedious sample preparation process as well long elution time, GC/MS is 
considered as a low throughput technique when compared to other techniques 
like LC/MS or NMR spectroscopy (Pasikanti et al., 2008). Nonetheless, the 
ease of metabolite identification by GC/MS along with its high sensitivity and 
resolution makes it a feasible option in non targeted metabolic profiling. So far 
GC/MS has been used for tissue-based metabolic profiling of mice liver (Xin 
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et al., 2006), heart, muscle and adipose tissue (Atherton et al., 2006), human 
ovarian tissue (Denkert et al., 2006) and human colon tissue (Denkert et al., 
2008).  
This chapter deals with the development and validation of a GC/MS 
method for non-targeted metabolic profiling of human colon tissue. In this 
study, a suitable GC/MS method was developed, sample preparation steps 
were optimized and different validation parameters such as sensitivity, 
selectivity, linearity of response, precision, freeze-thaw cycle stability, auto-






Standard compounds such as standard alkane series (C-10 to C-40), L-alanine, 
L-valine, glycine, L-threonine, L-proline, L-phenylalanine, L-tyrosine, myo-
inositol, uridine, uracil, D-glucose, D-mannose, D-galactose, L-(+)-lactic acid, 
fumaric acid, D-(+)-malic acid, arachidonic acid, phosphoric acid and 
cholesterol were obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA). 
Spectroscopy grade methanol, chloroform and toluene were obtained from 
Tedia (Fairfield, OH, USA) and water used for the study was purified with a 
Milli-Q water purification system (Millipore, Billerica, MA, USA). N, O-bis 
(trimethylsilyl) trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane 
(TMCS), N-methyl-N-trifluoroacetamide (MSTFA) with 1% 
trimethylchlorosilane (TMCS) and methoxyamine hydrochloride in pyridine 
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(MOX) were obtained from Thermo Fisher Scientific (Rockford, IL, USA) 
while sodium sulphate was obtained from Sigma-Aldrich (St. Louis, MO, 
USA). 
 
2.2.2. Human colon tissue samples 
 
Human colon tissues were provided by the Department of Colorectal Surgery, 
Singapore General Hospital (SGH), Singapore. The utilization of human tissue 
was approved by the institutional review board (IRB) at the SGH (IRB 
reference number 260/2007). For method development and validation, one 
representative normal colon tissue (3.00 g) was snap-frozen immediately 
following surgery and then stored at -80ºC until processing. The tissue was 
subsequently cut and divided into tissue masses of about 20 mg each for the 
GC/MS method development and validation. 
 
2.2.3. Sample preparation 
 
For the development of the sample preparation protocol, previously reported 
sample preparation strategies (James et al., 2004; Lin et al., 2007; Lisec et al., 
2006; Pasikanti et al., 2008) were used as references. Various parameters such 
as different methods of extraction (homogenization alone, homogenization 
followed by ultra-sonication, ultra-sonication alone) and time periods of ultra-
sonication (40, 60 and 100 min), weights of colonic tissue samples (5 to 40 
mg) and derivatization strategies (incubation with BSTFA or MSTFA at 70ºC 
for 30 min and overnight methoximation using MOX followed by incubation  
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Figure 2.1. GC/MS chromatograms depicting results of development and 
optimization of sample preparation method. A: No appreciable difference 
observed between different extraction strategies. [Sonication for 100 min 
opted for ease of sample preparation].; B: Effect of different tissue weights on 
GC/MS profile [20 mg chosen as minimal weight for tissue]; C: Effect of 
different derivatization strategies [MOX effecting resolution as compared to 
MSTFA alone]. 









with MSTFA at 70ºC for 30 min) were explored to optimize the final sample 
preparation protocol. Some of the results obtained during development and 
optimization of sample preparation method are presented in Figure 2.1. 
 Using the optimized method, each colon tissue was weighed accurately 
and transferred to 15 mL glass centrifuge tubes. 1  mL  of  a  mono-phasic  
mixture  of chloroform-methanol-water in ratio of 20:50:20 (v/v) was added to 
each sample and the tissue sample along with the extraction solvent system 
was ultra-sonicated in a bath ultra-sonicator at ambient temperature (24ºC) for 
100 min and then vortex-mixed for 2 min. The samples were subsequently 
centrifuged at 1800 g units for 3 min and 0.8 mL of the supernatant was 
collected separately from each sample in 15 mL glass tube. The collected 
supernatant was concentrated to complete dryness at 50ºC for 30 min using 
Turbovap LV nitrogen evaporator (Caliper Life Sciences, Hopkinton, MA, 
USA). 100 µL of toluene kept anhydrous with sodium sulphate was added to 
each of the dried tissue extracts, vortex-mixed for 1 min and again evaporated 
to complete dryness using Turbovap LV in order to eliminate any trace of 
water which might interfere with the GC/MS analysis. The dried samples were 
then derivatized by adding 100 µL of MSTFA with 1% TMCS to each sample. 
The samples were then vortex-mixed for 1 min and incubated at 70ºC for 30 
min. After incubation, samples were again vortex-mixed for 1 min and then 







2.2.4. GC/MS analysis 
 
Analysis was performed on a Shimadzu QP2010 GC/MS system (Shimadzu, 
Kyoto, Japan). A HP-5MS 30 m × 250 µm (i.d.) fused silica capillary column 
(Agilent J&W Scientific, Folsom, CA, USA), chemically bonded with a 5% 
diphenyl 95% dimethylpolysiloxane cross-linked stationary phase (0.25 µm 
film thickness), was used with open split interface. Helium was used as the 
carrier gas at 1.2 mL/min and the injector split ratio was set to 1:5. An 
injection volume of 1 µL was used and the solvent cut-off time was 5 min. 
The injector and source temperatures were kept at 250 and 200ºC, 
respectively. Oven temperature was kept at 60ºC for 3 min, increased at 7ºC 
per min to 140ºC where it was held for 4 min and further increased at 5ºC per 
min to 310ºC where it remained for 6 min. The MS was operated in EI 
ionization mode at 70 eV. Data acquisition was performed in the full scan 
mode from m/z 50 to 650 with a scan time of 0.5 s. To detect and eliminate 
retention time (Rt) shift, standard alkane series mixture (C-10 to C-40) was 
injected periodically into the GC/MS system during analysis of each batch of 
samples. Chromatogram acquisition and preliminary compound identification 
by the National Institute of Standards and Technology (NIST) and Wiley EI 
mass spectral library search were performed using the Shimadzu GCsolution 
(Version 2.5) software. Rt correction of peaks based on Rt of standard alkane 
series mixture (C-10 to C-40) was performed using the automatic adjustment 
of Rt function of the Shimadzu GCsolution software. The chromatograms of 
all the samples analyzed were subjected to noise reduction and baseline 
correction using metAlign software (http://www.metalign.nl) prior to 
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integration of peak area. Integrated peak areas of multiple derivative peaks 
belonging to each of the same metabolites (D-mannose, D-galactose, D-
glucose, myo-inositol) were summed and considered as single compound. All 
known artifact peaks, such as peaks due to column bleed and MSTFA artifact 
peaks were not considered in the final data analyses. Data normalization to a 
constant sum of the chromatographic peak area was carried out before 
statistical analyses. 
 
2.2.5. Method validation 
 
All the method validation studies, except for linearity validation, were carried 
out using unspiked human normal colon tissue samples (~20 mg each) 
according to the US-FDA guidelines for bio-analytical method validation with 
suitable modifications wherever necessary (FDA, 2001). A relative stability of 
100 ± 15% and relative standard deviation (RSD) of 15% were considered as 
acceptable in our method validation. Calculations of method validation results 
were performed using Microsoft Excel 2007 software. 
 
2.2.5.1. Freeze-thaw cycle and auto-sampler stability 
 
For each stability study, 6 human colon tissues of ~20 mg each were used. In 
order to evaluate the freeze-thaw stability, the samples were stored at -80ºC 
for 24 h and then thawed unassisted at room temperature (24ºC). When 
completely thawed, the samples were refrozen for 24 h at -80ºC. The freeze-
thaw cycle was repeated two more times and then the samples were processed 
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and analyzed in the third cycle. The results obtained were compared with that 
obtained from samples which were not subjected to freeze-thaw cycles in 
order to determine the freeze-thaw stability. Auto-sampler stability was 
evaluated by keeping the samples in the auto-sampler (24ºC) and re-injecting 
them after 50 h. 
 
2.2.5.2. Long-term stability 
 
Human colon tissue samples, stored at -80ºC, were processed and analyzed at 
intervals of 1 month and 3 months, respectively. At each sampling point, 
triplicate samples of ~20 mg each were analyzed. The results obtained were 
compared with that of samples analyzed on the first day of method validation. 
 
2.2.5.3. Intra- and inter-day precision 
 
6 human colon tissues of ~20 mg each were processed and analyzed for 
determination of both intra- and inter-day precision. The inter-day precision 





The selectivity of the GC/MS method was investigated by comparing the 
chromatogram of blank sample (solvent blank) to that of processed sample 
(~20 mg of human colon tissue). 
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 2.2.5.5. Linearity 
 
19 of the identified endogenous metabolites were selected to investigate the 
linear response of the GC/MS method. These compounds cover a wide range 
of GC Rt (9.85-53.70 min), and belong to various classes of metabolites 
(amino acids, organic acids, fatty acids, inorganic acids, sugars, alcohols, 
pyrimidines and steroids) with diverse physicochemical properties. As all the 
19 metabolites were endogenously present in colon tissue, it was practically 
not possible to obtain “blank” human colon tissue devoid of these metabolites. 
Therefore we validated the linearity of response by spiking the corresponding 
standard compounds before extraction by the solvent mixture composed of 
chloroform, methanol and water in the ratio of 20:50:20 (v/v). and then taken 
through the entire sample preparation process. The concentrations of standard 
compounds were calculated with respect to 20 mg of colon tissue. For 
instance, a spiked amount of 200 µg of any standard compound was 
considered equivalent to a concentration of 200 µg per 20 mg of colon tissue 
that is 10 µg/mg of colon tissue. The calibration curve of each of the 19 
analytes was constructed by linear regression of the absolute integrated peak 




The main objective of our study was to develop an optimal GC/MS method for 
the profiling of endogenous metabolites of colon tissue. Therefore, instead of 
determining limit of detection (LOD) and limit of quantification (LOQ) of 
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individual metabolites, it was considered comparatively more important to 
determine the minimal amount of colon tissue that was required to produce a 
reasonably sensitive profiling of the endogenous metabolites. In our method 
development, different weights of colon tissue (5, 10, 20 and 40 mg) were 
processed and analyzed to determine an optimal balance between tissue weight 
and generation of sufficient GC/MS data. 
 
2.3. Results and discussion 
 
While exploring various parameters during pre-validation development of 
sample preparation method, extraction of colon tissue samples by ultra-
sonication for 100 min and derivatization using 100 µL of MSTFA at 70ºC for 
30 min, were found to be optimal in terms of extraction of metabolites and 
metabolite extraction and coverage. Overnight methoximation of samples 
using MOX reagent prior to derivatization with MSTFA is considered a 
conventional step in sample preparation protocol for metabolic profiling 
(James et al., 2004). The methoximated derivatives of the monosaccharides 
were found to elute in quick succession in our GC/MS method as compared to 
the non-methoximated monosaccharides, thus affecting chromatographic 
resolution. Moreover overnight methoximation at 37ºC also meant 
comparatively longer sample processing time. Based on these factors, 
methoximation was eliminated from our colon tissue preparation protocol. As 
a result, multiple peaks were generated for the monosaccharides and their 
cumulative peak areas were used in the data analysis. A representative GC/MS 
chromatogram of normal human colon tissue is shown in Figure 2.2. 
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GC/MS analysis lead to the identification of 53 metabolites belonging 
to diverse chemical classes such as amino acids, organic acids, inorganic 
acids, monosaccharides, aldehydes, amines, amides, fatty acids, fatty acid 
esters, polyols and pyrimidines (Figure 2.2, Table 2.1). As our developed 
GC/MS method was the first method to be reported for metabolic profiling of 
human colorectal tissue samples, it was not feasible to compare it with other 
reported GC/MS method. However, in a concomitant study by another group a 
GC/TOFMS method for profiling of CRC tissue samples was used to obtain 
around 700 chromatographic peaks per sample (Denkert et al., 2008). 
However it should be noted that the MS used in their study was a TOFMS 
which allows spectral deconvolution of coeluting peaks and therefore it is not 
practical to compare it with our GC-single quadrupole MS platform. Later, 
when we used our developed sample preparation protocol and analyzed our 
samples using GCxGC/TOFMS (described in Chapter 5) we were able to 
obtain more than 800 chromatographic peaks per sample indicating that our 
developed method is quite comparable with that of Denkert et al. 
Peaks with similarity index (SI) more than 70% were assigned 
compound names while those having less than 70% SI were considered as 
unknown compound. Identities of selected metabolites preliminarily identified 
by NIST mass spectral library were further confirmed by comparison of their 
mass spectra and Rt with those obtained using commercially available 
reference standards (L-alanine, L-valine, glycine, L-threonine, L-proline, L-
phenylalanine, L-tyrosine, myo-inositol, uridine, uracil, D-glucose, D-
mannose, D-galactose, L-(+)-lactic acid, fumaric acid, D-(+)-malic acid, 
arachidonic acid, phosphoric acid, boric acid, formaldehyde and cholesterol). 
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In actual clinical situations where colon tissues are collected from the 
hospital, stored and processed in the laboratory, the samples would ideally not 
be subjected to more than 2 freeze-thaw cycles. In this study, the stability of 
the colon tissue samples was validated over 3 freeze-thaw cycles. Since the 
stability studies were carried out using unspiked human colon tissue, all 53 
identified metabolites (Table 2.1) were used in the validation studies. In 
clinical sample analysis, multiple samples may be submitted for batch 
analysis. As the analysis time for each sample is about 1 h, the time difference 
between the analyses of the first and final samples can be appreciable. In this 
study, a batch analysis of 50 samples was assumed and hence, the stability of 
processed samples was validated over 50 h while being kept in the auto-
sampler. As colon tissue collected from the hospital may not be analyzed 
immediately, a long-term stability study was also performed (up to 3 months) 
where the samples were kept at -80ºC. As shown in Table 2.1., the relative 
stability of all the 53 metabolites was within the acceptable limits of 100 ± 
15% for all three freeze-thaw, auto-sampler and long-term stability studies. 
Our results implied that human colon tissues are stable over 3 freeze-thaw 
cycles and when kept at -80ºC for up to 3 months. Our results also confirmed 
that batch analysis can be performed for up to 50 processed samples with 
minimum compromise in the integrity of the metabolites. These findings are 
important in guiding future GC/MS profiling of human colon tissue in terms of 
the collection, processing, storage and analysis of the samples. 
All the 53 identified metabolites were taken into consideration to 
investigate the precision of the method. The RSD of all the 53 metabolites in 
terms of intra- and inter-day precision studies was found to be less than 15% 
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(Table 2.1.). The high precision of the developed GC/MS method observed in 
our study is pertinent to the success of a metabolic profiling study since the 
variations in the levels of the metabolites should be an outcome due to an 
environmental or pathological perturbation rather than a compromise in the 
precision of the analytical method. A comparison of GC/MS chromatogram of 
blank and processed colon tissue samples revealed interferences during the 
first 6 min of the chromatogram due to MSTFA artifacts which would not 
interfere with the peaks of relevant metabolites. Thus the developed GC/MS 
method was found to be sufficiently selective. 
Each of the 19 metabolites selected for investigating the linearity study 
showed a satisfactory linear response as evident from their respective r
2
 values 
(Table 2.2.). GC/MS analysis involves tissue metabolite extraction and 
derivatization. The latter process may affect the linearity of the method. As 
metabolic profiling of the colon tissue is a semi-quantitative experiment, it 
becomes important to validate the linearity of the detection. 
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Figure 2.2. Representative GC/MS metabolite profile of normal human colon tissue. The numbering of metabolite peaks corresponds to peak 


























1 month 3 months   
1 Formaldehyde 100.58 98.99 100.80 102.22 1.92 2.20 
2 Ethylamine 101.78 97.62 100.72 99.61 1.85 2.15 
3 L-Norvaline 101.33 100.18 103.35 103.96 1.50 1.47 
4 Boric acid 100.50 100.70 101.50 102.44 1.36 1.43 
5 Methyl cyclopent-3-ene 103.59 98.35 105.62 109.54 3.01 3.22 
6 Lactate 100.45 99.25 100.39 101.78 1.79 1.73 
7 L-Valine 101.84 100.24 100.50 101.92 1.67 2.09 
8 L-Alanine 97.69 94.28 92.68 95.05 4.84 5.18 
9 Glycine derivative 99.95 99.54 102.72 103.74 2.38 2.50 
10 Pyruvate 101.03 101.21 103.75 102.97 2.00 2.06 
11 (S)-2-amino-4-methyl-pentanamide 100.48 100.11 100.70 102.52 1.52 1.52 
12 Ethanethioic acid 101.13 100.42 101.41 104.79 1.33 1.33 
13 L-Valine derivative 100.44 100.58 102.15 102.12 2.40 2.31 
14 L-Serine derivative 98.71 98.70 99.05 101.36 1.97 1.93 
15 Phosphate 100.51 101.77 102.25 100.63 2.25 2.20 
16 L-Threonine derivative 97.86 94.80 97.02 97.93 2.61 2.52 
17 L-Proline derivative 100.69 100.67 99.46 102.20 2.22 2.55 
18 Glycine 98.88 101.18 99.76 100.57 3.93 5.25 
a. Similar numbers are used to mark the peaks in the GC/MS chromatogram as shown in Figure 2.1. 
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1 month 3 months   
19 Uracil 103.94 106.57 110.75 114.32 9.24 12.37 
20 Fumarate 100.24 105.55 95.70 105.45 6.48 6.44 
21 L-Threonine 100.51 103.88 97.50 104.47 4.61 4.59 
22 L-Methionylglycine 87.32 103.02 89.79 85.13 12.51 13.53 
23 2-Hydroxy-3-methylvalerate 102.09 102.76 101.93 102.85 1.72 1.86 
24 Methylamine 100.74 99.86 100.77 102.03 1.50 1.49 
25 Malate 101.44 102.18 101.40 102.83 1.69 1.74 
26 L-Proline 101.65 99.84 102.92 104.01 2.59 4.25 
27 Phenylalanine 98.46 99.10 99.36 103.39 2.89 3.59 
28 Creatinine enol 114.30 113.07 111.67 108.71 6.78 11.23 
29 D-γ-lactone-xylonic acid 92.01 96.06 94.53 104.46 8.87 10.95 
30 L-α-glycerophosphate 102.32 101.23 101.27 102.30 3.43 3.66 
31-A,B D-Mannose 105.84 98.33 89.83 93.17 7.27 8.52 
32-A,B D-Galactose 100.58 101.83 99.55 98.72 1.76 1.80 
33 Cadaverine 104.26 98.78 100.78 100.98 4.11 4.12 
34 L-Tyrosine 100.82 100.65 101.23 101.97 3.23 3.77 
35-A,B,C D-Glucose 100.87 99.12 102.48 106.05 2.20 2.14 
36-A,B,C Myo-inositol 103.21 102.12 107.94 105.92 1.65 1.77 


























1 month 3 months   
37 Palmitic acid 100.78 99.69 97.45 98.77 4.42 4.79 
38 Margaric acid 97.38 98.60 98.55 103.69 3.83 4.79 
39 (Z,Z)-9,12-Octadecadienoic acid 93.35 99.35 97.17 98.27 4.96 5.83 
40 Oleic acid 100.74 102.05 103.48 107.23 2.29 3.00 
41 Stearic acid 100.03 101.28 104.84 102.61 5.65 5.60 
42 Mannose-6-phosphate 101.03 100.51 100.84 103.78 1.17 1.19 
43 1-Hexadecanol 85.04 106.99 85.57 86.40 11.76 11.83 
44 D-Glucose-6-phosphate 99.37 99.24 100.69 101.09 2.47 2.47 
45 Arachidonic acid 113.62 104.05 98.32 102.64 6.42 6.91 
46 D-Glucopyranose-6-phosphate 90.63 98.25 103.84 101.36 11.73 11.67 
47 Uridine 98.28 90.32 109.55 111.31 8.56 9.22 
48 11,14-Eicosadienoic acid 98.40 95.83 90.00 94.59 5.36 5.23 
49 11-Eicosenoic acid 108.76 103.27 99.94 110.71 9.34 8.86 
50 1-O-Heptadecylglycerol 100.09 106.46 94.72 105.31 7.51 7.47 
51 1-Monooleoylglycerol 94.49 102.74 86.48 87.42 11.14 11.38 
52 Propyl octadecanoate 94.14 105.28 101.11 108.94 9.49 9.04 
53 Cholesterol 85.26 101.85 85.54 85.86 10.14 10.10 





Table 2.2. Results of linearity of response of 19 selected standard metabolites 









Lactate 0.025-10.0 0.9988 
Fumarate 0.25-10.0 0.9963 
Malate 0.5-10.0 0.9979 
L-Alanine 0.05-10.0 0.9967 
L-Valine 0.025-10.0 0.9962 
L-Proline 0.5-10.0 0.9938 
L-Threonine 0.5-10.0 0.9944 
L-Phenylalanine 1.0-10.0 0.9954 
D-Glucose 0.1-10.0 0.9994 
D-Mannose 0.25-10.0 0.9929 
D-Galactose 0.25-10.0 0.9998 
Uridine 0.5-10.0 0.9972 
Arachidonic acid 0.5-10.0 0.9985 
Cholesterol 0.5-10.0 0.9956 
Phosphate 0.5-10.0 0.9962 
Myo-inositol 0.5-10.0 0.9908 
L-Tyrosine 0.25-10.0 0.9950 
Glycine 0.5-10.0 0.9953 
Uracil 1.0-10.0 0.9974 
 
During method development, it was determined that at least 20 mg of 
colon tissue sample was needed to generate a reasonably sensitive profiling of 
the endogenous metabolites. So far Denkert et al. had demonstrated that 5 mg 
of tissue is sufficient to produce satisfactory metabolic profile using gas 
chromatography coupled to time of flight mass spectrometry (GC/TOFMS) 
(Denkert et al., 2006, 2008). The relatively greater amount of tissue needed in 
our case was possibly related to the difference in the inherent sensitivity of our 





A suitable GC/MS method for the non-targeted metabolic profiling of human 
colon tissue was developed and successfully validated in terms of its sample 
stability, reproducibility, selectivity, linear response and sensitivity. Our 
developed GC/MS method could be used alone or in conjunction with other 
complementary analytical techniques like NMR, especially HR-MAS NMR 
spectroscopy for the comprehensive non-targeted metabolic profiling of 










NON-TARGETED METABOLIC PROFILING OF COLORECTAL 




In this chapter, tissue-based non-targeted metabolic profiling of CRC using 
GC/MS is described.  The GC/MS method that we developed and validated, 
(described in Chapter 2) was utilized for the said purpose. The clinical 
samples consisted of CRC and normal colon tissues obtained from 31 CRC 
patients.  The data obtained was subjected to multivariate as well as univariate 
statistical analyses to identify marker metabolites expressed differentially in 




3.2.1. Clinical population and tissue samples 
 
Clinical data such as age, gender, ethnicity, location of primary tumor, 
histological staging and grade were obtained from a prospectively maintained 
computerized database at the Singapore Polyposis Registry & the Colorectal 
Cancer Research Laboratory, Department of Colorectal Surgery, SGH. The 
anatomical and clinicopathological characteristics related to the clinical tissue 
samples analyzed by GC/MS are summarized in Table 3.1. The study 
population comprised of 31 patients with a mean age of 67 ± 13 years at the 
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time of cancer diagnosis. 3 patients were younger than 50 years old (T11, T13 
and T21). There were 18 males (58%) and 13 females (42%). The majority 
(87%) of the patients were Chinese (n = 27), while the remaining comprised 2 
Indians (T5 and T27), 1 Malay (T7) and 1 of other ethnicity (T16, T23; n = 1). 
The CRC anatomical site, tissue histology, tumor grade, TNM and Dukes 
stages are presented in Table 3.1. There were 22 left-sided tumors (defined as 
those arising distal to the splenic flexure) of which 14 were in the 
rectosigmoid or rectum. The tumors were predominantly moderately 
differentiated (81%; n = 25), and the remaining 6 comprised 2 each of 
mucinous, well and poorly differentiated tumors. Although not presented in 
Table 3.1., tumor invasion of neighboring organs, lesion nature and 
dimension, and presence of angiolymphatic or perineural invasion were also 
noted. This study was approved by the IRB at the SGH (IRB reference number 
260/2007). Matched CRC and normal tissue (n = 63) were obtained from the 
31 CRC patients during surgery. Among these subjects, 1 patient provided two 
matched pairs of tissues (M23, T23, M16 and T16), while another only 
provided the normal mucosa (M19). None of the patients received neoadjuvant 
chemotherapy or radiotherapy prior to surgical excision. Resection of tissue 
samples were carried out by trained personnel at Singapore General Hospital. 
Fresh tumor tissue and matched normal mucosa were snap-frozen immediately 
following excision of the specimen at surgery, then stored at -80°C until 
processing. Tumor specimens were carefully micro-dissected to ensure that at 
least 90% of the analyzed tissue contained cancer cells. Matched normal 
tissues were taken at least 5-10 cm away from the edges of the tumor. All 
CRC tissues and matched normal tissue were cut and weighed accurately  
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Table 3.1. Summary of anatomical and clinicopathological characteristics of 
















 Caecum Adenocarcinoma MD T3N0M0 B 
M16 T16
b
 Caecum Adenocarcinoma MD T3N0M0 B 
M7 T7 Caecum Adenocarcinoma MD T3N2M0 C 
M4 T4 Ascending colon Adenocarcinoma MD T3N1M0 C 
M2 T2 Hepatic flexure Adenocarcinoma MD T2N0M1 D 
M1 T1 Transverse colon Adenocarcinoma MD T3N2M0 C 
M8 T8 Transverse colon Adenocarcinoma MD T3N2M0 C 
M30 T30 Transverse colon Adenocarcinoma MD T3N0M0 B 
M31 T31 Descending colon Adenocarcinoma MD T3N0M0 B 
M19 - Descending colon Adenocarcinoma PD T4N1M0 C 
M6 T6 Sigmoid colon Adenocarcinoma PD T2N1M0 C 
M33 T33 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M24 T24 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M28 T28 Sigmoid colon Adenocarcinoma MD T3N0M0 B 
M29 T29 Sigmoid colon High-grade dysplasia MD T2N0M0 A 
M32 T32 Sigmoid colon Adenocarcinoma WD T4N0M0 B 
M27 T27 Sigmoid colon Mucinous M T3N1M0 C 
M17 T17 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M3 T3 Rectosigmoid colon Adenocarcinoma MD T2N0M1 D 
M15 T15 Rectosigmoid colon Adenocarcinoma MD T1N0M0 A 
M11 T11 Rectosigmoid colon Adenocarcinoma WD T3N1M0 C 
M25 T25 Rectum Adenocarcinoma MD T3N2M0 C 
M10 T10 Rectum Adenocarcinoma MD T3N1M1 D 
M5 T5 Rectum Adenocarcinoma MD T2N0M0 B 
M12 T12 Rectum Adenocarcinoma MD T2N0M0 A 
M26 T26 Rectum Adenocarcinoma MD T3N0M0 B 
M22 T22 Rectum Adenocarcinoma MD T3N0M0 A 
M9 T9 Rectum Adenocarcinoma MD T2N0M0 B 
M13 T13 Rectum Adenocarcinoma MD T4N0M1 D 
M20 T20 Rectum Mucinous M T3N1M0 C 
M21 T21 Rectum Adenocarcinoma MD T3N0M0 B 
M18 T18 Rectum Adenocarcinoma MD T3N0M1 D 
a 
For each T (CRC) sample, matched M (normal) tissue was provided, with the 
exception of M19 (i.e. no matched T19). 
b 
M16, T16, M23 and T23 were obtained from one patient. 
c 
MD, WD, M and PD are moderately differentiated, well-differentiated, 






where approximately 20 mg of each tissue was reserved for GC/MS analysis. 
The samples were kept at -80°C until analysis. The remaining specimens were 
preserved in formalin and submitted for routine histological examination with 
hematoxylin and eosin staining by a gastrointestinal pathologist to determine 
the tumor stage and differentiation. 
 
3.2.2. GC/MS analysis 
 
Tissue samples for GC/MS analysis were prepared as per the procedure 
described in section 2.2.3 of Chapter 2. The same GC/MS conditions as 
described in section 2.2.4. of Chapter 2 were used for analysis. The total 
analysis time (including sample preparation and data acquisition) for each 
sample was approximately 200 min.   
 
3.2.3. GC/MS data analysis 
 
All known artifact peaks, such as peaks due to column bleed and MSTFA 
artifact peaks, were not considered in the final data analyses. The GC/MS data 
was pre-processed by normalization to a constant sum of the chromatographic 
peak area before chemometric and statistical analyses. The normalization step 
was used to account for variations of the overall concentrations of samples 
caused by subtle variations in wet weight of tissue samples, variations 
introduced during sample preparation and variations caused by instrument 
response. Metabonomic/metabolomic responses and fluxes mainly influence a 
certain number of metabolites in body fluids and consequently certain number 
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of peaks of the corresponding chromatogram/spectrum. These specific 
changes are visible as relative changes of concentrations of few metabolites 
related to the concentrations of all other metabolites, which represent the 
overall concentration of the sample. Usually these specific relative changes are 
of interest in metabolic profiling studies in contrast to the overall 
concentration of the sample. Therefore, a normalization step, which 
compensates for the differences of the overall concentration, is crucial, as 
variations of the overall concentrations obscure specific changes of 
metabolites. As internal standards are usually spiked into tissue matrix and 
then subjected through sample preparation procedure they can account for the 
variations caused by sample preparation, instrument response but they cannot 
account for variations introduced by subtle variations in tissue wet weight. 
Although normalization to total area may become suboptimal in case of huge 
metabolic changes but still it is a popular normalization method and has been 
successfully used in other tissue based metabolic profiling studies (Denkert et 
al., 2006, 2008; Wang et al., 2005; Yang et al., 2007). The normalized data 
was subjected to PCA to identify clustering trends and outliers followed by 
OPLS-DA (Bylesjö et al., 2006) using chemometric SIMCA-P software 
(Umetrics, Umeå, Sweden). The data were mean-centered and Pareto-scaled 
during chemometric data analysis. An independent ‘t’ test with Welch’s 
correction using SPSS software (Version 11.0, SPSS Inc., Chicago, IL, USA) 
was used for the comparison of the marker metabolite levels to determine their 
statistical significant differences between the CRC and normal mucosa groups 
(p < 0.05 was considered to be statistically significant). The Welch correction 
is designed to provide a valid t-test in the presence of unequal population 
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variances. Receiver operating characteristic (ROC) is a graphical plot of the 
sensitivity, or true positive rate, vs. false positive rate (1 − specificity or 1 − 
true negative rate), for a binary classifier system as its discrimination threshold 
is varied. Each point on the ROC curve represents a sensitivity/specificity pair 
corresponding to a particular decision threshold. The area under the ROC 
curve is a measure of how well a parameter can distinguish between two 
diagnostic groups (diseased/normal). ROC analysis was performed using the 
GraphPad Prism software (Version 5.02., GraphPad Software Inc., La Jolla, 
CA, USA) to validate the robustness of the OPLS-DA model using the cross-
validated (7-fold) predicted Y values. Cross-validation is a procedure where 
multiple models are generated each excluding a different portion of the data 
(in our case every 7th sample), such that all samples are excluded once and 
once only. Predicted classifications (Y values) were then generated for each 
set of excluded samples using the appropriate model, in order to estimate the 
predictive performance of the classification algorithm. The area under the 
ROC curve denoted as AUC was calculated using the trapezoidal rule. 
 
3.3. Results and discussion 
 
In total, 31 tumor samples and 32 normal tissues from 31 CRC patients were 
analyzed by GC/MS (Table 3.1.). The representative chromatograms of CRC 
and normal tissue extracts are illustrated in Figure 3.1. From the 
chromatogram, it was clear that the GC/MS platform was highly reproducible 
in the elution time of the metabolites. The PCA plot using the GC/MS data has 
been presented in Figure 3.2. The scores plot of the OPLS-DA model 
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generated using the GC/MS data has been presented in Figure 3.3. [2 LV, 
R
2
(Y) = 0.849, Q
2




(cum) are the latent 
variables, fraction of the sum of squares of all Y values explained by the 
current latent variable and cumulative Q
2
 for the extracted latent variable, 
respectively. Q
2





The overall explained variance, R
2
Y, has the same expression as Q
2
 but 
calculated for a model generated with all the training data (Keun et al., 2003). 
The model was subjected subsequently to ROC analysis using the cross-
validated predicted Y values (Figure 3.4., AUC 0.9726). An AUC value of 1.0 
corresponds to a prediction model with 100% sensitivity and 100% specificity, 
whereas an AUC value of 0.5 correspond to a poor predictive model. The high 
AUC values of the ROC analysis indicated that the OPLS-DA model was 
robust in this discrimination. The marker metabolites that were responsible for 
the separation of CRC specimens from their matched normal tissues in the 
OPLS-DA model are summarized in Table 3.2. Except for fumarate, malate, 
mannose, galactose, glucose and AA which were found to be present at higher 
levels in normal tissues, the remaining marker metabolites were found in 
greater amounts in the CRC specimens. All the metabolites were found to be 
statistically different between the two test groups (p < 0.05). The marker 
metabolites as presented in Table 3.2. are also labelled in Figure 3.1. to aid 
visualization of their Rt. OPLS-DA was also performed with different 
combinations of anatomical sites and Dukes stages of CRC specimens as test 
classifiers. However, no valid model was obtained. In addition to the existing 
literature, the Human Metabolome database (HMDB) (Wishart et al., 2009) 
and the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and 
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Lactate 9.85 Organic acid Standard 40.1 <0.0001 
Phosphate 14.65 Inorganic acid Standard 6.1 <0.05 
Glycine 15.40 Amino acid Standard 38.5 <0.0001 
Fumarate 16.76 Organic acid Standard -20.1 <0.05 
Malate 21.41 Organic acid Standard -25.1 <0.0005 
L-Proline 22.37 Amino acid Standard 71.6 <0.05 
















Monosaccharide Standard -67.0 <0.0001 
Palmitic acid 35.53 Fatty acid NIST 38.1 <0.0001 
Margaric acid 37.44 Fatty acid NIST 64.2 <0.01 
Oleic acid 38.90 Fatty acid NIST 13.1 <0.05 
Stearic acid 39.44 Fatty acid NIST 39.0 <0.0001 
Arachidonic acid 41.71 Fatty acid Standard -16.7 <0.05 
Uridine 42.18 Pyrimidine 
nucleoside 
Standard 102.4 <0.0001 
11-Eicosenoic acid 42.51 Fatty acid NIST 59.6 <0.0005 
1-Monooleoylglycerol 47.96 Polyol 
derivative 
NIST 119.5 <0.0001 
Cholesterol 53.70 Steroid Standard 13.8 <0.005 
a
 Metabolite identification using standard compound or NIST library search. 
b
 Positive and negative percentages indicate higher levels of metabolites in 
cancer and normal tissues, respectively. 
c
 Statistical p value calculated using the independent ‘t’-test with Welch’s 
correction (significance at p < 0.05). 
d




















Figure 3.3. OPLS-DA scores plot discriminating CRC from normal tissues 







Figure 3.4. ROC curve determined using the cross-validated predicted Y 












Goto, 2000) were also used to obtain information about the identified marker 
metabolites and their related metabolic pathways, respectively.   
Using GC/MS, lactate and glycine were consistently found to be higher 
in CRC specimens while glucose was consistently lower (Table 3.2.). Lactate 
is an end product of glycolysis that increases rapidly during hypoxia and 
ischemia. Hypoxic regions of tumors develop when a tumor outgrows its 
vasculature. As increased lactate levels have been associated with a range of 
tumors (Grifﬁn and Shockcor, 2004), our observation in this study was not 
unexpected. Higher levels of glucose uptake, consumption and conversion to 
lactate is a common observation in tumor cells even in high oxygen 
conditions, and was first observed by Otto Warburg (Warburg et al., 1956). 
Glycine can be formed from the glycolytic intermediate 3-phosphoglycerate, 
and its increased levels in CRC could relate to this glycolytic phenotype.  
ROC curve generated with
cross-validated predicted Y values




































Alternatively, glycine is an important source of the one-carbon units for de 
novo purine synthesis, as shown by NMR experiments in the MCF7 breast 
tumor line (Fu et al., 2001).  Hence the observed increase in glycine content 
could reflect enhanced nucleotide synthesis. 
Based on the GC/MS non-targeted metabolic profiling approach, 
monounsaturated fatty acids (oleic acid and 11-eicosenoic acid) were found to 
be elevated in CRC specimens when compared to normal tissues (Table 3.2.). 
It is an established fact that 18-carbon chain length monounsaturated lipids 
were implicated in the apoptotic process (Griffin and Shockcor, 2004). 
Moreover such fatty acids have been shown to have tumor promoting effects 
in murine models of cancer and are often considered as a risk factor for CRC 
(Reddy, 1986, 1992). 
Our GC/MS data indicated clearly that AA level was reduced in CRC 
specimens compared to normal tissues (Table 3.2.). The depletion of AA in 
CRC tissue substantiated the overexpression of COX-2 and LOX enzymes in 
CRC which catalyze the conversion of AA to eicosanoids viz. PGs. TXs, 
HETEs and LTs which act as inflammatory mediators. Alteration in the 
endogenous levels of AA emphasizes the role of these eicosanoids in bridging 
inflammation and CRC (Kashfi and Rigas, 2005; Sano et al., 1995; Shureiqi 
and Lippman, 2001; Smith, 1992; Soslow et al., 2000; Soumaoro et al., 2006). 
The geographical incidence of CRC correlates well with high fat diets 
(Lipkin et al., 1999). Patients with CRC, have high levels of faecal bile acids 
and cholesterol. It is thought that faecal bile acids and cholesterol metabolites 
may act as promoters, co-carcinogens or carcinogens in large bowel 
tunmorigenesis. Cholesterol is an obligatory precursor of bile acids and 3-
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hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase is involved in 
its synthesis. Higher levels of cholesterol were associated with the CRC 
specimens as demonstrated by GC/MS (Table 3.2.). This finding is consistent 
with earlier reports on the overexpression of HMG-CoA in colon cancer cell 
lines (Hentosh et al., 2001; Wachtershauser et al., 2001). 
In line with other studies (Denkert et al., 2008; Ong et al., 2010), we 
also found lower levels of malate and fumarate in the CRC specimens (Table 
3.2.) which are most likely related to deregulation of tricarboxylic acid (TCA) 
cycle and the higher energy demand in tumors. Uridine, a pyrimidine 
nucleoside, was also elevated in CRC specimens (Table 3.2.). These 





GC/MS was successfully utilized to profile metabolites in CRC and normal 
biopsied tissue specimens obtained from CRC patients. The data thus obtained 
was subjected to OPLS-DA which in turn generated a robust model capable of 
discriminating CRC from normal tissues. Moreover chemically diverse marker 
metabolites were identified which suggested perturbations of processes such 
as tissue hypoxia, glycolysis, TCA cycle, steroid metabolism, nucleotide 
biosynthesis, lipid metabolism and biosynthesis of eicosanoids. However the 
GC/MS data was unable to generate any OPLS-DA model capable of 





NON-TARGETED METABOLIC PROFILING OF COLORECTAL 




HR-MAS NMR spectroscopy is a solid state NMR technique in which the 
sample is spun rapidly at an angle of 54.7° (“magic angle”) with respect to the 
magnetic field resulting in attenuation of line broadening effects and 
generation of high resolution NMR spectra. HR-MAS NMR spectroscopy is a 
valuable analytical platform for metabolic profiling of intact tissue specimens. 
The probe heads used for HR-MAS NMR spectroscopy are capable of 
studying the samples in rapid rotation (4-6 kHz) around an axis of 54.7° tilted 
relative to that of the static magnetic field. As a result, chemical shift 
anisotropy, contributions from dipolar couplings and susceptibility distortions 
are largely reduced providing high-resolution spectra from semisolid and solid 
samples, such as tissues. HR-MAS NMR spectroscopy has been used in the 
analysis of gastrointestinal biopsies (Backshall, 2009; Seierstad et al., 2008; 
Tugnoli et al., 2006a; Wang et al, 2005, 2007, 2008), prostate tumors (Cheng 
et al., 2005; Swanson et al., 2003, 2006; Teichert et al., 2008), breast tumors 
(Sitter et al., 2006), brain tissue (Barton et al., 1999; Cheng et al., 1996, 1997, 
2000; Tugnoli et al., 2006b; Tzika et al., 2007), renal cancer biopsies (Moka et 
al., 1998; Tate et al., 2000), heart tissue (Bollard et al., 2003) and liver tissue 
(Bollard et al., 2000; Duarte et al., 2005; Rooney et al., 2003; Wang et al., 
2003). The sensitivity and resolution of HR-MAS NMR spectroscopy is 
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comparatively lower than MS techniques. However, the main advantage of 
HR-MAS NMR spectroscopy over MS and liquid state NMR techniques is 
that it requires minimal sample preparation and the metabolic space covered is 
independent of the choice of solvent(s) used for extraction of metabolites from 
tissues (Beckonert et al., 2010; Schenetti et al., 2006). 
 In this chapter, HR-MAS NMR spectroscopy has been used as an 
analytical platform for the non-targeted metabolic profiling of CRC and 
normal tissue specimens obtained from CRC patients. The HR-MAS NMR 
analysis, data pre-treatment and pre-processing by Matlab were carried out by 
our collaborators at the Imperial College London, UK.  Raw spectral data 
analysis by Chenomx, multivariate statistics by SIMCA and pathway mapping 
of marker metabolites using KEGG were carried out at the Department of 




4.2.1. Clinical population and tissue samples 
 
The same cohort of clinical samples (described in Table 3.1. of Chapter 3) 
which was used for GC/MS analysis, was used for HR-MAS NMR 
spectroscopy analysis. However due to limited size of each tissue block, all the 
tissues (n=63) were analyzed using GC/MS, while 47 tissues were analyzed 
using HR-MAS NMR spectroscopy, of which 18 pairs were matched samples. 
The anatomical and clinicopathological characteristics of the clinical tissue 
samples analyzed by HR-MAS NMR spectroscopy are summarized in Table  
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4.1. Collection, handling and storage of tissue samples were carried out in the 
same manner as described in section 3.2.1. of Chapter 3. About 10 mg of each 
tissue specimen was accurately weighed and kept at -80ºC until HR-MAS 
NMR spectroscopy analysis. 
Table 4.1. Summary of anatomical and clinicopathological characteristics of 













M23 T23 Caecum Adenocarcinoma MD T3N0M0 B 
- T7 Caecum Adenocarcinoma MD T3N2M0 C 
M4 T4 Ascending colon Adenocarcinoma MD T3N1M0 C 
M1 - Transverse colon Adenocarcinoma MD T3N2M0 C 
M30 T30 Transverse colon Adenocarcinoma MD T3N0M0 B 
M31 T31 Descending colon Adenocarcinoma MD T3N0M0 B 
M19 - Descending colon Adenocarcinoma PD T4N1M0 C 
M6 - Sigmoid colon Adenocarcinoma PD T2N1M0 C 
M33 T33 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M24 T24 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M28 T28 Sigmoid colon Adenocarcinoma MD T3N0M0 B 
M29 T29 Sigmoid colon High-grade dysplasia MD T2N0M0 A 
M32 T32 Sigmoid colon Adenocarcinoma WD T4N0M0 B 
M27 T27 Sigmoid colon Mucinous M T3N1M0 C 
- T17 Sigmoid colon Adenocarcinoma MD T3N1M0 C 
M3 T3 Rectosigmoid colon Adenocarcinoma MD T2N0M1 D 
M15 - Rectosigmoid colon Adenocarcinoma MD T1N0M0 A 
M11 - Rectosigmoid colon Adenocarcinoma WD T3N1M0 C 
M25 T25 Rectum Adenocarcinoma MD T3N2M0 C 
M10 T10 Rectum Adenocarcinoma MD T3N1M1 D 
- T5 Rectum Adenocarcinoma MD T2N0M0 B 
M12 - Rectum Adenocarcinoma MD T2N0M0 A 
M26 T26 Rectum Adenocarcinoma MD T3N0M0 B 
M22 T22 Rectum Adenocarcinoma MD T3N0M0 A 
M9 T9 Rectum Adenocarcinoma MD T2N0M0 B 
M13 - Rectum Adenocarcinoma MD T4N0M1 D 
M20 T20 Rectum Mucinous M T3N1M0 C 
M21 T21 Rectum Adenocarcinoma MD T3N0M0 B 
M18 - Rectum Adenocarcinoma MD T3N0M1 D 
a 
T (CRC) tissue, M (normal) tissue. 
b 
MD, WD, M and PD are moderately differentiated, well-differentiated, 




4.2.2. HR-MAS NMR spectroscopy analysis 
 
HR-MAS NMR spectroscopic analysis including sample pretreatment was 
carried out at the Imperial College London, UK, as per the validated protocol 
which has been recently published (Beckonert et al., 2010). Each accurately 
weighed intact tissue (about 10 mg) was bathed in D2O solution for 15 s. The 
tissue was inserted into a zirconium oxide 4 mm outer diameter rotor with an 
additional drop of D2O to provide a field-frequency lock for the NMR 
spectrometer. An insert was placed into the rotor to make a spherical sample 
volume of 25 µL. A cap was finally added as a closure of the rotor and the 
assembled device was used immediately for NMR analysis. All samples were 
randomized during analysis to reduce any potential systematic errors.  
All 
1
H NMR spectra were recorded on a Bruker AV-600 NMR 
spectrometer (Rheinstetten, Germany) operating at 600.11 MHz for 
1
H, 
equipped with a HR-MAS at a spin rate of 5000 Hz. Sample temperature was 
regulated using cooled N2 gas at 10 ºC during the acquisition of spectra to 
minimize spectral degradation. Two different types of 
1
H NMR experiments 
were carried out for each sample, a one-dimensional (1D) Nuclear Overhauser 
effect spectroscopy (NOESY) experiment with water suppression and a 1D 
Carr-Purcell-Meiboom-Gill (CPMG) spin-echo experiment. CPMG pulse 
sequence is widely used to measure spin-spin relaxation time T2 and thus the 
CPMG sequence generated spectra can be edited by T2 relaxation times to 
reduce signals from high molecular weight species or systems in intermediate 
chemical exchange (Zhang and Hirasaki, 2003).  1D NOESY is a selective 1-
D experiment that uses shaped pulses to selectively excite specific resonances 
66 
 
in order to observe isolated dipolar couplings. The 1D NOESY experiment 
generates a corresponding unedited spectrum with improved solvent peak 
suppression (Teahan et al., 2006). The CPMG spin-echo experiment gave the 
clearest signature of metabolic changes between the cancer and normal tissues, 
with little extra information contained in the higher molecular weight 
components. As such, results obtained from the CPMG experiments were used 
for further data analysis. CPMG spin-echo spectra were obtained using the 
pulse sequence [recycle delay (RD)-90º-(τ-180º-τ)n - acquire FID], with a 
spin-spin relaxation delay, 2nτ, of 240 ms. The RD was 2 s. The 90º pulse 
length was 6.9-9.0 µs. A total of 256 transients were collected into 32 K data 
points with a spectral width of 20 ppm. 
1
H MAS NMR spectra of tissues were 
manually phased and baseline corrected using XwinNMR 3.5 (Bruker 
Analytik, Rheinstetten, Germany). The 
1
H NMR spectra were referenced to 
the methyl resonance of alanine at δ 1.47. The total analysis time (including 
sample preparation, optimization of NMR parameters and data acquisition) of 
HR-MAS NMR spectroscopy for each sample was approximately 40 min. 
Although a greater mass of the tissue (> 20 mg) is recommended to fill the 
rotor space for MAS analysis, the ~10 mg tissue used in our experiments 
generated good signal sensitivity and resolution. For assignment purposes, 
two-dimensional (2D) correlation spectroscopy (COSY) and J-resolved 







4.2.3. HR-MAS NMR spectroscopy data analysis 
 
The data generated from HR-MAS NMR spectroscopy were analyzed in two 
different ways –  
1. Using Matlab (Version 7, The Mathworks, Inc., Natwick, MA, USA) 
followed by manual identification of metabolites and statistical analyses. 
2. Using Chenomx NMR suite software (Version 6.1., Chenomx Inc., Alberta, 
Canada) followed by statistical analyses. 
 
4.2.3.1. HR-MAS NMR spectroscopy data analysis using Matlab and 
manual identification of metabolites 
 
The spectra over the range of δ -1.0 to 10.0 were imported into Matlab using 
in-house script developed by Dr. Rachel Cavill, Dr. Tim Ebbels and Dr. 
Hector Keun at the Imperial College London, UK. All spectra were “binned” 
into 0.01 ppm regions. Probabilistic quotient normalization of the spectra 
using the median spectrum to estimate the most probable quotient was carried 
out before chemometric and statistical analyses (Dieterle et al., 2006). The 
binned data were analyzed initially by OPLS-DA using SIMCA-P software 
(Umetrics, Umeå, Sweden), generating a model classifying normal from tumor 
[3 LV, R
2
Y = 0.843, Q
2
(cum) = 0.653] and the correlated loadings were used 
to help identify the spectral regions discriminating between these groups. 
These differential spectra regions were subsequently confirmed via visual 
inspection of the NMR spectra. The marker metabolites were assigned 
subsequently. The peak intensities of the spectra region related to the marker 
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metabolites were integrated from the full-resolution data. All processed data 
were mean-centered and Pareto-scaled during chemometric data analysis. A 
secondary OPLS-DA model was created using the marker metabolite 
intensities as variables. The residual water resonance signal (δ 4.50-5.19) and 
the spectral region (δ 1.0 to 0.5) were removed prior to analysis. The peak 
intensities of the spectra region related to the marker metabolites were 
integrated in Matlab using the full-resolution data and a local linear baseline 
correction. An independent „t‟ test with Welch‟s correction was used for the 
comparison of the marker metabolite levels to determine their statistical 
significant differences between the CRC and normal mucosa groups (p < 0.05 
was considered to be statistically significant). ROC analysis was performed 
using GraphPad Prism software (Version 5.02., GraphPad Software Inc., La 
Jolla, CA, USA) to validate the robustness of the OPLS-DA model(s) using 
the cross-validated (7-fold) predicted Y-values. 
 
4.2.3.2. HR-MAS NMR spectroscopy data analysis using Chenomx NMR 
suite software 
 
Processed NMR spectra for all the samples present in the form of Bruker „1r‟ 
files were imported and converted to Chenomx NMR suite format (.cnx) using 
the processor module of Chenomx NMR suite. As no chemical shape indicator 
(CSI) was present in the samples, all the NMR spectra were referenced to the 
methyl resonance of alanine at δ 1.47. After conversion of the NMR spectra of 
all the samples into .cnx format, metabolite identification and quantification 
were carried out using the in-built spectral library of the profiler module of 
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Chenomx NMR software. The resulting data were normalized before 
chemometric analyses. The normalized data were analyzed using PCA 
followed by OPLS-DA using SIMCA-P software (Umetrics, Umeå, Sweden). 
All processed data were mean-centered and unit-variance (UV) scaled during 
chemometric data analysis. An independent „t‟ test with Welch‟s correction 
was used for the comparison of the marker metabolite levels to determine their 
signiﬁcant differences between the CRC and normal tissues groups (p < 0.05 
was considered as statistically signiﬁcant). ROC analysis was performed using 
GraphPad Prism to validate the robustness of the OPLS-DA model using the 
cross-validated (7-fold) predicted Y-values. 
 
4.3. Results and discussion 
 
In total, 22 tumor samples and 25 normal tissues obtained from 29 CRC 
patients were analyzed by HR-MAS NMR spectroscopy (Table 4.1.). The 
representative HR-MAS NMR spectra of CRC and normal tissue are shown in 
Figure 4.1. The marker metabolites which were identified from NMR data 
processed using Matlab followed by manual metabolite assignment, are 





(cum) = 0.518] and the ROC curve (AUC = 0.9542) are shown in 
Figures 4.2. and 4.3., respectively. The set of marker metabolites identified 
from NMR data processed by Chenomx NMR suite software is shown in 
Table 4.3. The HMDB (Wishart et al., 2009) and the KEGG (Kanehisa and 
Goto, 2000) were referred to acquire information on the identified marker 
metabolites and related metabolic pathways, respectively.  
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Lipids and glucose were found to be present at higher levels in normal 
tissues compared to CRC tissues, while choline-containing compounds 
(ChoCC), taurine, scyllo-inositol, glycine, phosphoethanolamine (PE), lactate 
and phosphocholine (PC) were present at higher levels in the CRC specimens. 
Our HR-MAS NMR results indicated clearly higher levels of both saturated 
and unsaturated lipids and/or fatty acids in normal tissues compared to CRC 
specimens (Table 4.2.). The lower lipid levels in the CRC specimens were 
likely to be associated with higher metabolic turnover and demand in 
membrane biosynthesis for cell propagation leading to a higher utilization rate 
of lipids, particularly triglycerides. Another class of compounds that were 
found to be perturbed in tumors is the choline-containing compounds (ChoCC) 
such as choline, PC, phosphatidylcholine, glycerophosphocholine and PE, all 
important precursors of constituents of cell membranes (Glunde et al., 2006; 
Griffin and Shockcor, 2004). Consistent with earlier observations, (Moreno et 
al., 1993) PC and PE were found in our study to be present at higher levels in 
the CRC specimens based on the results of HR-MAS NMR spectroscopy 
(Tables 4.2. and 4.3.). Taurine is important in osmoregulation and its level was 
found to be increased in several tumors including CRC (Griffin and Shockcor, 
2004; Moreno et al., 1993). Scyllo-inositol is an osmolyte that was found to be 
higher in normal human colon as compared to the different longitudinal levels 
of the healthy gut (Wang et al., 2007). Our results showed that scyllo-inositol 
was further elevated in CRC compared to normal colon tissues and suggested 
the localized change in osmotic regulation in CRC tumor. Like GC/MS, HR-
MAS NMR data also showed that levels of lactate and glycine were 
consistently higher in CRC specimens while glucose was consistently lower. 
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Finally, OPLS-DA was performed using the full-resolution data with different 
combinations of anatomical sites and Dukes stages of CRC specimens as test 
classiﬁers. For this experiment, the data related to the normal tissues were 
excluded during analysis. 
 









Table 4.2. Marker metabolites identified by HR-MAS NMR spectroscopy 
(data processed by Matlab with manual metabolite assignment). 
  
















Lipids 0.90 CH3 M 1D -83.3 <0.01 
 2.00 CH2-C=C M  -48.0 <0.05 
 5.28-
5.44 





 3.21 N(CH3)3 s (multiple) 1D, 
COSY 
82.7 <0.05 
Taurine 3.25 NCH2 T 1D, JRES, 
COSY 
115.8 <0.0001 
3.42 SCH2 T 152.3 <0.0001 
Scyllo-
inositol 
3.34 Half δ-CH2 S 1D, JRES 39.1 <0.05 
Glycine 3.55 CH2 S 1D, JRES 24.4 0.1751 
PE
d
 3.99 OCH2 M 1D, JRES, 
COSY 
46.0 0.0541 





 4.19 OCH2 T 1D, JRES, 
COSY 
75.6 <0.01 
Glucose 4.64 1-CH D 1D, JRES, 
COSY 
-45.8 <0.05 
5.23 1-CH D 1D, JRES, 
COSY 
-63.3 <0.01 
a. d, m, q, s and t are doublet, multiplet, quartet, singlet and triplet, 
respectively. 
b. Positive and negative percentages indicate higher levels of metabolites 
in CRC and normal tissues, respectively. 
c. p value calculated using the independent „t‟-test with Welch‟s 
correction (significance at p < 0.05). 
d. ChoCC, PE and PC are choline-containing compounds, 







Table 4.3. Marker metabolites identified by HR-MAS NMR spectroscopy 
(data processed by Chenomx NMR suite). 
 
Metabolite δ 1H (ppm) Identified 
By 










 3.2, 3.5, 4.0  Chenomx library 55.3  <0.0005  
Taurine 3.3, 3.4 Chenomx library 72.0  <0.0001  
Glycine 3.6 Chenomx library 47.6  <0.005  
PE
c
 3.2, 4.0 Chenomx library 51.7  <0.0005  
Lactate 1.3, 4.1 Chenomx library 55.4  <0.0001  
PC
c
 3.2, 3.6, 4.2 Chenomx library 58.8  <0.0005  
Glucose 3.2, 3.4, 3.5, 
3.7, 3.8, 3.9, 
4.6, 5.2 




a. Positive and negative percentages indicate higher levels of metabolites 
in CRC and normal tissues, respectively. 
b. p value calculated using the independent „t‟-test with Welch‟s 
correction (significance at p < 0.05). 
c. ChoCC, PE and PC are choline-containing compounds, 
phosphoethanolamine and phosphocholine, respectively. 
 
 
The colon class comprised all samples obtained from ceacum, ascending, 
transverse and descending colon and sigmoid colon, while the rectum class 
consisted of samples obtained from the rectosigmoid colon and rectum. Figure 
4.6 shows the OPLS-DA model scores generated from the NMR data 
(processed by Matlab with manual metabolite assignment) using anatomical 
sites as classifiers [7 LV, R
2
(Y) = 0.983, Q
2
(cum) = 0.625]. The corresponding 
ROC curve (AUC = 1.00) is shown in Figure 4.7. Normal tissue samples did 
not show any clustering trend based on anatomical site when subjected to 
PCA. Our results suggested that CRC harbors distinct metabolic phenotype 
according to the anatomical location of the tumor. However the NMR data 
processed by Chenomx was unable to generate any such OPLS-DA model 




Figure 4.2. OPLS-DA scores plot discriminating CRC from normal tissues 
based on marker metabolites detected by HR-MAS NMR (data processed by 
Matlab with manual metabolite assignment). 
  
 
Figure 4.3. ROC curve determined using the cross-validated predicted Y-
values of the HR-MAS NMR OPLS-DA model (data processed by Matlab 
with manual metabolite assignment). 
 
ROC curve generated with
cross-validated predicted Y values





































Figure 4.4. OPLS-DA scores plot discriminating CRC from normal tissues 





Figure 4.5. ROC curve determined using the cross-validated predicted Y-
values of the HR-MAS NMR OPLS-DA model (data processed by Chenomx 
NMR suite). 
 
ROC curve generated with
cross-validated predicted Y values





































Figure 4.6. OPLS-DA scores plot discriminating colon from rectal cancers 






Figure 4.7. ROC curve determined using the cross-validated predicted Y-
values of the HR-MAS NMR OPLS-DA model with anatomical site as 
classifier. 
ROC curve generated with
cross-validated predicted Y values





































scyllo-inositol in the Chenomx library. No valid OPLS-DA model was 




HR-MAS NMR spectroscopy-based non-targeted metabolic profiling 
generated pertinent data using CRC and normal biopsied tissue specimens 
obtained from CRC patients. The data thus obtained was subjected to 
chemometric analyses which in turn generated OPLS-DA models capable of 
discriminating CRC from normal tissues as well as the anatomical site of 
tumors. The high AUC values of the respective ROC curves confirmed that 
the OPLS-DA models were robust in nature. The marker metabolites 
identified by HR-MAS NMR spectroscopy indicated deregulations in tissue   
hypoxia,   glycolysis,   nucleotide   biosynthesis,   osmoregulation   and   lipid  
metabolism. However, the HR-MAS NMR spectroscopy data was unable to 









NON-TARGETED METABOLIC PROFILING OF COLORECTAL 




GC×GC/TOFMS consists of two capillary columns having complementary 
stationary phases. The primary or first-dimension column is non-polar in 
nature allowing separation of large number of compounds belonging to 
different chemical classes. As a result, each individual narrow 
chromatographic fraction eluting out of the primary column consists of 
analytes with closely similar volatilities. The secondary or second-dimension 
column is polar in nature which allows fast separation of analytes having close 
volatilities. Therefore, the two columns operate orthogonally generating a 2D 
plane of separation for the analytes and resulting in a synergistically enhanced 
peak capacity obtained by the two individual columns. The modulator device 
which acts as the interface between the two columns performs three main 
functions - 1. accumulation and trapping of eluent of primary column, 2. 
refocusing and 3. rapid release of the adjacent fractions of the primary column 
into the secondary column. Cryogenic modulators are typically used for this 
purpose (Beens et al., 2001; Khummueng et al., 2006). TOFMS are the 
preferred detectors for GC×GC as they can acquire 50 or more mass spectra 
per second necessary for proper reconstruction of the very fast eluted second-
dimension peaks, and enable reliable spectral deconvolution of co-eluting 
peaks.  Although the analysis time of GC×GC/TOFMS is usually shorter as 
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compared to GC/MS, the amount of information provided per sample per unit 
time is not compromised. Apart from the increased number of detectable peaks 
as compared to GC/MS, spectral purity is much improved in GC×GC/TOFMS, 
which in turn aids in mass spectral deconvolution and compound 
identification. Despite the many advantages of using GC×GC/TOFMS in non-
targeted metabolic profiling, one of its biggest challenges is the complexity 
and large volume of the generated data (Adahchour et al., 2008; Dimandja et 
al., 2003; Ryan et al., 2005). GC×GC/TOFMS has already been successfully 
utilized in non-targeted metabolic profiling (Koek et al., 2007; Mohler et al., 
2006; Pasikanti et al., 2010; Sinha et al., 2004; Welthagen et al., 2005). Thus it 
is pertinent to explore GC×GC/TOFMS as an analytical platform for non-
targeted metabolic profiling of CRC in order to gain greater metabolic space 
coverage as compared to GC/MS and HR-MAS NMR spectroscopy. This 





5.2.1. Clinical population and tissue samples 
 
The same cohort of tissue specimens that was used for GC/MS analysis was 
subjected to analysis by GC×GC/TOFMS. Please refer to Table 3.1. of 






5.2.2. Validation of analytical performance of GC×GC/TOFMS  
 
As the same set of samples which were analyzed by GC/MS was used for 
GC×GC/TOFMS analysis and the same sample preparation protocol (section 
2.2.3. of Chapter 2) was followed, separate sample stability studies were not 
further performed. The different sample stability studies were carried out 
while validating our GC/MS method and are described in Chapter 2. Due to 
the large number of chromatographic peaks generated by GC×GC/TOFMS 
(about 800 peaks in the case of colon tissue samples) and inherent 2D nature 
of separation, the applicability and feasibility of conventional analytical 
method validation parameters is limited. Therefore to evaluate the analytical 
performance of GC×GC/TOFMS we adopted an alternative approach in which 
we used quality control (QC) samples in conjunction with chemometric 
analyses. The QC samples were prepared by processing about 20 mg aliquots 
of a normal colon tissue sample, as per our developed sample preparation 
protocol (section 2.2.3. of Chapter 2). These QC samples were injected 
periodically during analysis of the clinical samples. After analysis, the 
chromatographic data generated for the QC samples were subjected to 
chemometric analyses along with that of the clinical samples. The analytical 
performance of GC×GC/TOFMS was considered as satisfactory if the QC 







5.2.3. GC×GC/TOFMS analysis 
 
Tissue samples for GC×GC/TOFMS analysis were prepared as per the 
procedure described in section 2.2.3 of Chapter 2. The samples were 
randomized to nullify any system effect before analysis. Analysis was carried 
out using a Pegasus GC×GC/TOFMS (Leco Corp., St. Joseph, MI, USA) 
system comprising an Agilent 7890 GC and Pegasus IV TOFMS. A dual-
stage, quad jet thermal consumable free modulator was used. The N2 gas for 
the modulator was chilled by a closed-loop immersion cooler (FTS, Stone 
Ridge, NY, USA) which was set at a temperature of -80°C. Helium was used 
as the carrier gas at a constant flow rate of 1.0 mL/min. An injection volume 
of 1 µL and an injector split ratio of 1:10 were used. A DB-1 [30 m × 250 μm 
(i.d.) × 0.25 μm] fused silica capillary column (Agilent J&W Scientific, 
Folsom, CA, USA) and a Rxi
®
-17 [1 m × 100 μm (i.d.) × 0.10 μm] fused silica 
capillary column (Restek Corp., Bellefonte, PA, USA) were used as the 
primary and secondary columns, respectively. The temperature gradient used 
for the primary column was 60ºC for 0.2 min, increased at 5ºC/min to 125ºC 
and further increased at 15ºC/min to 270ºC where it was kept for 25 min. The 
secondary column was always maintained at 10°C higher temperature than the 
primary column temperature. The modulator temperature offset was +20°C 
relative to the secondary column. The solvent acquisition delay was 500 s. A 
modulation period of 4 s with hot pulse time of 0.8 s was used. The injector, 
front inlet, transfer line, and ion source temperatures were kept constant at 
250, 250, 270 and 200°C, respectively. The MS was operated using EI mode 
(70 eV) at a detector voltage of 1650 V. A scan range of m/z 50 to 650 and an 
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acquisition rate of 100 spectra/s were used for data acquisition. Chromatogram 
acquisition, noise reduction, baseline correction, smoothing, library matching 
and peak area calculation were carried out using the ChromaTOF software 
(Version 4.21, Leco Corp.). Only peaks having signal-to-noise ratio (s/n) 
greater than 100 were considered and peak area was computed by the software 
using unique mass. Peaks with SI more than 70% were assigned compound 
names while those having less than 70% SI were considered as unknown 
compound. Identities of selected metabolites were further confirmed by 
comparison of their mass spectra and Rt with those obtained using 
commercially available reference standards. 
 
5.2.4. GC×GC/TOFMS data analysis 
 
The Statistical Compare feature of ChromaTOF software was used to align 
analytes from chromatograms belonging to different samples and to generate 
data table consisting of sample names and area of analytes.  The normalization 
of each sample was done by dividing the area of each analyte by the total peak 
area of all the analytes present in the sample. The normalized data was 
subjected to PCA to identify outliers and innate clustering trends using 
SIMCA-P software (Umetrics, Umeå, Sweden). The data were mean-centered 
and UV-scaled during chemometric data analysis. After PCA, OPLS-DA was 
performed to generate a model discriminating CRC from normal tissue 
specimens and to identify marker metabolites responsible for such 
discrimination. OPLS-DA was also carried out using anatomical site and 
Duke‟s stage of CRC as classifiers. An independent „t‟ test with Welch‟s 
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correction using SPSS software (Version 11.0, SPSS Inc., Chicago, IL, USA) 
was used for the comparison of the marker metabolite levels to determine their 
significant differences between the CRC and normal tissue groups (p < 0.01 
was considered to be statistically significant).  ROC analysis was also 
performed using GraphPad Prism software (Version 5.02., GraphPad Software 
Inc., La Jolla, CA, USA) to validate the robustness of the OPLS-DA model 
using the cross-validated predicted Y values. 
 
5.3. Results and discussion 
 
GC×GC/TOFMS was used for the non-targeted metabolic profiling of 31 
tumor samples and 32 normal tissues obtained from 31 CRC patients. Figure 
5.1. shows the surface  and  contour  plots  of  a  representative  
GC×GC/TOFMS  chromatogram  of human colon tissue. The analytical 
performance of GC×GC/TOFMS was found to be satisfactory as the PCA plot 
of all the samples showed that all the QC samples were clustered together 
(Figure 5.2.). The OPLS-DA model [2 LV, R
2
Y = 0.979, Q
2
(cum) = 0. 932] 
generated from the GC×GC/TOFMS data and the corresponding ROC curve 
(AUC = 1.000) are shown in Figures 5.3. and 5.4., respectively. However no 
valid OPLS-DA model was obtained using anatomical site of CRC tumor or 
Duke‟s stage as classifier. The 44 marker metabolites identified on the basis of 
the OPLS-DA model (Figure 5.3.) and which were found to be significantly 
different between CRC and normal tissue group (p < 0.01, Welch „t‟ test) are 
summarized in Table 5.1. All the marker metabolites except squalene, AA, 
mannose, galactose, glucose, ribitol, fumarate, malate, oxalate and succinate,  
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Figure 5.1. A. Surface plot of GC×GC/TOFMS chromatogram of human 
colon tissue. 
B. Contour plot of GC×GC/TOFMS chromatogram of human colon tissue 





Figure 5.2. PCA plot of CRC and normal tissues along with QC samples 




Figure 5.3. OPLS-DA scores plot discriminating CRC from normal tissues 










Figure 5.4. ROC curve determined using the cross-validated predicted Y 
values of the GC×GC/TOFMS OPLS-DA model. 
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were found to be higher in CRC tissues as compared to normal tissues (Table 
5.1.). Out of the 44 marker metabolites identified by GC×GC/TOFMS, 19 
metabolites were also identified by GC/MS and 3 metabolites by HR-MAS 
NMR spectroscopy. The directions of fold changes of the common marker 
metabolites were found to be consistent across the three different analytical 
platforms reinforcing the clinical validity and robustness of these marker 
metabolites in characterizing CRC. In this section we focus our discussion 
only on those exclusive marker metabolites which were identified by 
GC×GC/TOFMS as the other marker metabolites identified by either GC/MS 
or HR-MAS NMR spectroscopy have been discussed in Chapters 3 and 4. The 
HMDB (Wishart et al., 2009) and the KEGG (Kanehisa and Goto, 2000) were 
utilized to get information about the identified marker metabolites and their 




























 Amino acid Standard 115.2 <0.0001 
L-Proline
a
 Amino acid Standard 83.3 <0.0001 
L-Phenylalanine
a
 Amino acid Standard 28.9 <0.01 
L-Alanine Amino acid Standard 90.9 <0.001 
L-Leucine Amino acid Standard 82.2 <0.0001 
L-Valine Amino acid Standard 88.2 <0.001 
L-Serine Amino acid Standard 42.3 <0.01 
L-Threonine Amino acid Standard 95.5 <0.01 
L-Isoleucine Amino acid Standard 148.7 <0.0001 
Picolinic acid Amino acid NIST 94.1 <0.0001 
L-Methionine Amino acid Standard 30.8 <0.01 
L-Aspartic acid Amino acid Standard 28.9 <0.01 
β-Alanine Amino acid NIST 184.9 <0.001 
Aminomalonic acid Amino acid NIST 311.9 <0.0001 
1-Methyl-hydantoin Amino ketone NIST 34.3 <0.001 
a
 Profiled also by GC/MS. 
b 
Profiled also by GC/MS and HR-MAS NMR spectroscopy. 
c 
Metabolite identification using standard compound or NIST library search. 
d
 Positive and negative percentages indicate higher levels of metabolites in 
cancer and normal tissues, respectively. 
e
 Statistical p value calculated using the independent „t‟-test with Welch‟s 
































 Fatty acid NIST 52.5 <0.0001 
Margaric acid
a
 Fatty acid NIST 21.6 <0.01 
Oleic acid
a
 Fatty acid NIST 118.4 <0.0001 
Stearic acid
a
 Fatty acid NIST 20.5 <0.001 
Arachidonic acid
a
 Fatty acid Standard -38.7 <0.001 
11-Eicosenoic acid
a
 Fatty acid NIST 25.6 <0.01 
Myristic acid  Fatty acid  NIST 86.1  <0.0001  
Pentadecanoic acid  Fatty acid  NIST 71.1  <0.01  
Linolenic acid  Fatty acid  NIST 128.2  <0.0001  
Lignoceric acid  Fatty acid  NIST 122.9  <0.0001  
Phosphate
a
  Inorganic acid  Standard 47.1  <0.0001  
D-Mannose
a
  Monosaccharide  Standard -50.9  <0.01  
D-Galactose
a
  Monosaccharide  Standard -72.6  <0.01  
D-Glucose
b
  Monosaccharide  Standard -91.0  <0.0001  
L-Arabinose  Monosaccharide  NIST 54.5  <0.0001  
a
 Profiled also by GC/MS. 
b 
Profiled also by GC/MS and HR-MAS NMR spectroscopy. 
c 
Metabolite identification using standard compound or NIST library search. 
d
 Positive and negative percentages indicate higher levels of metabolites in 
cancer and normal tissues, respectively. 
e
 Statistical p value calculated using the independent „t‟-test with Welch‟s 
































  Organic acid  Standard 94.6  <0.0001  
Fumarate
a
  Organic acid  Standard -14.7  <0.01  
Malate
a
  Organic acid  Standard -64.3  <0.0001  
Oxalate  Organic acid  Standard -118.3  <0.001  
Succinate  Organic acid  Standard -62.5  <0.01  
Maleic acid  Organic acid  Standard 43.6  <0.0005  
Pantothenic acid  Organic acid  NIST 188.2  <0.005  
Glycerol  Polyol  Standard 59.9  <0.0001  
Ribitol  Polyol  Standard -59.1  <0.005  
1-Monooleoylglycerol
a
  Polyol derivative  NIST 97.5  <0.01  
Uracil  Pyrimidine derivative  Standard 86.3  <0.0001  
Uridine
a
  Pyrimidine nucleoside  Standard 141.0  <0.0001  
Cholesterol
a
 Steroid  Standard 65.5  <0.0001  
Squalene Triterpene NIST -34.5 <0.01 
a
 Profiled also by GC/MS. 
b 
Profiled also by GC/MS and HR-MAS NMR spectroscopy. 
c 
Metabolite identification using standard compound or NIST library search. 
d
 Positive and negative percentages indicate higher levels of metabolites in 
cancer and normal tissues, respectively. 
e
 Statistical p value calculated using the independent „t‟-test with Welch‟s 








 Recent studies suggest that the enzyme phosphoglycerate 
dehydrogenase (PHGDH) which oxidizes the glycolytic intermediate 3-
phosphoglycerate to initiate serine biosynthesis, is over-expressed in breast 
cancer and helps cancer cells to proliferate rapidly (Locasale, et al., 2011; 
Possemato et al., 2011). This further implies that the suppression of PHGDH 
can be a new therapeutic target.  Using GCxGC/TOFMS we observed higher 
levels of L-serine and glycine in cancer tissues which indicated branching of 
serine biosynthetic pathway from glycolysis and its upregulation, the end 
product of which is glycine. Our findings using human CRC tissue samples, 
were actually made before the findings by Locasale et al. and Possemato et al. 
and suggested that there is also a possible existence of this particular form of 
metabolic deregulation in human CRC.  
Squalene acts as the metabolic precursor of cholesterol. Reduced level 
of squalene justifies the corresponding increase in cholesterol in CRC tissues. 
Moreover squalene has been shown to possess chemopreventive effect in rat 
models of CRC. It is a constituent of dietary oils like olive oil and this finding 
further emphasizes the influence of diet in CRC development (Rao et al., 
1998). The endogenous levels of several fatty acids (myristic acid, 
pentadecanoic acid, lignoceric acid, linolenic acid in addition to those detected 
by GC/MS except AA), glycerol, cholesterol and polyol derivatives (Table 
5.1.) were found to be significantly elevated in CRC tissue. This indicated the 
high biosynthetic rate of  these  metabolites  to  meet  energy  demand  and  
rapid  generation  of  lipid bio-components of cell membrane in fast 
proliferating tumor cells (Garber, 2006; Ong et al., 2010). Apart from this, 
previous studies have shown that such fatty acids act as tumor promoters in 
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murine cancer models and increase the risk of CRC in humans (Reddy, 1986, 
1992). Lignoceric acid is a very long chain fatty acid (24 carbon atoms long) 
which acts as a tissue marker of peroxisomal disorder and is associated with 
perturbation in lipid metabolism (Wishart et al., 2009). This metabolite was 
found in higher levels in CRC tissues than in normal tissues suggesting 
definite alteration of lipid metabolism in CRC.     
In accordance with other studies (Denkert et al., 2008; Ong et al., 
2010), we also found that several proteinogenic amino acids were significantly 
elevated in CRC tissues (Table 5.1.). This observation can be attributed to 
increased protein synthesis in malignant cells as seen in different forms of 
cancer including CRC (Griffin and Shockcor, 2004). β-Alanine and L-proline 
play important role in osmoregulation (Burg and Ferraris, 2008). Higher levels 
of these two amino acids along with taurine and scyllo-inositol (identified by 
HR-MAS NMR spectroscopy) in CRC suggested altered osmoregulation. 
Aminomalonic acid is an amino acid which originates from defects in protein 
synthesis. Higher level of this metabolite in CRC suggested the possible 
existence of erratic protein synthesis (Wishart et al., 2009).  
Picolinic acid is produced under inflammatory conditions and acts as 
an inducer of some inflammatory cytokines (Bosco et al., 2000; Wishart et al., 
2009). Elevated levels of picolinic acid along with reduced levels of AA 
(major metabolic precursor of eicosanoids which act as inflammatory 
mediators) in CRC tissue further emphasize the significant association of 
inflammation with CRC (Kashfi and Rigas, 2005; Sano et al., 1995; Shureiqi 
and Lippman, 2001; Smith, 1992; Soslow et al., 2000; Soumaoro et al., 2006). 
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Succinate and oxalate were found to be reduced in CRC tissues along 
with fumarate and malate (also identified by GC/MS). This finding 
corroborated with the perturbation of TCA cycle in response to altered energy 
demand in CRC.  
Higher level of pantothenic acid (vitamin B5) was found in CRC as 
compared to normal colon tissues. Similar observation was obtained 
previously in a rat model of colon adenocarcinoma (Baker et al., 1981) 
suggesting that high vitamin B5 content is required for catalysis of metabolism 
associated with rapid proliferation of tumors. 
A comparison of the three analytical platforms that we used for the 
non-targeted metabolic profiling of CRC is presented in Table 5.2. Although 
GC×GC/TOFMS was found to be superior to GC/MS and HR-MAS NMR in 
terms of metabolic space coverage, HR-MAS NMR spectroscopy proved to be 
more advantageous in terms of the ease of sample preparation and the shorter 
total analysis time. Moreover, HR-MAS NMR spectroscopy was the only 
platform which was able to discriminate anatomical site of CRC tumor while 
the other two platforms failed to do so. It was not possible to cover all the 
metabolite classes using the three analytical platforms. Therefore it is always 
recommended to use multiple and complimentary analytical platforms to cover 
as much metabolic space as possible. Metabolite classes such as lyso-
phospholipids, sphingolipids, oxylipins, glycolipids, glycerolipids, 
glucoronides, pterins, quinones, lipoamides, carnitines, retinoids are some of 




In some cases metabolite identification was not possible because of 
low SI. These “missed” or “unknown” metabolites constituted about 17% of 
the total metabolites analyzed by the method. However this amount can be an 
overestimate particularly in case of GCxGC/TOFMS data because second 
dimensional separation can split a single peak of an unknown analyte into 
multiple peaks resulting in an apparent increase in the number of unknown 
analytes. The unknown metabolites constitute a constant challenge in the field 
of metabolic profiling. Online databases such as the Golm‟s database and the 
HMDB database could be used to identify the unknowns in some cases but the 
coverage of such databases is still limited and in future collaborative efforts 
are required to build more comprehensive databases which can aid in finding 
the identity of unknowns. Even if any unknown metabolite contributed 
significantly to the chemometric separation of CRC and normal tissue, it was 
not considered to be significant as it did not provide any useful information 
regarding metabolic pathway or aided in biological interpretation of metabolic 
profiling results.   
In order to enhance the information obtained from non-targeted 
metabolic profiling of CRC, it was pertinent to map and cross-compare the 
marker metabolites identified using all the three analytical platforms with 
regards to the human metabolic pathways. For this purpose the KegArray 
application (Version 1.2.3) of KEGG was used. This application facilitated the 
association of metabolites with organism specific KEGG metabolic pathway 
maps. The findings about the key sets of marker metabolites, related metabolic 






GC×GC/TOFMS was able to provide coverage of comparatively more 
metabolic space as evident from the identification of 44 marker metabolites 
belonging to various chemical classes. A robust OPLS-DA model capable of 
discriminating CRC from normal tissue groups was generated on the basis of 
GC×GC/TOFMS metabolic profiles. However no valid OPLS-DA model was 
obtained using the Dukes stage or anatomical site of CRC as classifier. The 
marker metabolites identified using all the three analytical platforms were 
associated with perturbations in metabolic pathways such as glycolysis, TCA 
cycle, lipid metabolism, amino acid metabolism and nucleotide metabolism. 
Deregulation of these metabolic pathways suggested the existence of 
conditions like tissue hypoxia, altered osmoregulation, rapid proliferation, 
high energy demand of cancer cells and inflammatory environment in CRC. 
These perturbations of metabolic pathways shed light on the carcinogenesis of 




Table 5.2. Comparison of different analytical platforms used for non-targeted metabolic profiling of CRC. 
 
Parameters HR MAS NMR GC/MS GC×GC/TOFMS 
Sample preparation  simple tedious tedious 
Total analysis time  40 min 200 min 190 min 
No. of chromatographic peaks  not applicable ~75 ~800 
No. of marker metabolites  9 19 44 
Chemical class of metabolites  acyl phosphate, lipid, amino 
acid, monosaccharide, polyol,  
organic acid, choline 
containing compounds  
monosaccharide, amino acid, 
steroid, organic acid, fatty acid, 
polyol, polyol derivative, 
inorganic acid, pyrimidine 
nucleoside. 
monosaccharide, amino acid, 
triterpene, amino ketone, steroid, 
organic acid, fatty acid, polyol 
derivative, inorganic acid, 




(cum) of OPLS-DA model  
(CRC vs. Normal) 
 
0.779 0.784 0.934 
Q
2
(cum) of OPLS-DA model 
(Anatomical site of tumor) 












 Major metabolic process
b
 Biological relevance 
D-Mannose (↓) Fructose and mannose metabolism Carbohydrate metabolism Enhanced carbohydrate metabolism 
especially glycolytic pathway to meet 
high energy demand of cancer cells under 
hypoxic conditions 
D-Galactose (↓) Galactose metabolism Carbohydrate metabolism 
D-Glucose (↓) Glycolysis Carbohydrate metabolism 
Lactate (↑) Glycolysis Carbohydrate metabolism 
Ribitol (↓) Pentose and glucuronate interconversions Carbohydrate metabolism 
Fumarate (↓) TCA cycle Carbohydrate metabolism Deregulation of TCA cycle caused by 
altered energy demand in cancer cells Malate (↓) TCA cycle Carbohydrate metabolism 
Succinate (↓) TCA cycle Carbohydrate metabolism 
Oxalate (↓) Glyoxylate and dicarboxylate metabolism Carbohydrate metabolism  
Palmitic acid (↑) Fatty acid biosynthesis Lipid metabolism Increased biosynthesis of lipid 
components of cell membrane to cope up 
with rapid growth of cancer cells 
Oleic acid (↑) Fatty acid biosynthesis Lipid metabolism 
Stearic acid (↑) Fatty acid biosynthesis Lipid metabolism 
γ-Linolenic acid (↑) Fatty acid biosynthesis Lipid metabolism 
Lignoceric acid (↑) Fatty acid biosynthesis Lipid metabolism 
Myristic acid (↑) Fatty acid biosynthesis Lipid metabolism 
Pentadecanoic acid (↑) Fatty acid biosynthesis Lipid metabolism 
Margaric acid (↑) Fatty acid biosynthesis Lipid metabolism 
Glycerol (↑) Glycerolipid metabolism Lipid metabolism 
Phosphocholine (↑) Glycerophospholipid metabolism Lipid metabolism 
Phosphoethanolamine (↑) Glycerophospholipid metabolism Lipid metabolism 
Cholesterol
c
 (↑) Steroid biosynthesis Lipid metabolism 
Squalene (↓) Steroid biosynthesis Lipid metabolism 
Cholesterol
c
 (↑) Primary bile acid biosynthesis Lipid metabolism Bile acids may act as tumor promoters or 
carcinogens in CRC 
a
 Metabolites are grouped together on basis of biological relevance, (↑): Elevated in CRC (↓): Reduced in CRC 
b
 Related to metabolites using KEGG 
c
 Metabolites found to be involved in more than one relevant metabolic pathway 
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 Major metabolic process
b
 Biological relevance 
L-Aspartic acid (↑) Alanine, aspartate and glutamate metabolism Amino acid metabolism Increased synthesis of proteins to meet 
demand of rapidly proliferating cancer 
cells 
L-Alanine (↑) Alanine, aspartate and glutamate metabolism Amino acid metabolism 
N-Methyl-hydantoin (↑) Arginine and proline metabolism Amino acid metabolism 
Glycine
c
 (↑) Glycine, serine and threonine metabolism Amino acid metabolism 
L-Serine (↑) Glycine, serine and threonine metabolism Amino acid metabolism 
L-Threonine (↑) Glycine, serine and threonine metabolism Amino acid metabolism 
L-Methionine (↑) Methionine biosynthesis Amino acid metabolism 
L-Phenylalanine (↑) Phenylalanine biosynthesis Amino acid metabolism 
L-Proline
c
 (↑) Proline biosynthesis Amino acid metabolism 
L-Leucine (↑) Valine, leucine and isoleucine biosynthesis Amino acid metabolism 
L-Isoleucine (↑) Valine, leucine and isoleucine biosynthesis Amino acid metabolism 
L-Valine (↑) Valine, leucine and isoleucine biosynthesis Amino acid metabolism 
L-Proline
c
 (↑) ATP-binding cassette (ABC) transport Membrane transport Osmoregulation to maintain the 
homeostasis of rapidly proliferating 
cancer cells 
β-Alaninec (↑) β-Alanine metabolism Amino acid metabolism 
Scyllo inositol (↑) Inositol phosphate metabolism Carbohydrate metabolism 
Taurine (↑) Taurine and hypotaurine metabolism Amino acid metabolism 
Glycine (↑) Purine metabolism Nucleotide metabolism Increased nucleotide biosynthesis to meet 
demand of rapidly proliferating cancer 
cells 
Uracil (↑) Pyrimidine metabolism Nucleotide metabolism 
Uridine (↑) Pyrimidine metabolism Nucleotide metabolism 
β-Alaninec (↑) Pyrimidine metabolism Nucleotide metabolism 
Arachidonic acid (↓) Eicosanoid biosynthesis Lipid metabolism Inflammation associated with CRC 
development Picolinic acid (↑) Tryptophan metabolism Amino acid metabolism 
a
 Metabolites are grouped together on basis of biological relevance, (↑): Elevated in CRC (↓): Reduced in CRC 
b
 Related to metabolites using KEGG 
c





DEVELOPMENT AND VALIDATION OF AN UPLC/MS/MS 
METHOD FOR TARGETED PROFILING OF EICOSANOIDS AND 




Different analytical platforms such as enzyme immunoassay (EIA) (Nicosia et 
al., 1992), radioimmunoassay (RIA) (Levine, 1986; Pugh and Thomas, 1994; 
Rigas et al., 1993; Rigas and Levine, 1984), GC/MS, gas chromatography 
tandem mass spectrometry (GC/MS/MS) (Capdevila et al., 1981, 1992; Catella 
et al, 1990; Hubbard et al., 1986; Tsikas, 1998; Tsukamoto et al, 2002), 
capillary electrophoresis with ultraviolet detection (Vandernoot and 
VanRollins, 2002), HPLC with fluorescence detection (Maier  et al., 2000; 
Nithipatikom  et al., 2000; Yue et al., 2004), LC/MS and liquid 
chromatography tandem mass spectrometry (LC/MS/MS) (Bolcato et al., 
2003; Hishinuma et al., 2007; Kempen et al., 2001; Margalit et al., 1996; 
Takabatake et al., 2002; Yang et al., 2006; Yue et al., 2007), have been used to 
determine selected sub-sets of the eicosanoids. Although GC/MS and 
GC/MS/MS with negative ion chemical ionization are the most commonly 
used techniques for the eicosanoids, tedious sample preparation steps 
including derivatization are necessary before analysis. EIAs and RIAs cannot 
determine eicosanoids simultaneously and are affected by cross reactivity. 
Moreover RIAs suffer from the disadvantage of radiation hazards. Fluorescent 
HPLC method is applicable but it suffers from long elution time and high 
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background noise (Yue et al., 2004). Although various LC/MS or LC/MS/MS 
methods have been used for identification and quantification of eicosanoids in 
different biological matrices such as microsomal incubates (Bolcato et al., 
2003), human synovial cell-culture (Takabatake et al., 2002), human blood 
(Margalit et al., 1996), rat brain tissue (Yue et al., 2007), mouse prostate tissue 
(Yang et al., 2006), human lung cancer cells, rat leukemia cells (Kempen et 
al., 2001) and mouse bone marrow-derived mast cells (Hishinuma et al., 
2007), they have not been explored for the determination of eicosanoids in 
human colon tissue. Unlike LC/MS, RIA (Pugh and Thomas, 1994; Rigas et 
al., 1993) and GC/MS (Bennett et al., 1987; Giardiello et al., 1998; Yang et 
al., 1998) were reported for the determination of eicosanoids in human colon 
tissue. 
In this chapter, we report the development and validation of an 
UPLC/MS/MS method for the simultaneous and fast determination of AA and 
biologically relevant eicosanoids in human colorectal tissue viz. prostaglandin 
E2 (PGE2), prostacyclin (PGI2) [assayed as its stable hydrolytic product 6-
keto-prostaglandin1α (6-k-PGF1α)], prostaglandin D2 (PGD2), leukotriene B4 
(LTB4), thromboxane A2 (TXA2) [assayed as its stable breakdown product 
thromboxane B2 (TXB2)], 13S-hydroxy-9Z,11E-octadecadienoic acid (13S-
HODE), 12-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12-HETE) and 8-
hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid (8-HETE). As prostaglandin 
F2α (PGF2α) does not play a role in CRC carcinogenesis, it was not profiled in 
our study (Wang and Dubois, 2008). As 15-LOX-2 which catalyze the 
conversion of AA to 15-hydroxy eicosatetraenoic acid (15-HETE) is not 
expressed in human colon tissue, 15-HETE was also excluded from our study 
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(Ikawa et al., 1999).  Although 13S-HODE is not a metabolic product of AA, 
it was included in our study as it has shown anticarcinogenic effect in CRC 






Butylated hydroxyl toluene (BHT), PGE2, 6-k-PGF1α, PGD2, LTB4, TXB2, 
13S-HODE, 12-HETE, 8-HETE and deuterated prostaglandin E2 (PGE2-d4) 
were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). 
PGE2-d4 was used as the internal standard (IS). AA and citric acid were 
obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA). HPLC-grade 
methanol and acetonitrile (ACN) were purchased from Tedia Company Inc. 
(Fairfield, OH, USA). HPLC-grade ethyl acetate and n-hexane were purchased 
from Fisher Scientific (Leicestershire, UK). Ammonium acetate and formic 
acid (FA), both of 99% purity, were purchased from VWR International Ltd. 
(Leicestershire, UK). Ultra pure grade phosphate buffer saline (PBS) was 
obtained from 1
st
 Base Private Limited (Singapore). Water used for the study 
was purified with a Milli-Q water purification system (Millipore, Billerica, 
MA, USA). Bovine serum albumin (BSA) and Coomassie
®
 Brilliant Blue G-






6.2.2. Human colon tissue samples 
 
Human colon tissues were provided by the Department of Colorectal Surgery, 
SGH, Singapore. The utilization of human tissue was approved by the 
SingHealth Centralised Institutional Review Board (CIRB), Singapore (CIRB 
reference number 2009/723/B). For method development and validation, one 
representative normal colon tissue (3 g) was snap-frozen immediately 
following surgery and then stored at -80ºC until processing. The tissue was 
subsequently cut and divided into tissue masses of about 10 mg each for the 
UPLC/MS/MS method development and validation. 
 
6.2.3. Sample preparation 
 
For the development of the sample preparation protocol, previously reported 
sample preparation strategies were used as references (Kempen et al., 2001; 
Yang et al., 2006). About 10 mg of each human colon tissue was weighed 
accurately and transferred to a 2 mL Eppendorf tube and 500 µL of ice-cold 
PBS containing 0.1% BHT was added to each sample. 20 µL of 1N citric acid 
and 10 µL of a 500 ng/mL stock solution of PGE2-d4 (IS) were added to each 
sample.  The samples were then homogenized for 2 min at a frequency of 25 
Hz using 4 mm inner diameter metal balls in a Retsch MM400 ball mill (Haan, 
Germany). Each homogenate was subsequently transferred to a 15 mL glass 
centrifuge tubes. 1 mL of n-hexane:ethyl acetate (1:1, v/v) was added to the 
aqueous homogenate and vortex-mixed for 2 min. Each sample was then 
centrifuged at 1800 g units for 3 min. The upper organic layer was collected 
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and the extraction process was repeated two more times. After extraction, 10 
µL of the lower aqueous layer was kept aside for protein assay as the amount 
of individual eicosanoids and AA in each tissue was normalized with respect 
to the total protein content. The organic phases obtained from three extractions 
were pooled and then evaporated to dryness under a stream of nitrogen at 
room temperature (24°C) using a Turbovap LV (Caliper Life Sciences, 
Hopkinton, MA, USA). Each sample was then reconstituted in 50 µL of 
methanol and used for UPLC/MS/MS analysis. 
 
6.2.4. Protein assay 
 
The protein content in tissue samples was determined using the Bradford assay 
via a 96 well plate format. The dye reagent was prepared by diluting 1 part of 
Coomassie
®
 Brilliant Blue G-250 dye concentrate with 4 parts of water 
followed by filtration to remove particulates. Protein standard solution of BSA 
(100 µg/mL) was prepared in PBS containing 0.1% BHT. For preparation of 
calibration curve, 2, 5, 10, 20 and 50 µL of the protein standard solution with 
corresponding 98, 95, 90, 80 and 50 µL of PBS containing 0.1% BHT were 
added in separate wells followed by addition of 25 µL of dye reagent to each 
well. For tissue samples, 10 µL of the lower aqueous layer obtained during 
sample preparation, 90 µL of PBS containing 0.1% BHT and 25 µL of dye 
reagent were added to each well. Solutions were mixed using a microplate 
mixer and incubated at room temperature (24ºC) for 5 min. The absorbance 
was then measured at 595 nm using a Tecan Infinite M200 microplate reader 
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(Tecan Group Ltd., Männedorf, Switzerland). The protein content in each 
sample was determined from the standard calibration curve. 
 
6.2.5. UPLC/MS/MS analysis 
 
Analysis of AA and eicosanoids was performed using an ACQUITY UPLC 
system (Waters, Milford, MA, USA) coupled to a 3200 QTRAP hybrid triple 
quadrupole linear ion trap mass spectrometer (Applied Biosystems, Foster 
City, CA, USA) equipped with a Turbo Ion Spray electrospray ionization 
(ESI) source. Multiple reaction monitoring (MRM) experiments were 
performed using negative ESI ionization mode. The dwell time used for all 
MRM experiments was 50 ms. The optimized source-dependent and 
compound-dependent MS parameters for the analytes are shown in Table 6.1. 
The collision-activated dissociation (CAD) gas was set to „Medium‟ 
throughout the experiments. The interface heater was kept on to maximize the 
ion signal and to avoid contamination of the ion optics. Chromatographic 
separations were carried out on an ACQUITY UPLC BEH C18 (1.7 µm 100 × 
2.1 mm i.d.) column (Waters, Milford, MA, USA). The column and 
autosampler temperature were maintained at 45 and 4 °C, respectively. The 
optimized mobile phase consisted of 0.1% FA in water (solvent A) and 0.1% 
FA in ACN (solvent B). The mobile phase flow rate was 0.4 mL/min. The 
optimized elution condition is shown in Table 6.2. A partial loop with needle 
overfill injection mode was used and the injection volume was 2 µL. The 
analysis time for each sample was 5.5 min. Data acquisition and processing 
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were performed using the Analyst software (Version 1.4.2, Applied 
Biosystems, Foster City, CA, USA). 
 
6.2.6. Method validation 
 
US-FDA guidelines for bioanalytical method validation and International 
Conference on Harmonization (ICH) guidelines on analytical method 
validation with suitable modifications were followed for the method validation 
studies (FDA, 2001; ICH 1994, 1996). During method validation, parameters 
such as selectivity, sensitivity, matrix effect, linearity, accuracy, precision, 
extraction efficiency and autosampler stability of samples were investigated. 
Calculations of method validation results were carried out using the Microsoft 




Selectivity of the developed UPLC/MS/MS method was investigated by 
comparing the chromatograms of blank and standard samples. The blank 
sample comprising 500 µL of ice-cold PBS containing 0.1% BHT was 
subjected to sample preparation as described earlier. The standard sample 
containing all the standard metabolites (at concentrations of 10 pg/mg and 5 
ng/mg of colon tissue for eicosanoids and AA, respectively) was used for 





Table 6.1. Optimized source- and compound-dependent MS parameters 
 
Source-dependent parameters 
Curtain gas (psi) 15 
Ion spray voltage (V) -4500 
Temperature (°C)  500 
Nebulizer gas 1 (psi)  40 
Nebulizer gas 2 (psi) 45 
Compound-dependent parameters 













1α  369.2→163.0 -55 -6 -38 -1 
TXB
2 
 369.1→169.2 -35 -4 -26 -1 
PGE
2 
 351.3→271.2 -19 -6 -27 -1 
PGE2-d4 (IS) 355.1→275.3 -30 -5 -27 -2 
PGD
2 
 351.3→189.2 -20 -4 -28 -1 
LTB
4 
 335.1→195.2 -48 -4 -23 -1 
13S-HODE  295.1→277.0 -30 -7 -21 -1 
8-HETE  319.2→155.2 -30 -5 -22 -1 
12-HETE  319.1→179.0 -30 -7 -21 -1 
AA 303.1→259.0 -45 -5 -21 -1 
a







cell exit potential 
 
Table 6.2. Optimized UPLC elution conditions 
 
Time (min) % Solvent A
a





0.00 50 50 6 
3.70 5 95 4 
4.35 5 95 6 
4.50 50 50 6 
5.50 50 50 6 
a 
Solvent A: 0.1% FA in water, solvent B: 0.1% FA in ACN  
b 
Different curves of the UPLC gradient were used to optimize the 






The limit of detection (LOD) and limit of quantification (LOQ) of each 
metabolite were determined as per ICH guidelines (ICH, 1994, 1996). The 
LODs and LOQs of metabolites were calculated using equations 1 and 2 with 
regards to three calibration curves. 
 
LOD = 3.3 × (SD of y intercept) ÷ average slope (equation 1) 
LOQ = 10 × (SD of y intercept) ÷ average slope (equation 2) 
 
In addition to the determination of the LOD and LOQ of individual 
metabolites, it was important to determine the minimal amount of colon tissue 
that was required to produce a reasonably sensitive profiling of endogenous 
eicosanoids and AA. In our method development, different weights of colon 
tissue (5, 10 and 20 mg) were processed and analyzed to determine an optimal 
balance between tissue weight and sensitivity limit of the UPLC/MS/MS 
assay.  
 
6.2.6.3. Matrix effect 
 
The matrix effect was investigated using the post-extraction spike method 
(spiked in matrix extract) in which the peak areas of standard metabolites in 
neat solvent were compared to that obtained from standard metabolites spiked 
in matrix post-extraction (Bottcher et al., 2007). As all the eicosanoids and AA 
profiled in our study were present endogenously in human colon tissue, it was 
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impossible to obtain „blank‟ human colon tissue devoid of these metabolites. 
To negate the endogenous occurrence of these metabolites which could 
interfere with our evaluation of matrix effect, the peak area observed in the 
case of standard metabolites spiked in matrix post-extraction was corrected by 
subtracting the basal peak area of metabolites in unspiked matrix. For this 
purpose, one representative normal colon tissue was divided into aliquots of 
about 10 mg each and homogenized in a ball mill using 500 µL of ice-cold 
PBS containing 0.1% BHT for each sample. The homogenates thus obtained 
were pooled and mixed so that a matrix homogenate with uniform basal 
amount of endogenous metabolites was obtained. The homogenate was further 
redistributed into 500 µL aliquots. Each aliquot was then subjected to 
extraction as per our sample preparation method. Standard metabolites were 
spiked subsequently into the matrix extract at low (30 pg/mg and 15 ng/mg of 
colon tissue for eicosanoids and AA, respectively), medium (300 pg/mg and 
40 ng/ mg of colon tissue for eicosanoids and AA, respectively) and high 
(4000 pg/mg and 300 ng/mg of colon tissue for eicosanoids and AA, 
respectively) concentration levels. Three replicates were used for each 
concentration level. The basal peak areas of the metabolites in matrix were 
determined using three replicates of 500 µL of matrix homogenate devoid of 
any standard metabolite. The matrix effect was then evaluated using equation 
3. 
Matrix effect = [1-(A1 – A2) ÷ A3] × 100 (equation 3) 
where, 
A1 = mean peak area of sample consisting of matrix extract spiked with 
standard metabolite  
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A2 = mean basal peak area of metabolite present in matrix 
A3 = mean peak area of standard metabolite in neat solvent 
 
6.2.6.4. Linearity and accuracy 
 
Stock solutions of standard metabolites were prepared in methanol containing 
0.1% BHT. Due to the unavailability of metabolite-free „blank‟ matrix, the 
standard addition method was adopted to study the linearity and accuracy of 
our assay. The calibration standards and quality control (QC) samples were 
prepared by spiking standard metabolites into 500 µL aliquots of matrix 
homogenate (prepared as per method described in “matrix effect” section and 
having uniform basal amount of metabolites) and then subjecting them to 
sample preparation as described earlier. The concentrations of the metabolites 
in the calibration standards and QC samples were calculated with reference to 
10 mg of colon tissue. For instance, a spiked amount of 500 pg of an 
eicosanoid was considered equivalent to a concentration of 500 pg of 
eicosanoid per 10 mg of colon tissue or 50 pg/mg of colon tissue. The 
concentration range used for calibration of the 8 eicosanoids was 10-5000 
pg/mg of colon tissue whereas that for AA was 5-500 ng/mg of colon tissue. 
As per FDA guidelines for bioanalytical method validation QC samples should 
be used at three different concentrations (Bansal and DeStefano, 2007; FDA, 
2001): 
 Low QC: three times the lower limit of quantification (prepared QC: 3 
times 10 pg/mg i.e 30 pg/mg)  
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 Medium QC: ~mid value of calibration range (prepared QC: 300 
pg/mg) 
 High QC: ~70-85% of higher limit of quantification (prepared QC: 
80% of 5000 pg/mg i.e. 4000 pg/mg). 
Similarly, as per guidelines the QC samples for AA were prepared at three 
concentrations of 15, 40 and 300 ng/mg of colon tissue. The basal peak area of 
a metabolite (determined using three replicates of 500 µL of matrix 
homogenate devoid of any standard metabolite) was subtracted from the 
observed peak areas of the metabolite in calibration samples to account for the 
endogenous occurrence of each metabolite in the matrix. The resulting peak 
areas were divided by the IS peak areas and the ratios were plotted against 
nominal concentration to construct calibration curve for each metabolite. The 
constructed calibration curves were used to determine the concentrations of 
the metabolites in the QC samples. The observed concentration of a metabolite 
in QC sample was corrected by subtracting the basal concentration of the 
metabolite (determined using three replicates of 500 µL of matrix homogenate 
devoid of any standard metabolite). The accuracy of the developed method 
was determined by measuring the percentage deviations of the observed 
concentrations of calibration samples and corrected concentrations of the QC 
samples from the nominal concentrations. A percentage deviation within 







6.2.6.5. Intra- and inter-day precision 
 
Both intra- and inter-day precision were determined using QC samples 
(prepared by standard addition method) at three different nominal 
concentrations viz. 30, 300 and 4000 pg/mg of colon tissue for the 8 
eicosanoids and 15, 40 and 300 ng/mg of colon tissue for AA, respectively. 
The observed concentration of a metabolite in QC sample was corrected as 
discussed previously. The inter-day precision values were determined on three 
different days (first, second and third day of method validation). A relative 
standard deviation (RSD) of 15% was considered as satisfactory in our method 
validation. 
 
6.2.6.6. Autosampler stability 
 
In order to evaluate the stability of the extracted metabolites in the 
autosampler of the UPLC system, 6 human colon tissues of about 10 mg each 
were processed. The extracted samples were injected into the UPLC/MS/MS 
system (0 h), kept in the autosampler (4ºC) and re-injected after 24 h. The 
autosampler stability was determined by comparing the peak area of each 









6.2.6.7. Extraction efficiency 
 
The extraction efficiency was estimated at three concentration levels viz. 30, 
300 and 4000 pg/mg of colon tissue for the 8 eicosanoids and 15, 40 and 300 
ng/mg of colon tissue for AA. The standard metabolites were spiked into 
aliquots of 500 µL of matrix homogenate and processed as per our sample 
preparation protocol. The peak area of a metabolite obtained in the case of 
spiked samples was corrected by subtraction of basal peak area of the 
metabolite (determined using three replicates of 500 µL of matrix homogenate 
devoid of any standard metabolite) and was compared to the peak area of the 
unextracted standard metabolite to determine the extraction efficiency. 
 
6.3. Results and discussion 
 
During our preliminary UPLC/MS/MS method development, different mobile 
phase combinations comprising methanol, 0.1% FA in water, 0.1% FA in 
ACN and 10 mM ammonium acetate were attempted. Based on the quality of 
peak shape and resolution of metabolites, it was confirmed that mobile phase 
comprising 0.1% FA in water and 0.1% FA in ACN yielded the best results. A 
representative UPLC/MS/MS chromatogram of a sample comprising all the 
standard metabolites is shown in Figure 6.1. The total analysis time for each 
sample was short (5.5 min) as compared to previously reported methods 
(Hishinuma et al., 2007; Hubbard et al., 1986; Kempen et al., 2001; Maier et 
al., 2000; Takabatake et al., 2002; Tsukamoto et al., 2002; Yang et al., 2006; 
Yue et al., 2004, 2007). This supported the potential profiling of human CRC 
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samples by clinical laboratories where a short turn-around time is expected 
from the physicians.  
The developed UPLC/MS/MS method was found to be selective with 
regards to all the MRM transitions, as considerable interferences were not 
observed when a blank sample was compared with a sample containing all the 
standard metabolites. While this finding was not unexpected due to the high 
selectivity of MRM experiments, it was pertinent to confirm that the profiled 
metabolites were derived from endogenous AA and eicosanoids and not other 
impurities or co-metabolites. The high selectivity of the method is essential to 
ensure that the observed perturbations in the levels of the inflammatory 
marker metabolites were related to the pathology of CRC and not due to 
chance correlation. The minimal amount of fresh colon tissue required to 
generate a reasonably sensitive profiling of endogenous AA and eicosanoids 
was found to be 10 mg. The establishment of this parameter would help guide 
clinician scientists in understanding and accommodating the requirement of 
the targeted profiling assay in addition to other tests such as histopathological 
assessment and genomic profiling of the colon tissues. While evaluating 
matrix effect (Figure 6.2.), we observed concentration-independent ion 
suppression for all the profiled analytes. The ion suppression due to matrix 
effect was found to be minimal ranging from 5 to 13 % across the three 
investigated concentration levels. 
The calculated values of LOQ and LOD for all the eicosanoids and AA 
are shown in Table 6.3. Although the LOQ and LOD values were found to be 
higher than previously reported methods (Hubbard et al., 1986; Tsukamoto et 
al., 2002; Yue et al., 2004, 2007), our method was found to be sufficiently 
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sensitive as the profiled endogenous levels of AA and eicosanoids in human 
colon tissue were above the respective LOQs and LODs. The UPLC/MS/MS 
method was validated over a calibration range of 10-5000 pg/mg of colon 
tissue for the 8 eicosanoids and 5-500 ng/mg of colon tissue for AA. All the 
analytes showed satisfactory linearity of response as evident from their 
average correlation coefficients of greater than 0.99 (Table 6.3.). The accuracy 
of the developed method was found to be satisfactory as the percentage 
deviations of the observed concentrations of calibration and QC samples from 
the nominal concentrations were all within the acceptable limit of ±15% for all 
the metabolites. The RSDs of all the metabolites in terms of intra- and inter-
day precision were found to be less than 15% (Table 6.4.). In addition, the 
relative stability of each metabolite was found to be within the acceptable 
limits of 100 ± 15% when kept in the autosampler at 4ºC for 24 h (Table 6.4.). 
Our results implied that batch analysis of clinical samples can be performed 
for up to 260 processed samples without compromising the chemical integrity 
of each metabolite. The extraction efficiencies of all the metabolites were 
consistent as indicated by the low SD values (0.94-6.25) and this is critical for 








Figure 6.2. Matrix effect on profiled metabolites (represented by mean 
























1α  10-5000 0.9998 1.52 4.61 
TXB
2 
 10-5000 0.9996 2.73 8.29 
PGE
2 
 10-5000 0.9998 1.74 5.27 
PGD
2 
 10-5000 0.9999 2.43 7.35 
LTB
4 
 10-5000 0.9997 3.19 9.68 
13S-HODE  10-5000 0.9998 2.28 6.91 
8-HETE  10-5000 0.9998 1.24 3.75 














AA 5-500 0.9910 1.24 3.75 
a
 pg/mg of colon tissue; 
b













Intra-day precision  
(% RSD) 

































1α  2.69 4.80 6.22 4.36 5.54 7.21 96.44±3.77 
TXB
2 
 1.89 2.07 5.74 4.41 4.48 5.54 91.77±6.09 
PGE
2 
 3.07 1.99 4.57 2.84 6.46 7.28 94.34±3.67 
PGD
2 
 3.34 3.04 5.83 3.80 6.25 9.79 97.34±1.65 
LTB
4 
 0.63 2.85 2.72 5.31 5.63 4.99 95.32±3.98 
13S-HODE  1.45 3.65 5.41 3.17 3.84 8.07 98.86±6.55 
8-HETE  3.03 3.28 2.39 6.69 5.29 7.49 89.89±3.92 


























AA 2.55 3.67 7.02 3.41 3.76 8.00 87.42±0.82 
a
 pg/mg of colon tissue; 
b 
ng/mg of colon tissue;  
c 
Values are expressed as mean % stability ± SD 
 
 















1α 79.74±6.30 83.85±1.77 86.55±1.58 
TXB
2
 82.28±4.56 85.53±4.82 85.44±3.33 
PGE
2
 78.30±3.12 79.02±2.65 81.37±1.58 
PGD
2
 79.17±9.55 80.70±4.15 83.71±1.84 
LTB
4
 78.78±5.09 85.12±1.53 85.73±1.51 
13S-HODE 75.98±5.27 81.54±3.55 86.62±3.27 
8-HETE 81.16±6.64 85.13±2.54 86.09±2.21 








AA 79.65±7.52 79.87±4.63 83.63±3.65 
a
 Values are expressed as mean ± SD; 
b











An UPLC/MS/MS-based analytical platform was developed and validated 
successfully (in terms of selectivity, sensitivity, matrix effect, precision, 
accuracy, extraction efficiency, linear response and sample stability) for the 
simultaneous profiling of AA and 8 eicosanoids in human colon tissue. Our 
rapid profiling method has the potential to be applied in clinical trials to 
determine the effect of NSAIDs on the endogenous levels of eicosanoids so as 
to better elucidate the mechanism and value of NSAID-based adjuvant therapy 





TARGETED PROFILING OF EICOSANOIDS AND ARACHIDONIC 




Cumulative evidences indicate an association between inflammation and CRC. 
IBD is an important risk factor for the development of CRC. Inflammation is 
also likely to be involved with other forms of sporadic as well as heritable 
CRC (Coussens and Werb, 2002; Mantovani et al., 2008; Kraus and Arber, 
2009; Terzic et al., 2010). The link between CRC and inflammation is further 
reinforced by the preventive effect of NSAIDs in the development of CRC. 
NSAIDs exert their pharmacological effect primarily by inhibiting COX 
enzyme (Chan et al., 2005; Smalley and DuBois, 1997). The expression of 
COX-2 and LOX enzymes which are involved in the biosynthesis of 
eicosanoids gets perturbed in CRC. As a consequence fluctuations in the 
endogenous levels of these eicosanoids are expected which in turn play a 
prominent role in inflammation mediated development of CRC (Kashfi and 
Rigas, 2005; Melstrom et al., 2008; Sano et al., 1995; Soslow et al., 2000; 
Soumaoro et al., 2006; Steele et al., 1999; Wang and Dubois, 2008, 2010). The 
pathways of AA metabolism are shown in Figure 7.1. Therefore, the targeted 
and simultaneous profiling of biologically relevant eicosanoids viz. PGE2, 
PGI2 [assayed as its stable hydrolytic product 6-k-PGF1α (Brash et al., 2007)], 
PGD2, LTB4, TXA2 [assayed as its stable breakdown product TXB2 
(Needleman et al., 1976)], 13S-HODE, 12-HETE, 8-HETE and their major 
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metabolic precursor AA, could shed molecular insight into the role of 
inflammation in CRC carcinogenesis and progression.  
In this chapter the targeted profiling of endogenous AA and 
eicosanoids in matched pairs of CRC and normal tissues obtained from 36 
CRC patients is described. For this purpose, the UPLC/MS/MS method that 




7.2.1. Clinical population and tissue samples 
 
Because of ethical reasons, the amount of tissue that can be removed from 
patients while performing colonoscopy or surgery is limited. The first cohort 
of tissue samples obtained was fully utilized for non-targeted metabolic 
profiling study and this necessitated the use of a second cohort for our targeted 
profiling study. Clinical data such as age, gender, ethnicity, location of 
primary tumor, histological staging and grade were obtained from a 
prospectively maintained computerized database from the Singapore Polyposis 
Registry & the Colorectal Cancer Research Laboratory, Department of 
Colorectal Surgery, SGH. The anatomical and clinicopathological 
characteristics of the clinical tissue samples analyzed by UPLC/MS/MS are 
summarized in Table 7.1. The study population comprised 36 patients with a 
mean age of 59 ± 19 years at the time of cancer diagnosis. There were 20 
males (56%) and 16 females (44%). The majority (80.5%) of the patients were 
Chinese (n = 29), while the remaining comprised 5 Malays (C10, C21, C31, 
120 
 
C33, C34), 1 Indian (C11) and 1 of other ethnicity (C5). There were 28 left-
sided tumors (defined as those arising distal to the splenic ﬂexure) of which 19 
were in the rectosigmoid or rectum. This study was approved by the CIRB at 
the SGH (CIRB reference number 2009/723/B). Matched CRC and normal 
tissues (n = 72) were obtained from the 36 CRC patients during surgery. Fresh 
tumor tissue and normal tissue were snap-frozen immediately following 
excision of the specimen at surgery, then stored at -80 °C until processing. 
Resection of tissue samples were carried out by trained personnel at Singapore 
General Hospital. Tumor specimens were carefully micro-dissected to ensure 
that at least 90% of the analyzed tissue contained cancer cells. Matched 
normal tissues were taken at least 5-10 cm away from the edges of the tumor. 
All CRC tissues and matched normal tissues were cut and weighed accurately 
where approximately 10 mg of each tissue were reserved for UPLC/MS/MS 
analysis. The samples were kept at -80 °C until analysis. 
 
7.2.2. UPLC/MS/MS analysis 
 
Tissue samples for UPLC/MS/MS analysis were prepared as per the procedure 
described in section 6.2.3. of chapter 6. The protein content of each tissue 
sample was determined as per the method described in section 6.2.4. of 
Chapter 6. The same UPLC/MS/MS conditions as mentioned in section 6.2.5. 








7.2.3. UPLC/MS/MS data analysis 
 
The amount of individual eicosanoids and AA in tissue samples as determined 
by UPLC/MS/MS were normalized with respect to total protein content. The 
normalized data were subjected to paired samples ‘t’ test using SPSS software 
(Version 11.0, SPSS Inc., Chicago, IL, USA) to identify metabolites 
significantly different between the CRC and normal tissue groups (p <0.05 
was considered to be statistically significant). In order to verify any probable 
association between the endogenous levels of metabolites and Dukes stage of 
CRC or anatomical site of tumor, Spearman’s correlation analysis was also 
carried out using the SPSS software. 
 
7.3. Results and discussion 
 
The endogenous levels of AA and 8 eicosanoids in 36 matched pairs of CRC 
and normal colon tissues are shown in Figure 7.2. and summarized in Table 
7.2. The levels of these inflammatory mediators in CRC and normal tissues 
were compared statistically using paired samples ‘t’ test. Among the 
metabolites, 6-k PGF1α, PGE2, 12-HETE, 13S-HODE and AA were found to 
be significantly different between CRC and normal colon tissues (p<0.05). 
These inflammatory metabolic markers are therefore important in 
characterizing the phenotype of human CRC. However, it was noted that no 
significant correlation was found between the levels of the profiled 




Figure 7.1. Pathways for Arachidonic acid metabolism. 
COX: cyclooxygenase; LOX: lipoxygenase; AA: arachidonic acid; PG: 
prostaglandin; PGI2: prostacyclin; 6-kPGF1α: 6-keto-prostaglandin1α; HETE: 
hydroxy-eicosatetraenoic acid; EET: epoxy-eicosatrienoic acid; DiHETE: 
dihydroxy-eicosatetraenoic acid; 13S-HODE: 13S-hydroxy-9Z,11E-




















N1 C1 Sigmoid Adenocarcinoma MD T2N2M0 C 
N2 C2 Sigmoid Adenocarcinoma MD T3N2M0 C 
N3 C3 Hepatic flexure Adenocarcinoma PD T3N2M0 C 
N4 C4 Rectosigmoid Adenocarcinoma MD T3N0M0 B 
N5 C5 Rectum Adenocarcinoma MD T2N0M0 A 
N6 C6 Rectum Adenocarcinoma MD T3N1M0 C 
N7 C7 Ascending colon Adenocarcinoma MD T3N0M0 B 
N8 C8 Rectum Adenocarcinoma MD T3N0M0 B 
N9 C9 Rectosigmoid Adenocarcinoma WD T3N0M0 B 
N10 C10 Ascending colon Mucinous M T2N1M0 C 
N11 C11 Rectum Mucinous M T4N1M0 C 
N12 C12 Rectum Adenocarcinoma PD T3N1M0 C 
N13 C13 Rectum Adenocarcinoma MD T3N0M0 B 
N14 C14 Sigmoid Adenocarcinoma MD T3N0M0 B 
N15 C15 Rectum Adenocarcinoma MD T3N0M0 B 
N16 C16 Caecum Adenocarcinoma MD T3N0M0 B 
N17 C17 Rectum Adenocarcinoma MD T3N0M0 B 
N18 C18 Sigmoid Adenocarcinoma MD T4N0M0 B 
N19 C19 Caecum Adenocarcinoma WD T3N1M0 C 
N20 C20 Rectum Adenocarcinoma MD T3N2M0 C 
N21 C21 Hepatic flexure Adenocarcinoma MD T3N1M0 C 
N22 C22 Caecum Adenocarcinoma MD T3N0M0 B 
N23 C23 Rectum Adenocarcinoma MD T2N0M0 A 
N24 C24 Sigmoid Adenocarcinoma MD T2N1M0 C 
N25 C25 Sigmoid Adenocarcinoma PD T2N1M0 C 
N26 C26 Rectum Adenocarcinoma PD T3N0M0 B 
N27 C27 Rectum Adenocarcinoma MD T3N0M0 B 
N28 C28 Sigmoid Adenocarcinoma MD T3N0M0 B 





 - Adenocarcinoma MD - - 
N31 C31 Sigmoid Adenocarcinoma MD T4N2M0 C 
N32 C32 Rectosigmoid Adenocarcinoma MD T4N2M0 C 
N33 C33 Rectum Adenocarcinoma MD T3N0M0 C 
N34 C34 Sigmoid Adenocarcinoma MD T3N1M0 B 
N35 C35 Rectosigmoid Adenocarcinoma MD T3N0M0 B 
N36 C36 Ascending colon Adenocarcinoma MD T3N0M0 B 
a
 For each C (CRC) sample, matched N (normal) tissue was provided. 
b
 MD, WD, PD and M are moderately differentiated, well-differentiated, 
poorly differentiated and mucinous, respectively. 
c






6-k PGF1α, a stable non-enzymatic hydrolytic product of unstable PGI2, 
was found to be higher in normal colon as compared to CRC colon tissue. This 
finding corroborated with the previous results published by Rigas et al. (1993). 
PGI2 showed cytoprotective activity on gastric mucosal surfaces and was 
determined to be important for maintaining normal vasculature (Wang and 
Dubois, 2008). PGI2 and its stable synthetic analogues such as Cicaprost were 
shown to prevent lung and liver metastases in murine models of prostate 
(Schirner and Schneider, 1992), ovarian (Schirner and Schneider, 1991), 
mammary (Schirner et al., 1994; Schirner and Schneider, 1992), skin 
(Costantini et al., 1988) and lung (Lapis et al., 1990; Sava et al., 1989) 
carcinomas. In addition, these compounds demonstrated inhibitory effect on 
the growth of established micrometastases after the removal of primary 
mammary tumors in rats (Schirner and Schneider, 1997). Mechanistic studies 
have further revealed that PGI2 and its analogues exhibited both direct and 
indirect antimetastatic effects by interfering with tumor cell-host interactions 
and potentiating host immune competency (Schirner et al., 1998). Recently it 
has been shown that platelets play an important role in metastasis and the 
antimetastatic effect of PGI2 could be partially attributed to its inherent 
antiplatelet property (Gay and Felding-Habermann, 2011).   
In this study, a significantly higher content of PGE2 was found in CRC 
compared to normal colon tissue. This finding was consistent with the results 
of previous studies (Bennett et al., 1987; Rigas et al., 1993). The role of PGE2 



























% fold change  





1α  17.91±13.56 2.59±2.41 <0.00001 -590.8 
TXB
2 
 4.23±2.08 4.38±3.34 0.798 3.3 
PGE
2 
 11.98±12.60 32.01±19.46 0.00001 62.6 
PGD
2 
 16.62±7.89 17.86±5.52 0.489 7.0 
LTB
4 
 1.27±0.32 1.51±1.02 0.221 15.5 
13S-HODE  22.30±15.84 15.11±11.71 0.040 -47.5 
8-HETE  1.74±1.59 2.09±1.42 0.357 16.8 













% fold change  




AA 14.93±6.41 10.92±5.13 0.001 -36.7 
a
 Values are expressed as mean±SD 
b
 Statistical p value calculated using paired samples ‘t’ test (significance at 
p<0.05) 
c
 Positive and negative percentages indicate higher levels of analytes in CRC 




biosynthesis of PGE2 and 15-hydroxyprostaglandin dehydrogenase (15-
PGDH)-dependent degradation of PGE2, determine its steady-state cellular 
levels. The expression of 15-PGDH was found to be reduced in CRC 
(Backlund et al., 2005; Yan et al., 2004) whereas the levels of COX-2 and 
PGE synthase were elevated (Yoshimatsu et al., 2001). The fluctuations of 
these enzymes resulted subsequently in the elevated levels of PGE2 in CRC 
tissue which in turn contributed to CRC development by promoting 
angiogenesis (Tsujii et al., 1998), metastasis (Tsujii et al., 1997), 
immunosuppression (Kojima et al., 2001),  proliferation (Sheng et al., 2001) 
and inhibiting apoptosis (Sheng et al., 1998). These effects exerted by PGE2 
are mediated through the activation of various signaling pathways. PGE2 
causes up-regulation of β-catenin transcriptional activity and phosphorylation 
of the EGF receptor resulting in activation of oncogenic phosphatidyl-inositol-
3-kinase (PI3K), serine/threonine protein kinase (Akt) and rat sarcoma viral 
oncogene-mitogen activated protein kinase (RAS-MAPK) cascade (Pai et al., 
2002). PGE2 also activates the peroxisome proliferator activated receptor-δ 
(PPARδ) via stimulation of PI3K and stimulates expression of the angiogenic 
factor VEGF, the proliferation promoting factor cyclin D1 and the anti-
apoptotic factor bcl-2 (Wang and Dubois, 2008, 2010). PGE2 causes activation 
of Tcf-4 transcription factors via stabilization of β-catenin in CRC cells and 
consequently also activates the Wnt signaling pathway (Castellone et al., 
2005). Moreover several downstream pathways of PGE2 may act as a positive 




Our study further demonstrated that the endogenous levels of 12-
HETE was significantly higher in CRC as compared to normal colon tissue. 
Evidences from in vitro studies indicated that 12-HETE enhanced adhesion, 
migration and metastasis of cancer cells (Chopra et al., 1991; Honn et al., 
1992; Liu et al., 1995; Nie et al., 1998). Moreover in vivo studies have shown 
that 12-HETE plays an important role in carcinogenesis in murine skin tumor 
(Krieg et al., 1995) and human prostate cancer (Shureiqi and Lippman, 2001). 
13S-HODE was found to be significantly higher in normal tissues as 
compared to CRC samples. This observation is corroborated by other studies 
(Shureiqi et al., 1999, 2010). In vitro studies in CRC cell lines have shown that 
13S-HODE exerts an antitumorigenic effect by promoting apoptosis and 
causing cell cycle arrest (Shureiqi and Lippman, 2001).  Moreover linoleic 
acid which acts as the metabolic precursor of 13S-HODE has been shown to 
have an inhibitory effect in murine model of skin cancer (Fischer et al., 1996).  
Interestingly, various in vitro studies have shown that the tumor promoting 
effects of 12-HETE, are counteracted by 13S-HODE as well as PGI2 and its 
analogues (Grossi et al., 1989; Honn et al., 1992; Liu et al., 1991; Tang et al., 
1993). These observations suggested that stable PGI2 analogues and LOX 
modulators could also be investigated as potential chemotherapeutic agents in 
CRC. 
Finally, we observed that the level of AA was significantly decreased 
in CRC colon tissue. This observation was consistent with our earlier findings 
where CRC was profiled using GC×GC/TOFMS- and GC/MS-based 
metabolic profiling platforms (Chan et al., 2009). The depleted levels of AA in 
CRC tissue could be attributed to the overexpression of COX-2 enzyme which 
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catalyzes the conversion of AA to eicosanoids (Kashfi and Rigas, 2005; Sano 




Targeted profiling of eicosanoids and AA in 36 matched pairs of CRC and 
normal tissues were carried out using UPLC/MS/MS. The results indicated 
significantly higher levels of AA and antitumorigenic eicosanoids such as 
PGI2 (assayed as its stable product 6-k PGF1α) and 13S-HODE in normal 
tissues whereas pro-tumorigenic eicosanoids such as PGE2 and 12-HETE were 
found to be higher in CRC tissue specimens. However no significant 
association was observed between the endogenous levels of the profiled 
metabolites with CRC stage or anatomical site of tumor. The findings implied 
definite deregulation of eicosanoid biosynthetic pathways and suggested that a 
complicated interplay between eicosanoids is involved in inflammation 









In my PhD project, both non-targeted metabolic profiling and targeted 
metabolic profiling of eicosanoids and AA in CRC using biopsied tissue 
specimens obtained from CRC patients were carried out. For global non-
targeted metabolic profiling of CRC, three different analytical platforms 
namely GC/MS, HR-MAS NMR spectroscopy and GC×GC/TOFMS were 
explored. Prior to its application for non-targeted profiling the GC/MS method 
was developed and validated successfully in terms of sample stability, 
reproducibility, selectivity, linear response and sensitivity. HR-MAS NMR 
spectroscopic analysis including sample pretreatment was carried out at the 
Imperial College London, UK, as per the validated protocol which has been 
published recently (Beckonert et al., 2010). For validation of analytical 
performance of GC×GC/TOFMS an alternative approach involving QC 
samples and multivariate statistical analyses was used successfully. Although 
GC×GC/TOFMS proved to be better than GC/MS and HR-MAS NMR 
spectroscopy with respect to the extent of metabolic space coverage, HR-MAS 
NMR spectroscopy proved to be more advantageous in terms of sample 
preparation and total analysis time. The data generated by the three analytical 
platforms in conjunction with chemometric analysis led to the identification of 
marker metabolites belonging to diverse chemical classes such as 
monosaccharides, amino acids, triterpenes, amino ketones, steroids, organic 
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acids, fatty acids, fatty acid esters, polyols, polyol derivatives, pyrimidine 
derivatives, pyrimidine nucleosides, acyl phosphates, lipids and choline 
containing compounds. Although the OPLS-DA models generated on the basis 
of profiled data using the three analytical platforms were capable of 
discriminating normal tissues from malignant ones, no valid OPLS-DA model 
was obtained using CRC stage as classifier. This implied that the metabolic 
phenotype associated with CRC, although distinct from that of normal tissue, 
is not sensitive enough to discriminate the different stages of CRC. Of the 
three analytical methods used, only HR-MAS NMR spectroscopy-based 
metabolic profiling was able to produce a valid OPLS-DA model capable of 
discriminating anatomical site of tumor. This finding is interesting as the 
hazard of recurrence and metastasis in rectal cancer is 1.5 times that in colon 
cancer (Li et al., 2007). Thus, our results suggested that CRC harbors distinct 
metabolic signatures according to the anatomical location of tumor which may 
be exploited in future to better understand the distinction between colon and 
rectal cancers. The identified marker metabolites when linked to metabolic 
pathways using KEGG database revealed perturbations of biochemical 
processes such as glycolysis, TCA cycle, amino acid metabolism, fatty acid 
biosynthesis, steroid biosynthesis, eicosanoid biosynthesis, bile acid 
biosynthesis, nucleotide metabolism and osmoregulation. Majority of these 
observations can be attributed to the high energy demand, tissue hypoxia and 
altered synthetic rate of cellular components of rapidly proliferating tumor 
cells. Moreover our non-targeted metabolic profiling study using 
GCxGC/TOFMS suggested the branching of serine biosynthetic pathway from 
glycolysis and its upregulation, the end product of which is glycine. Recent 
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studies suggest that the enzyme phosphoglycerate dehydrogenase (PHGDH) 
which oxidizes the glycolytic intermediate 3-phosphoglycerate to initiate 
serine biosynthesis, is over-expressed in breast cancer and helps cancer cells to 
proliferate rapidly (Locasale, et al., 2011; Possemato et al., 2011). This further 
implies that the suppression of PHGDH could be a new therapeutic target.  
Our findings using human CRC tissue samples, were actually made before the 
findings by Locasale et al. and Possemato et al. and suggested that there is also 
a possible existence of this particular form of metabolic deregulation in human 
CRC. In addition to this, altered eicosanoid biosynthetic pathway as indicated 
by reduced AA levels in CRC tissues and presence of comparatively higher 
levels of picolinic acid in CRC tissues, implied an association of inflammatory 
environment with CRC development.  
The strong evidence of association between inflammation and CRC 
and the significant role played by eicosanoids in it, as well as the altered 
expression of COX-2 and LOX enzymes involved in eicosanoid biosynthesis 
in CRC, formed our objective to carry out targeted metabolic profiling of 8 
biologically relevant eicosanoids and the major metabolic precursor AA to 
record the fluctuations of these inflammatory metabolites and to understand 
their implicated roles in inflammation mediated CRC carcinogenesis better. 
For this purpose an UPLC/MS/MS-based method was developed and validated 
successfully (in terms of selectivity, sensitivity, precision, accuracy, extraction 
efficiency, linear response and sample stability) for the simultaneous profiling 
of AA and 8 eicosanoids in human colorectal tissue. Targeted profiling of 
eicosanoids and AA in 36 matched pairs of CRC and normal tissues revealed 
significantly higher levels of 6-k PGF1α (stable hydrolytic product of unstable 
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PGI2), 13S-HODE and AA in normal tissues whereas PGE2 and 12-HETE 
were found to be higher in CRC tissue specimens. However, no significant 
correlation was obtained between the endogenous levels of the profiled 
metabolites with CRC stage or anatomical site of tumor. Both non-targeted 
profiling of CRC using GC×GC/TOFMS and GC/MS and targeted profiling 
showed diminished levels of AA in CRC tissues which could be attributed to 
the overexpression of COX-2 enzyme in CRC. These findings suggested 
deregulation of eicosanoid biosynthetic pathways and suggested that a 
complex interaction between pro-tumorigenic eicosanoids such as PGE2 and 
12-HETE and antitumorigenic eicosanoids such as PGI2 and 13S-HODE is 
intimately involved in inflammation-associated CRC carcinogenesis.       
 
8.2. Future directions 
 
As one of our aims was to elucidate the metabolic phenotype associated with 
CRC and to verify its potential to be utilized for staging and prognosis of 
CRC, we used biopsied tissue specimens for our non-targeted metabolic 
profiling experiments. This is due to the fact that tissue provides site specific 
information and is less susceptible to variation as compared to serum, urine or 
faeces. During the progress of our project, concurrent studies were conducted 
by other research groups which involved non- targeted metabolic profiling of 
CRC using other biomatrices like serum (Ma et al., 2010; Ludwig et al., 2009; 
Qiu et al., 2009), urine (Qiu et al., 2010; Wang et al., 2010) and faecal water 
extracts (Monleón et al., 2009). Such findings have opened the way for 
utilizing non-targeted metabolic profiling as a minimally invasive or non-
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invasive diagnostic tool for CRC. However, large scale clinical studies are 
required in the future to establish and validate such metabolic profiling-based 
diagnostic methods as suitable alternatives to existing diagnostic methods of 
CRC. With the development of LC/NMR/MS hybrid techniques (Lindon et al., 
2000, 2004), it will be interesting to explore such analytical platforms for non-
targeted metabolic profiling of CRC in the future so as to expand the 
metabolic space covered currently by the existing methods. Other biomatrices 
such as saliva and dried blood spot can also be investigated for non-targeted 
metabolic profiling of CRC. Proteomic study of exosomes from CRC ascites 
(Choi et al., 2011) has paved the way for future metabolic profiling studies of 
such exosomes. In our non-targeted metabolic profiling study we found 
metabolic perturbations related to lipid metabolism which also warrants 
lipidomic study of CRC in future to gain additional insight.   
The results obtained from our targeted profiling of eicosanoids 
supported the concept of using aspirin and other NSAIDs as preventive agents 
or adjuvant therapeutic agents as they act primarily by inhibiting COX 
enzyme. However, verification of the mechanistic aspect of NSAID-based 
therapy in CRC requires large scale clinical trials to be conducted in future. In 
fact an international, multi-centre, double-blind randomized phase III clinical 
trial (ASCOLT, http://indox.org.uk/research/clinical/ascolt) that utilizes 
Aspirin as an adjuvant treatment for CRC is currently being conducted by our 
collaborators at SGH, Singapore. Our rapid UPLC/MS/MS profiling method 
has the potential to be applied in such clinical trials to determine the effect of 
aspirin or other NSAIDs on the endogenous levels of eicosanoids so as to 
better elucidate the mechanism and value of NSAID-based adjuvant therapy in 
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improving the prognosis of human CRC. Our targeted profiling results also 
implied that PGI2 analogs and LOX modulators can also be explored in the 
future as potential chemotherapeutic agents in CRC. Future studies can also be 
carried out to elucidate the possible association of antiplatelet property of PGI2 
with its antimetastatic function (Gay and Felding-Habermann, 2011). 
Moreover, targeted metabolic profiling of other key metabolic pathways like 
components of amino acid, fatty acid, carbohydrate or nucleotide metabolism 
that get altered in CRC can be carried out in future so as to better elucidate the 
molecular mechanisms involved in CRC development and to identify potential 






Adahchour M, Beens J, Brinkman UA. 2008. Recent developments in the 
application of comprehensive two-dimensional gas chromatography. J 
Chromatogr A 1186(1-2):67-108. 
Astler VA, Coller FA. 1954. The prognostic significance of direct extension of 
carcinoma of the colon and rectum. Ann Surg 139:846-852. 
Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, 
Griffin JL. 2006. A combined 1H-NMR spectroscopy- and mass 
spectrometry-based metabolomic study of the PPAR-alpha null mutant 
mouse defines profound systemic changes in metabolism linked to the 
metabolic syndrome. Physiol Genomics 27:178-186. 
Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne 
GL, Katkuri S, DuBois RN. 2005. 15-Hydroxyprostaglandin 
dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 
280(5):3217-3223. 
Backshall A, Allferez D, Telchert F, Wilson ID, Wilkinson RW, Goodlad RA, 
Keun HC. 2009. Detection of metabolic alterations in non-tumor 
gastrointestinal tissue of the Apc (Min/+) mouse by H-1 MAS NMR 
spectroscopy. J Proteome Res 8(3):1423-1430. 
Baker H, Frank O, Chen T, Feingold S, DeAngelis B, Baker ER. 1981. 
Elevated vitamin levels in colon adenocarcinoma as compared with 
metastatic liver adenocarcinoma from colon primary and normal 
adjacent tissue. Cancer 47(12):2883-2886. 
136 
 
Ballinger AB, Anggiansah C. 2007. Colorectal cancer. BMJ 335(7622):715-
718. 
Bansal S, DeStefano A. 2007. Key elements of bioanalytical method 
validation for small molecules. The AAPS Journal  9(1) article 11. 
Bao Y, Zhao T, Wang X, Qiu Y, Su M, Jia W. 2009. Metabonomic variations 
in the drug-treated type 2 diabetes mellitus patients and healthy 
volunteers. J Proteome Res 8(4):1623-1630. 
Barbas C, Adeva N, Aguilar R, Rosillo M, Rubio T, Castro M. 1998. 
Quantitative determination of short-chain organic acids in urine by 
capillary electrophoresis. Clin Chem 44(6 Pt 1):1340-1342. 
Barbas C, Moraes EP, Villasenor A. 2011. Capillary electrophoresis as a 
metabolomics tool for non-targeted fingerprinting of biological 
samples. J Pharm Biomed Anal 55(4):823-831. 
Barton SJ, Howe FA, Tomlins AM, Cudlip SA, Nicholson JK, Bell BA, 
Griffiths JR. 1999. Comparison of in vivo 1H MRS of human brain 
tumours with 1H HR-MAS spectroscopy of intact biopsy samples in 
vitro. MAGMA 8(2):121-128. 
Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC, 
Nicholson JK. 2010. High-resolution magic-angle-spinning NMR 
spectroscopy for metabolic profiling of intact tissues. Nat Protoc 
5(6):1019-1032. 
Beens J, Adahchour M, Vreuls RJ, van Altena K, Brinkman UA. 2001. 
Simple, non-moving modulation interface for comprehensive two-
dimensional gas chromatography. J Chromatogr A 919:127-132. 
137 
 
Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. 1987. 
Measurement of arachidonate and its metabolites extracted from 
human normal and malignant gastrointestinal tissues. Gut 28(3):315-
318. 
Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM, Ong CN, Cheah PY, Eu 
KW, Hew CL. 2006. Proteomic analysis of colorectal cancer reveals 
alterations in metabolic pathways: mechanism of tumorigenesis. Mol 
Cell Proteomics 5(6):1119-1130. 
Bolcato CA, Frye RF, Zemaitis MA, Poloyac SM. 2003. Determination of 20-
hydroxyeicosatetraenoic acid in microsomal incubates using high-
performance liquid chromatography-mass spectrometry (HPLC-MS). J 
Chromatogr B Analyt Technol Biomed Life Sci 794(2):363-372. 
Bollard ME, Garrod S, Holmes E, Lindon JC, Humpfer E, Spraul M, 
Nicholson JK. 2000. High-resolution (1)H and (1)H-(13)C magic angle 
spinning NMR spectroscopy of rat liver. Magn Reson Med 44(2):201-
207. 
Bollard ME, Murray AJ, Clarke K, Nicholson JK, Griffin JL. 2003. A study of 
metabolic compartmentation in the rat heart and cardiac mitochondria 
using high-resolution magic angle spinning 1H NMR spectroscopy. 
FEBS Lett 553(1-2):73-78. 
Bollard ME, Xu J, Purcell W, Griffin JL, Quirk C, Holmes E, Nicholson JK. 
2002. Metabolic profiling of the effects of D-galactosamine in liver 




Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. 2000. 
The tryptophan catabolite picolinic acid selectively induces the 
chemokines macrophage inflammatory protein-1 alpha and -1 beta in 
macrophages. J Immunol 164(6):3283-3291. 
Bottcher C, Roepenack-Lahaye EV, Willscher E, Scheel D, Clemens S. 2007. 
Evaluation of matrix effects in metabolite profiling based on capillary 
liquid chromatography electrospray ionization quadrupole time-of-
flight mass spectrometry. Anal Chem 79(4):1507-1513. 
Boudonck KJ, Mitchell MW, Nemet L, Keresztes L, Nyska A, Shinar D, 
Rosenstock M. 2009. Discovery of metabolomics biomarkers for early 
detection of nephrotoxicity. Toxicol Pathol 37(3):280-292. 
Brash AR, Jackson EK, Saggese CA. 1983. Metabolic disposition of 
prostacyclin in humans. J Pharmacol Exp Ther. 226, 78-87. 
Brenner DE, Rennert G. 2005. Fecal DNA biomarkers for the detection of 
colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst 
97(15):1107-1109. 
Broadhurst D, Kell DB. 2006. Statistical strategies for avoiding false 
discoveries in metabolomics and related experiments. Metabolomics 2, 
171-196. 
Burg MB, Ferraris JD. 2008. Intracellular organic osmolytes: function and 
regulation. J Biol Chem 283(12):7309-7313. 
Buyse M, Piedbois Y, Piedbois P, Gray R. 2000a. Tumour site, sex, and 
survival in colorectal cancer. Lancet 356(9232):858. 
Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois 
P. 2000b. Relation between tumour response to first-line chemotherapy 
139 
 
and survival in advanced colorectal cancer: a meta-analysis. Meta-
Analysis Group in Cancer. Lancet 356(9227):373-378. 
Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. 
2006. OPLS discriminant analysis: combining the strengths of PLS-
DA and SIMCA classification. J Chemometrics 20:341-351. 
Capdevila J, Chacos N, Werringloer J, Prough RA, Estabrook RW. 1981. 
Liver microsomal cytochrome P-450 and the oxidative metabolism of 
arachidonic acid. Proc Natl Acad Sci USA 78(9):5362-5366. 
Capdevila J, Wei S, Yan J, Karara A, Jacobson HR, Falck JR, Guengerich FP, 
DuBois RN. 1992. Cytochrome P-450 arachidonic acid epoxygenase. 
Regulatory control of the renal epoxygenase by dietary salt loading. J 
Biol Chem 267(30):21720-21726. 
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. 2005. 
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-
beta-catenin signaling axis. Science 310(5753):1504-1510. 
Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. 1990. Endogenous 
biosynthesis of arachidonic acid epoxides in humans: increased 
formation in pregnancy-induced hypertension. Proc Natl Acad Sci 
USA 87(15):5893-5897. 
Chan AT, Giovannucci EL. 2010. Primary prevention of colorectal cancer. 
Gastroenterology 138(6):2029-2043. 
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, 
Fuchs CS. 2005. Long-term use of aspirin and nonsteroidal anti-




Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, 
Nicholson JK, Keun HC. 2009. Metabolic profiling of human 
colorectal cancer using high-resolution magic angle spinning nuclear 
magnetic resonance (HR-MAS NMR) spectroscopy and gas 
chromatography mass spectrometry (GC/MS). J Proteome Res 
8(1):352-361. 
Chang KL, New LS, Mal M, Goh CW, Aw CC, Browne ER, Chan EC. 2011. 
Metabolic profiling of 3-nitropropionic acid early-stage Huntington's 
disease rat model using gas chromatography time-of-flight mass 
spectrometry. J Proteome Res 10(4):2079-2087. 
Cheah PY. 1990. Hypotheses for the etiology of colorectal cancer-an 
overview. Nutr Cancer 14(1):5-13. 
Chen C, Gonzalez FJ, Idle JR. 2007. LC-MS-based metabolomics in drug 
metabolism. Drug Metab Rev 39(2-3):581-597. 
Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P, Ying K, Chen E, Zhang W. 
2007. A study of the volatile organic compounds exhaled by lung 
cancer cells in vitro for breath diagnosis. Cancer 110(4):835-844. 
Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. 
2000. Quantification of microheterogeneity in glioblastoma multiforme 
with ex vivo high-resolution magic-angle spinning (HRMAS) proton 
magnetic resonance spectroscopy. Neuro Oncol 2(2):87-95. 
Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. 
2005. Metabolic characterization of human prostate cancer with tissue 
magnetic resonance spectroscopy. Cancer Res 65(8):3030-3034. 
141 
 
Cheng LL, Lean CL, Bogdanova A, Wright SC, Jr., Ackerman JL, Brady TJ, 
Garrido L. 1996. Enhanced resolution of proton NMR spectra of 
malignant lymph nodes using magic-angle spinning. Magn Reson Med 
36(5):653-658. 
Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG. 
1997. Quantitative neuropathology by high resolution magic angle 
spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci 
USA 94(12):6408-6413. 
Chopra H, Timar J, Chen YQ, Rong XH, Grossi IM, Fitzgerald LA, Taylor 
JD, Honn KV. 1991. The lipoxygenase metabolite 12(S)-HETE 
induces a cytoskeleton-dependent increase in surface expression of 
integrin α IIb β 3 on melanoma cells. Int J Cancer 49 (5):774-786. 
Choi DS, Park JO, Jang SC, Yoon YJ, Jung JW, Choi DY, Kim JW, Kang JS, 
Park J, Hwang D, Lee KH, Park SH, Kim YK, Desiderio DM, Kim 
KP, Gho YS. 2011. Proteomic analysis of microvesicles derived from 
human colorectal cancer ascites. Proteomics 11(13):2745-2751. 
Cloarec O, Campbell A, Tseng LH, Braumann U, Spraul M, Scarfe G, Weaver 
R, Nicholson JK. 2007. Virtual chromatographic resolution 
enhancement in cryoflow LC-NMR experiments via statistical total 
correlation spectroscopy. Anal Chem 79(9):3304-3311. 
Coen M, Holmes E, Lindon JC, Nicholson JK. 2008. NMR-based metabolic 
profiling and metabonomic approaches to problems in molecular 
toxicology. Chem Res Toxicol 21(1):9-27. 
Costantini V, Fuschiotti P, Allegrucci M, Agnelli G, Nenci GG, Fioretti MC. 
1988. Platelet-tumor cell interaction: Effect of prostacyclin and a 
142 
 
synthetic analog on metastasis formation. Cancer Chemother 
Pharmacol 22(4):289-293. 
Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 
420(6917):860-867. 
Crawford NP, Colliver DW, Galandiuk S. 2003. Tumor markers and colorectal 
cancer: utility in management. J Surg Oncol 84(4):239-248. 
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, 
Starling N. 2010. Colorectal cancer. Lancet 375(9719):1030-1047. 
Daykin CA, Corcoran O, Hansen SH, Bjornsdottir I, Cornett C, Connor SC, 
Lindon JC, Nicholson JK. 2001. Application of directly coupled HPLC 
NMR to separation and characterization of lipoproteins from human 
serum. Anal Chem 73(6):1084-1090. 
Deans GT, Parks TG, Rowlands BJ, Spence RA. 1992. Prognostic factors in 
colorectal cancer. Br J Surg 79:608-613. 
Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek 
S, Konsgen D, Dietel M, Fiehn O. 2006. Mass spectrometry-based 
metabolic profiling reveals different metabolite patterns in invasive 
ovarian carcinomas and ovarian borderline tumors. Cancer Res 
66(22):10795-10804. 
Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, 
Niesporek S, Noske A, Buckendahl A, Dietel M, Fiehn O. 2008. 
Metabolite profiling of human colon carcinoma--deregulation of TCA 
cycle and amino acid turnover. Mol Cancer 7:72. 
143 
 
de Noo ME, Tollenaar RA, Deeldar AM, Bouwman LH. 2006. Current status 
and prospects of clinical proteomics studies on detection of colorectal 
cancer: Hopes and fears. World J Gastroenterology 12:6594-6601. 
Dieterle F, Ross A, Schlotterbeck G, Senn H. 2006. Probabilistic quotient 
normalization as robust method to account for dilution of complex 
biological mixtures. Application in 1H NMR metabonomics. Anal 
Chem 78(13):4281-4290. 
Dimandja JM, Clouden GC, Colon I, Focant JF, Cabey WV, Parry RC. 2003. 
Standardized test mixture for the characterization of comprehensive 
two-dimensional gas chromatography columns: the Phillips mix. J 
Chromatogr A 1019(1-2):261-272. 
Dolcet X, Llobet D, Pallares J, Matias-Guiu X. 2005. NF-kB in development 
and progression of human cancer. Virchows Arch 446(5):475-482. 
Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM. 2005. Progressive 
methylation during the serrated neoplasia pathway of the colorectum. 
Mod Pathol 18(2):170-178. 
Duarte IF, Stanley EG, Holmes E, Lindon JC, Gil AM, Tang H, Ferdinand R, 
McKee CG, Nicholson JK, Vilca-Melendez H, Heaton N, Murphy 
GM. 2005. Metabolic assessment of human liver transplants from 
biopsy samples at the donor and recipient stages using high-resolution 
magic angle spinning 1H NMR spectroscopy. Anal Chem 
77(17):5570-5578. 
Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, 
Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. 2007. Tumour 
144 
 
markers in colorectal cancer: European Group on Tumour Markers 
(EGTM) guidelines for clinical use. Eur J Cancer 43(9):1348-1360. 
Dukes CE. 1932. The classification of cancer of the rectum. J Path Bact 
35:323-332. 
Dunn WB, Bailey NJ, Johnson HE. 2005. Measuring the metabolome: current 
analytical technologies. Analyst 130(5):606-625. 
Dunn WB, Ellis DI. 2005. Metabolomics: Current analytical platforms and 
methodologies. Trends in Anal Chem 24:285-294. 
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2008. 
GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: 
IARC, Lyon, France: Available from: http://globocan.iarc.fr. 
FDA. 2001. Guidance for industry: bioanalytical method validation, FDA, US 
Department of Health and Human Services. Available: 
http://www.fda.gov/cder/guidance/4252fnl.pdf. 
Fiehn O. 2001. Combining genomics, metabolome analysis, and biochemical 
modelling to understand metabolic networks. Comp Funct Genomics 
2(3):155-168. 
Filella X, Molina R, Grau JJ, Pique JM, Garcia-Valdecasas JC, Astudillo E, 
Biete A, Bordas JM, Novell A, Campo E, et al. 1992. Prognostic value 
of CA 19.9 levels in colorectal cancer. Ann Surg 216(1):55-59. 
Fischer SM, Hagerman RA, Li-Stiles E, Lo HH, Maldve RE, Belury MA, 
Locniskar MF. 1996. Arachidonate has protumor-promoting action that 




Fleming I, Cooper J, Henson D. 1997. AJCC cancer staging manual. 
Lippincott-Raven, Philadelphia, USA. 
Foxall PJ, Lenz EM, Lindon JC, Neild GH, Wilson ID, Nicholson JK. 1996. 
Nuclear magnetic resonance and high-performance liquid 
chromatography-nuclear magnetic resonance studies on the toxicity 
and metabolism of ifosfamide. Ther Drug Monit 18(4):498-505. 
Fu TF, Rife JP, Schirch V. 2001. The role of serine hydroxymethyltransferase 
isozymes in one-carbon metabolism in MCF-7 cells as determined by 
(13)C NMR. Arch Biochem Biophys 393(1):42-50. 
Gallagher M, Wysocki CJ, Leyden JJ, Spielman AI, Sun X, Preti G. 2008. 
Analyses of volatile organic compounds from human skin. Br J 
Dermatol 159(4):780-791. 
Gamache PH, Meyer DF, Granger MC, Acworth IN. 2004. Metabolomic 
applications of electrochemistry/mass spectrometry. J Am Soc Mass 
Spectrom 15(12):1717-1726. 
Garber K. 2006. Energy deregulation: licensing tumors to grow. Science 
312(5777):1158-1159. 
Gay LJ, Felding-Habermann B. 2011. Contribution of platelets to tumour 
metastasis. Nat Rev Cancer 11(2):123-134. 
Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, 
Hubbard WC, Hamilton SR, Yang VW. 1998. Prostaglandin levels in 
human colorectal mucosa: effects of sulindac in patients with familial 
adenomatous polyposis. Dig Dis Sci 43(2):311-316. 
146 
 
Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. 2006. Choline 
phospholipid metabolism in cancer: consequences for molecular 
pharmaceutical interventions. Mol Pharm 3(5):496-506. 
Goodacre R, Broadhurst D, Smilde AK, Kristal BS, Baker JD, Beger R, 
Bessant C, Connor S, Calmani G, Craig A, Ebbels T, Kell DB, Manetti 
C, Newton J, Paternostro G, Somorjai R, Sjostrom M, Trygg J, Wulfert 
F. 2007. Proposed minimum reporting standards for data analysis in 
metabolomics. Metabolomics 3, 231-241. 
Graca G, Duarte IF, B JG, Carreira IM, Couceiro AB, Domingues Mdo R, 
Spraul M, Tseng LH, Gil AM. 2008. Metabolite profiling of human 
amniotic fluid by hyphenated nuclear magnetic resonance 
spectroscopy. Anal Chem 80(15):6085-6092. 
Grady WM. 2004. Genomic instability and colon cancer. Cancer Metastasis 
Rev 23(1-2):11-27. 
Griffin JL, Lehtimaki KK, Valonen PK, Grohn OH, Kettunen MI, Yla-
Herttuala S, Pitkanen A, Nicholson JK, Kauppinen RA. 2003. 
Assignment of 1H nuclear magnetic resonance visible polyunsaturated 
fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase 
gene therapy-induced programmed cell death. Cancer Res 
63(12):3195-3201. 
Griffin JL, Shockcor JP. 2004. Metabolic profiles of cancer cells. Nat Rev 
Cancer 4(7):551-561. 
Groger T, Przyborowska AM, Waterman D, Bramley PM, Fraser PD, Tuchler 
M, Patel RKP, Halket JM. 2003. Ion trap LC/MS/MS and chemical 
147 
 
derivatization for metabolic profiling of GM foodstuffs. In: 
Proceedings of the 51st ASMS Conference, 8–12 June, Montreal. 
Grossi IM, Fitzgerald LA, Umbarger LA, Nelson KK, Diglio CA, Taylor JD, 
Honn KV. 1989. Bidirectional control of membrane expression and/or 
activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell 
adhesion by lipoxygenase products of arachidonic acid and linoleic 
acid. Cancer Res 49(4):1029-1037. 
Gunderson LL, Sosin H. 1974. Areas of failure found at re-operation (second 
or symptomatic look) following "curative surgery" for adenocarcinoma 
of the rectum: clinicopathologic correlation and implications for 
adjuvant therapy. Cancer 34:1278-1292. 
Halket JM, Waterman D, Przyborowska AM, Patel RK, Fraser PD, Bramley 
PM. 2005. Chemical derivatization and mass spectral libraries in 
metabolic profiling by GC/MS and LC/MS/MS. J Exp Bot 
56(410):219-243. 
Harrigan GG, Goodacre R. (eds). 2003. Metabolic Profiling: Its role in 
biomarker discovery and gene function analysis. Kluwer Academic 
Publishers, Boston, USA. 
Harrigan GG, LaPlante RH, Cosma GN, Cockerell G, Goodacre R, Maddox 
JF, Luyendyk JP, Ganey PE, Roth RA. 2004. Application of high-
throughput Fourier-transform infrared spectroscopy in toxicology 
studies: contribution to a study on the development of an animal model 
for idiosyncratic toxicity. Toxicol Lett 146(3):197-205. 
148 
 
Hentosh P, Yuh SH, Elson CE, Peffley DM. 2001. Sterol-independent 
regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in 
tumor cells. Mol Carcinog 32(3):154-166. 
Hishinuma T, Suzuki K, Saito M, Yamaguchi H, Suzuki N, Tomioka Y, 
Kaneko I, Ono M, Goto J. 2007. Simultaneous quantification of seven 
prostanoids using liquid chromatography/tandem mass spectrometry: 
the effects of arachidonic acid on prostanoid production in mouse bone 
marrow-derived mast cells. Prostaglandins Leukot Essent Fatty Acids 
76(6):321-329. 
Honn KV, Nelson KK, Renaud C, Bazaz R, Diglio CA, Timar J. 1992. Fatty 
acid modulation of tumor cell adhesion to microvessel endothelium 
and experimental metastasis. Prostaglandins 44 (5):413-429. 
Hubbard WC, Litterst CL, Liu MC, Bleecker ER, Eggleston JC, McLemore 
TL, Boyd MR. 1986. Profiling of prostaglandin biosynthesis in biopsy 
fragments of human lung carcinomas and normal human lung by 
capillary gas chromatography-negative ion chemical ionization mass 
spectrometry. Prostaglandins 32(6):889-906. 
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim 
W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, 
Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J 
Med 350(23):2335-2342. 
ICH. 1994. International Conference on Harmonization (ICH) validation of 
analytical methods: definitions and terminology. ICH Q2 A, Geneva. 
149 
 
ICH. 1996. International Conference on Harmonization (ICH) validation of 
analytical methods: methodology. ICH Q2 B, Geneva. 
Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. 1999. Expression of 15-
lipoxygenase-1 in human colorectal cancer. Cancer Res 59(2):360-366. 
Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, Townsend 
RR, Gordon JI. 2005. An integrated functional genomics and 
metabolomics approach for defining poor prognosis in human 
neuroendocrine cancers. Proc Natl Acad Sci USA 102(28):9901-9906. 
James CA, Breda M, Baratte S, Casati M, Grassi S, Pellegatta B, Sarati S, 
Frigerio E. 2004.  Analysis of drugs and metabolites in tissues and 
other solid matrices. Chromatographia 59:S149.  
Jasperson KW, Tuohy TM, Neklason DW, Burt RW. 2010. Hereditary and 
familial colon cancer. Gastroenterology 138(6):2044-2058. 
Jass JR. 1999. Serrated adenoma and colorectal cancer. J Pathol 187(5):499-
502. 
Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, Todd IP. 
1986. The grading of rectal cancer: historical perspectives and a 
multivariate analysis of 447 cases. Histopathology 10(5):437-459. 
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, 
Lieberman G, Griffing S, Bergsland E. 2003. Phase II, randomized 
trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) 
with FU/LV alone in patients with metastatic colorectal cancer. J Clin 
Oncol 21(1):60-65. 
Kaderbhai NN, Broadhurst DI, Ellis DI, Goodacre R, Kell DB. 2003. 
Functional genomics via metabolic footprinting: monitoring metabolite 
150 
 
secretion by Escherichia coli tryptophan metabolism mutants using FT-
IR and direct injection electrospray mass spectrometry. Comp Funct 
Genomics 4(4):376-391. 
Kashfi K, Rigas B. 2005. Is COX-2 a 'collateral' target in cancer prevention? 
Biochem Soc Trans 33(Pt 4):724-727. 
Kanehisa M, Goto S. 2000. KEGG: Kyoto Encyclopedia of Genes and 
Genomes. Nucleic Acids Res 28:27-30. 
Keun HC, Beckonert O, Griffin JL, Richter C, Moskau D, Lindon JC, 
Nicholson JK. 2002. Cryogenic probe 13C NMR spectroscopy of urine 
for metabonomic studies. Anal Chem 74(17):4588-4593. 
Keun, HC, Ebbels TMD, Antti H, Bollard ME, Beckonert O, Holmes E, 
Lindon JC, Nicholson JK. 2003. Improved analysis of multivariate data 
by variable stability scaling: application to NMR-based metabolic 
profiling. Anal Chim Acta 490:265-276. 
Khummueng W, Harynuk J, Marriott PJ. 2006. Modulation ratio in 
comprehensive two-dimensional gas chromatography. Anal Chem 
78(13):4578-4587. 
Kind T, Tolstikov V, Fiehn O, Weiss RH. 2007. A comprehensive urinary 
metabolomic approach for identifying kidney cancerr. Anal Biochem 
363(2):185-195. 
Koek MM, Muilwijk B, van Stee LL, Hankemeier T. 2008. Higher mass 
loadability in comprehensive two-dimensional gas chromatography-
mass spectrometry for improved analytical performance in 
metabolomics analysis. J Chromatogr A 1186(1-2):420-429. 
151 
 
Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, 
Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, 
Schoffski P, Micheel S, Hecker H. 2002. Clinical determinants of 
survival in patients with 5-fluorouracil-based treatment for metastatic 
colorectal cancer: results of a multivariate analysis of 3825 patients. 
Ann Oncol 13(2):308-317. 
Kojima M, Morisaki T, Uchiyama A, Doi F, Mibu R, Katano M, Tanaka M. 
2001. Association of enhanced cyclooxygenase-2 expression with 
possible local immunosuppression in human colorectal carcinomas. 
Ann Surg Oncol 8(5):458-465. 
Kraus S, Arber N. 2009. Inflammation and colorectal cancer. Curr Opin 
Pharmacol 9(4):405-410. 
Krieg P, Kinzig A, Ress-Loschke M, Vogel S, Vanlandingham B, Stephan M, 
Lehmann WD, Marks F, Furstenberger G. 1995. 12-lipoxygenase 
isoenzymes in mouse skin tumor development. Mol Carcinog 
14(2):118-129. 
Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. 2010. 
Primary colon cancer: ESMO Clinical Practice Guidelines for 
diagnosis, adjuvant treatment and follow-up. Ann Oncol 21 Suppl 
5:v70-77. 
Lakatos PL, Lakatos L. 2008. Risk for colorectal cancer in ulcerative colitis: 




Lapis K, Timar J, Papay J, Paku S, Szende B, Ladanyi A. 1990. Experimental 
metastasis inhibition by pretreatment of the host. Arch 
Geschwulstforsch 60 (2):97-102. 
Lee R, Ptolemy AS, Niewczas L, Britz-McKibbin P. 2007. Integrative 
metabolomics for characterizing unknown low-abundance metabolites 
by capillary electrophoresis-mass spectrometry with computer 
simulations. Anal Chem 79(2):403-415. 
Lenz EM, Wilson ID. 2007. Analytical strategies in metabonomics. J 
Proteome Res 6(2):443-458. 
Leon C, Rodriguez-Meizoso I, Lucio M, Garcia-Canas V, Ibanez E, Schmitt-
Kopplin P, Cifuentes A. 2009. Metabolomics of transgenic maize 
combining Fourier transform-ion cyclotron resonance-mass 
spectrometry, capillary electrophoresis-mass spectrometry and 
pressurized liquid extraction. J Chromatogr A 1216(43):7314-7323. 
Levine L. 1986. Radioimmunoassay for leukotrienes: some applications and 
limitations. Adv Prostaglandin Thromboxane Leukot Res 16:339-351. 
Li M, Li JY, Zhao AL, Gu J. 2007. Colorectal cancer or colon and rectal 
cancer? Clinicopathological comparison between colonic and rectal 
carcinomas. Oncology 73(1-2):52-57. 
Li NJ, Liu WT, Li W, Li SQ, Chen XH, Bi KS, He P. 2010. Plasma metabolic 
profiling of Alzheimer's disease by liquid chromatography/mass 
spectrometry. Clin Biochem 43(12):992-997. 
Lin CY, Huifeng W, Tjeerdema RS, Viant MR. 2007. Evaluation of 
metabolite extraction strategies from tissue samples using NMR 
metabolomics. Metabolomics 3:55-67. 
153 
 
Lindon JC, Holmes E, Nicholson JK. 2001. Pattern recognition methods and 
applications in biomedical magnetic resonance. Prog Nuc Magn Reson 
39:1-40. 
Lindon JC, Nicholson JK, Holmes E. 2007a. The handbook of metabonomics 
and metabolomics. Elsevier, The Netherlands. 
Lindon JC, Nicholson JK, Wilson ID. 2000. Directly coupled HPLC-NMR 
and HPLC-NMR-MS in pharmaceutical research and development. J 
Chromatogr B Biomed Sci Appl 748(1):233-258. 
Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. 2004. 
Metabonomics technologies and their applications in physiological 
monitoring, drug safety assessment and disease diagnosis. Biomarkers 
9(1):1-31. 
Lindon JC, Holmes E, Nicholson JK. 2007b. Metabonomics in pharmaceutical 
R&D. FEBS J 274(5):1140-1151. 
Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, Gallinger S, 
Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter 
J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, 
Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau 
SN, Boardman LA, Seminara D. 2005. Lower cancer incidence in 
Amsterdam-I criteria families without mismatch repair deficiency: 
familial colorectal cancer type X. JAMA 293(16):1979-1985. 
Lipkin M, Yang K, Edelmann W, Xue L, Fan K, Risio M, Newmark H, 
Kucherlapati R. 1999. Preclinical mouse models for cancer 
chemoprevention studies. Ann N Y Acad Sci 889:14-19. 
154 
 
Lisec J, Schauer N, Kopka J, Willmitzer L, Fernie AR. 2006. Gas 
chromatography mass spectrometry-based metabolite profiling in 
plants. Nat Protoc 1(1):387-396. 
Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, Butovich I, 
Honn KV. 1995. 12(S)-hydroxyeicosatetraenoic acid and 13(S)-
hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in 
melanoma cells: Role of receptor-mediated hydrolysis of inositol 
phospholipids. Proc Natl Acad Sci USA 92 (20):9323-9327. 
Liu B, Timar J, Howlett J, Diglio CA, Honn KV. 1991. Lipoxygenase 
metabolites of arachidonic and linoleic acids modulate the adhesion of 
tumor cells to endothelium via regulation of protein kinase C. Cell 
Regul 2(12):1045-1055. 
Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, 
Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou 
D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, 
Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara 
JM, Brugge JS, Cantley LC, Vander Heiden MG. 2011. 
Phosphoglycerate dehydrogenase diverts glycolytic flux and 
contributes to oncogenesis. Nat Genet 43(9):869-874.  
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, 
Somerfield MR, Hayes DF, Bast RC, Jr. 2006. ASCO 2006 update of 
recommendations for the use of tumor markers in gastrointestinal 
cancer. J Clin Oncol 24(33):5313-5327. 
155 
 
Longley DB, Allen WL, Johnston PG. 2006. Drug resistance, predictive 
markers and pharmacogenomics in colorectal cancer. Biochim Biophys 
Acta 1766(2):184-196. 
Ludwig C, Ward DG, Martin A, Viant MR, Ismail T, Johnson PJ, Wakelam 
MJ, Gunther UL. 2009. Fast targeted multidimensional NMR 
metabolomics of colorectal cancer. Magn Reson Chem 47 Suppl 
1:S68-73. 
Lynch HT, Lynch JF, Attard TA. 2009. Diagnosis and management of 
hereditary colorectal cancer syndromes: Lynch syndrome as a model. 
CMAJ 181(5):273-280. 
Ma Y, Liu W, Peng J, Huang L, Zhang P, Zhao X, Cheng Y, Qin H. 2010. A 
pilot study of gas chromatograph/mass spectrometry-based serum 
metabolic profiling of colorectal cancer after operation. Mol Biol Rep 
37(3):1403-1411. 
Mahadevan S, Shah SL, Marrie TJ, Slupsky CM. 2008. Analysis of 
metabolomic data using support vector machines. Anal Chem 
80(19):7562-7570. 
Maier KG, Henderson L, Narayanan J, Alonso-Galicia M, Falck JR, Roman 
RJ. 2000. Fluorescent HPLC assay for 20-HETE and other P-450 
metabolites of arachidonic acid. Am J Physiol Heart Circ Physiol 
279(2):H863-871. 
Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related 
inflammation. Nature 454(7203):436-444. 
Marnett LJ. 1992. Aspirin and the potential role of prostaglandins in colon 
cancer. Cancer Res 52(20):5575-5589. 
156 
 
Margalit A, Duffin KL, Isakson PC. 1996. Rapid quantitation of a large scope 
of eicosanoids in two models of inflammation: development of an 
electrospray and tandem mass spectrometry method and application to 
biological studies. Anal Biochem 235(1):73-81. 
Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, 
Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA. 
2008. Overexpression of 5-lipoxygenase in colon polyps and cancer 
and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin 
Cancer Res 14(20):6525-6530. 
Metrakos P. 2009. A "new era" in the treatment of colorectal cancer liver 
metastasis: the gloves are off! Ann Surg 249(6):887-888. 
Mohler RE, Dombek KM, Hoggard JC, Young ET, Synovec RE. 2006. 
Comprehensive two-dimensional gas chromatography time-of-flight 
mass spectrometry analysis of metabolites in fermenting and respiring 
yeast cells. Anal Chem 78(8):2700-2709. 
Moka D, Vorreuther R, Schicha H, Spraul M, Humpfer E, Lipinski M, Foxall 
PJ, Nicholson JK, Lindon JC. 1998. Biochemical classification of 
kidney carcinoma biopsy samples using magic-angle-spinning 1H 
nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 
17(1):125-132. 
Monleón D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. 2009. 
Metabolite profiling of fecal water extracts from human colorectal 
cancer. NMR Biomed 22(3):342-348. 
Moreno A, Rey M, Montane JM, Alonso J, Arus C. 1993. 1H NMR 
spectroscopy of colon tumors and normal mucosal biopsies; elevated 
157 
 
taurine levels and reduced polyethyleneglycol absorption in tumors 
may have diagnostic significance. NMR Biomed 6(2):111-118. 
Morris M, Watkins SM. 2005. Focused metabolomic profiling in the drug 
development process: advances from lipid profiling. Curr Opin Chem 
Biol 9(4):407-412. 
Needleman P, Moncada S, Bunting S. 1976. Identification of an enzyme in 
platelet microsomes which generates thromboxane A2 from 
prostaglandin endoperoxides. Nature 261, 558-560.   
 
Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 1995. 750 MHz 
1H and 1H-13C NMR spectroscopy of human blood plasma. Anal 
Chem 67(5):793-811. 
Nicholson JK, Lindon JC, Holmes E. 1999. 'Metabonomics': understanding the 
metabolic responses of living systems to pathophysiological stimuli via 
multivariate statistical analysis of biological NMR spectroscopic data. 
Xenobiotica 29(11):1181-1189. 
Nicosia S, Vigano T, Folco GC. 1992. Eicosanoids in allergic reactions: 
quantitative determination by enzyme immunoassay. Pharmacol Res 
26 Suppl 2:116-117. 
Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV. 
1998. Platelet-type 12-lipoxygenase in a human prostate carcinoma 




Nithipatikom K, Pratt PF, Campbell WB. 2000. Determination of EETs using 
microbore liquid chromatography with fluorescence detection. Am J 
Physiol Heart Circ Physiol 279(2):H857-862. 
Ong ES, Zou L, Li S, Cheah PY, Eu KW, Ong CN. 2010. Metabolic profiling 
in colorectal cancer reveals signature metabolic shifts during 
tumorigenesis. Mol Cell Proteomics. 
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. 2002. 
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for 
promoting colon cancer growth and gastrointestinal hypertrophy. Nat 
Med 8(3):289-293. 
Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, 
Chiong E, Chan EC. 2010. Noninvasive urinary metabonomic 
diagnosis of human bladder cancer. J Proteome Res 9(6):2988-2995. 
Pasikanti KK, Ho PC, Chan EC. 2008. Gas chromatography/mass 
spectrometry in metabolic profiling of biological fluids. J Chromatogr 
B Analyt Technol Biomed Life Sci 871(2):202-211. 
Pasikanti KK, Norasmara J, Cai S, Mahendran R, Esuvaranathan K, Ho PC, 
Chan EC. 2010. Metabolic footprinting of tumorigenic and 
nontumorigenic uroepithelial cells using two-dimensional gas 
chromatography time-of-flight mass spectrometry. Anal Bioanal Chem 
398(3):1285-1293. 
Petrik V, Loosemore A, Howe FA, Bell BA, Papadopoulos MC. 2006. 
OMICS and brain tumour biomarkers. Br J Neurosurg 20(5):275-280. 
Pham-Tuan H, Kaskavelis L, Daykin CA, Janssen HG. 2003. Method 
development in high-performance liquid chromatography for high-
159 
 
throughput profiling and metabonomic studies of biofluid samples. J 
Chromatogr B Analyt Technol Biomed Life Sci 789(2):283-301. 
Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, 
Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett 
FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu 
PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-
Kenudson M, Brachtel EF, Driggers EM, Sabatini DM. 2011. 
Functional genomics reveal that the serine synthesis pathway is 
essential in breast cancer. Nature 476(7360):346-350. 
Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau 
SN, Vogelstein B, Kinzler KW. 1992. APC mutations occur early 
during colorectal tumorigenesis. Nature 359(6392):235-237. 
Price KE, Lunte CE, Larive CK. 2008. Development of tissue-targeted 
metabonomics. Part 1. Analytical considerations. J Pharm Biomed 
Anal 46(4):737-747. 
Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, 
Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, 
Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, 
Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. 
2011. The human serum metabolome. PLoS One 6(2):e16957. 
Pugh S, Thomas GA. 1994. Patients with adenomatous polyps and carcinomas 
have increased colonic mucosal prostaglandin E2. Gut 35(5):675-678. 
Qiu Y, Cai G, Su M, Chen T, Liu Y, Xu Y, Ni Y, Zhao A, Cai S, Xu LX, Jia 




Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, 
Jia W. 2009. Serum metabolite profiling of human colorectal cancer 
using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 8(10):4844-
4850. 
Qizilbash AH. 1982. Pathologic studies in colorectal cancer. A guide to the 
surgical pathology examination of colorectal specimens and review of 
features of prognostic signiﬁcance. Pathol Annu 17:1-46. 
Rao CV, Newmark HL, Reddy BS. 1998. Chemopreventive effect of squalene 
on colon cancer. Carcinogenesis 19(2):287-290. 
Reddy BS. 1986. Amount and type of dietary fat and colon cancer: animal 
model studies. Prog Clin Biol Res 222:295-309. 
Reddy BS. 1992. Dietary fat and colon cancer: animal model studies. Lipids 
27(10):807-813. 
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, 
Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston 
M, Gallinger S. 2003. Tumor microsatellite-instability status as a 
predictor of benefit from fluorouracil-based adjuvant chemotherapy for 
colon cancer. N Engl J Med 349(3):247-257. 
Ridge JA, Daly JM. 1985. Treatment of colorectal hepatic metastases. Surg 
Gynecol Obstet 161(6):597-607. 
Rigas B, Goldman IS, Levine L. 1993. Altered eicosanoid levels in human 
colon cancer. J Lab Clin Med 122(5):518-523. 
Rigas B, Levine L. 1984. Arachidonic acid metabolism by rat liver cells (the 
C-9 cell line). J Pharmacol Exp Ther 231(2):230-235. 
161 
 
Rooney OM, Troke J, Nicholson JK, Griffin JL. 2003. High-resolution 
diffusion and relaxation-edited magic angle spinning 1H NMR 
spectroscopy of intact liver tissue. Magn Reson Med 50(5):925-930. 
Rozen P, Young GP, Levin B, Spann SJ. 2006. Colorectal cancer in clinical 
practice: prevention, early detection and management. Taylor and 
Francis, London, UK. 
Ryan D, Morrison P, Marriott P. 2005. Orthogonality considerations in 
comprehensive two-dimensional gas chromatography. J Chromatogr A 
1071(1-2):47-53. 
Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. 2004. 
Phase II trial of cetuximab in patients with refractory colorectal cancer 
that expresses the epidermal growth factor receptor. J Clin Oncol 
22(7):1201-1208. 
Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, 
Kato H, Kondo M, Hla T. 1995. Expression of cyclooxygenase-1 and -
2 in human colorectal cancer. Cancer Res 55(17):3785-3789. 
Sava G, Perissin L, Zorzet S, Piccini P, Giraldi T. 1989. Antimetastatic action 
of the prostacyclin analog iloprost in the mouse. Clin Exp Metastasis 
7(6):671-678. 
Schenetti L, Mucci A, Parenti F, Cagnoli R, Righi V, Tosi MR, Tugnoli V. 
2006. HR-MAS NMR spectroscopy in the characterization of human 
tissues: Application to healthy gastric mucosa. Concepts in Magnetic 
Resonance 28A:430-443. 
Schirner M, Kraus C, Lichtner RB, Schneider MR, Hildebrand M. 1998. 
Tumor metastasis inhibition with the prostacyclin analogue cicaprost 
162 
 
depends on discontinuous plasma peak levels. Prostaglandins Leukot 
Essent Fatty Acids 58(4):311-317. 
Schirner M, Lichtner RB, Schneider MR. 1994. The stable prostacyclin 
analogue cicaprost inhibits metastasis to lungs and lymph nodes in the 
13762NF MTLN3 rat mammary carcinoma. Clin Exp Metastasis 
12(1):24-30. 
Schirner M, Schneider MR. 1991. Cicaprost inhibits metastases of animal 
tumors. Prostaglandins 42(5):451-461. 
Schirner M, Schneider MR. 1992. The prostacyclin analogue cicaprost inhibits 
metastasis of tumours of R 3327 MAT Lu prostate carcinoma and 
SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 118(7):497-
501. 
Schirner M, Schneider MR. 1997. Inhibition of metastasis by cicaprost in rats 
with established SMT2A mammary carcinoma growth. Cancer Detect 
Prev 21(1):44-50. 
Seierstad T, Roe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, 
Gribbestad IS, Bathen TF. 2008. Principal component analysis for the 
comparison of metabolic profiles from human rectal cancer biopsies 
and colorectal xenografts using high-resolution magic angle spinning 
H-1 magnetic resonance spectroscopy. Molecular Cancer 7: 33. 
Shen H, Airiau CY, Brereton RG. 2002. Resolution of LC/1H NMR data 
applied to a three-component mixture of polyaromatic hydrocarbons. 
Chemom Intell Lab Syst 62, 61-78. 
163 
 
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. 1998. Modulation 
of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon 
cancer cells. Cancer Res 58(2):362-366. 
Sheng H, Shao J, Washington MK, DuBois RN. 2001. Prostaglandin E2 
increases growth and motility of colorectal carcinoma cells. J Biol 
Chem 276(21):18075-18081. 
Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy 
O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. 2010. 
Profiling lipoxygenase metabolism in specific steps of colorectal 
tumorigenesis. Cancer Prev Res 3(7):829-838. 
Shureiqi I, Lippman SM. 2001. Lipoxygenase modulation to reverse 
carcinogenesis. Cancer Res 61(17):6307-6312. 
Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, 
Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE. 
1999. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-
lipoxygenase-1 expression in human colon cancers. Carcinogenesis 
20(10):1985-1995. 
Sinha AE, Hope JL, Prazen BJ, Nilsson EJ, Jack RM, Synovec RE. 2004. 
Algorithm for locating analytes of interest based on mass spectral 
similarity in GC x GC-TOF-MS data: analysis of metabolites in human 
infant urine. J Chromatogr A 1058(1-2):209-215. 
Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. 
2006. Comparison of HR MAS MR spectroscopic profiles of breast 
cancer tissue with clinical parameters. NMR Biomed 19(1):30-40. 
164 
 
Smalley WE, DuBois RN. 1997. Colorectal cancer and nonsteroidal anti-
inflammatory drugs. Adv Pharmacol 39:1-20. 
Smit S, van Breemen MJ, Hoefsloot HC, Smilde AK, Aerts JM, de Koster CG. 
2007. Assessing the statistical validity of proteomics based biomarkers. 
Anal Chim Acta 592(2):210-217. 
Smith WL. 1992. Prostanoid biosynthesis and mechanisms of action. Am J 
Physiol 263(2 Pt 2):F181-191. 
Soga T. 2007. Capillary electrophoresis-mass spectrometry for metabolomics. 
Methods Mol Biol 358:129-137. 
Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. 2003. 
Quantitative metabolome analysis using capillary electrophoresis mass 
spectrometry. J Proteome Res 2(5):488-494. 
Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, 
Koki AT. 2000. COX-2 is expressed in human pulmonary, colonic, and 
mammary tumors. Cancer 89(12):2637-2645. 
Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, 
Enomoto M, Sugihara K. 2006. Expression of 5-lipoxygenase in 
human colorectal cancer. World J Gastroenterol 12(39):6355-6360. 
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman 
B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-
Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur 
S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, 
Beecher C, Chinnaiyan AM. 2009. Metabolomic profiles delineate 




Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. 1987. Prognostic 
indicators of colon tumors. The Gastrointestinal Tumor Study Group 
experience. Cancer 57:1866-1870. 
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, 
Sigman CC, Kelloff GJ. 1999. Lipoxygenase inhibitors as potential 
cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 
8(5):467-483. 
Sternberg A, Sibirsky O, Cohen D, Blumenson LE, Petrelli NJ. 1999. 
Validation of a new classiﬁcation system for curatively resected 
colorectal adenocarcinoma. Cancer 86:782-792. 
Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli 
NJ, Anderson GR. 1999. The onset and extent of genomic instability in 
sporadic colorectal tumor progression. Proc Natl Acad Sci U S A 
96(26):15121-15126. 
Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, 
Zektzer AS, Kurhanewicz J. 2008. Quantification of choline- and 
ethanolamine-containing metabolites in human prostate tissues using 
1H HR-MAS total correlation spectroscopy. Magn Reson Med 
60(1):33-40. 
Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, 
Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. 
2006. Quantitative analysis of prostate metabolites using 1H HR-MAS 
spectroscopy. Magn Reson Med 55(6):1257-1264. 
Takabatake M, Hishinuma T, Suzuki N, Chiba S, Tsukamoto H, Nakamura H, 
Saga T, Tomioka Y, Kurose A, Sawai T, Mizugaki M. 2002. 
166 
 
Simultaneous quantification of prostaglandins in human synovial cell-
cultured medium using liquid chromatography/tandem mass 
spectrometry. Prostaglandins Leukot Essent Fatty Acids 67(1):51-56. 
Tang DG, Grossi IM, Chen YQ, Diglio CA, Honn KV. 1993. 12(S)-HETE 
promotes tumor-cell adhesion by increasing surface expression of 
alpha V beta 3 integrins on endothelial cells. Int J Cancer 54(1):102-
111. 
Tate AR, Foxall PJ, Holmes E, Moka D, Spraul M, Nicholson JK, Lindon JC. 
2000. Distinction between normal and renal cell carcinoma kidney 
cortical biopsy samples using pattern recognition of (1)H magic angle 
spinning (MAS) NMR spectra. NMR Biomed 13(2):64-71. 
Teahan O, Gamble S, Holmes E, Waxman J, Nicholson JK, Bevan C, Keun 
HC. 2006. Impact of analytical bias in metabonomic studies of human 
blood serum and plasma. Anal Chem 78(13):4307-4318. 
Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, Jones DJ, 
Wilson ID, Farmer PB, Steward WP, Gant TW, Gescher AJ, Keun HC. 
2008. Metabolic profiling of transgenic adenocarcinoma of mouse 
prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual 
phospholipid metabolism. Prostate 68(10):1035-1047. 
Terzic J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon 
cancer. Gastroenterology 138(6):2101-2114 e2105. 
Tey J, Baggarley S, Lee KM. 2008. Cancer care in Singapore. Biomed 
Imaging Interv J 4(3):e38. 
Tolstikov VV, Lommen A, Nakanishi K, Tanaka N, Fiehn O. 2003. 
Monolithic silica-based capillary reversed-phase liquid 
167 
 
chromatography/electrospray mass spectrometry for plant 
metabolomics. Anal Chem 75(23):6737-6740. 
Trygg J, Holmes E, Lundstedt T. 2007. Chemometrics in metabonomics. J 
Proteome Res 6(2):469-479. 
Tsikas D. 1998. Application of gas chromatography mass spectrometry and 
gas chromatography tandem mass spectrometry to assess in vivo 
synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes 
and related compounds in humans. J Chromatogr B 717:201-245. 
Tsujii M, Kawano S, DuBois RN. 1997. Cyclooxygenase-2 expression in 
human colon cancer cells increases metastatic potential. Proc Natl 
Acad Sci USA 94(7):3336-3340. 
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. 1998. 
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. 
Cell 93(5):705-716. 
Tsukamoto H, Hishinuma T, Mikkaichi T, Nakamura H, Yamazaki T, 
Tomioka Y, Mizugaki M. 2002. Simultaneous quantification of 
prostaglandins, isoprostane and thromboxane in cell-cultured medium 
using gas chromatography-mass spectrometry. J Chromatogr B 
774:205-214. 
Tugnoli V, Mucci A, Schenetti L, Righi V, Calabrese C, Fabbri A, Di Febo G, 
Tosi MR. 2006a. Ex vivo HR-MAS Magnetic Resonance Spectroscopy 
of human gastric adenocarcinomas: a comparison with healthy gastric 
mucosa. Oncol Rep 16(3):543-553. 
Tugnoli V, Schenetti L, Mucci A, Parenti F, Cagnoli R, Righi V, Trinchero A, 
Nocetti L, Toraci C, Mavilla L, Trentini G, Zunarelli E, Tosi MR. 
168 
 
2006b. Ex vivo HR-MAS MRS of human meningiomas: a comparison 
with in vivo 1H MR spectra. Int J Mol Med 18(5):859-869. 
Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M, 
Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll 
RS, Black PM. 2007. Combination of high-resolution magic angle 
spinning proton magnetic resonance spectroscopy and microscale 
genomics to type brain tumor biopsies. Int J Mol Med 20(2):199-208. 
Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, 
Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC. 
2006. Huntington disease patients and transgenic mice have similar 
pro-catabolic serum metabolite profiles. Brain 129(Pt 4):877-886. 
Urpi-Sarda M, Monagas M, Khan N, Llorach R, Lamuela-Raventos RM, 
Jauregui O, Estruch R, Izquierdo-Pulido M, Andres-Lacueva C. 2009. 
Targeted metabolic profiling of phenolics in urine and plasma after 
regular consumption of cocoa by liquid chromatography-tandem mass 
spectrometry. J Chromatogr A 1216(43):7258-7267. 
Vandernoot VA, VanRollins M. 2002. Capillary electrophoresis of 
cytochrome P-450 epoxygenase metabolites of arachidonic acid. 2. 
Resolution of stereoisomers. Anal Chem 74(22):5866-5870. 
Vigneau-Callahan KE, Shestopalov AI, Milbury PE, Matson WR, Kristal BS. 
2001. Characterization of diet-dependent metabolic serotypes: 




Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, 
Nakamura Y, White R, Smits AM, Bos JL. 1988. Genetic alterations 
during colorectal-tumor development. N Engl J Med 319(9):525-532. 
Wachtershauser A, Akoglu B, Stein J. 2001. HMG-CoA reductase inhibitor 
mevastatin enhances the growth inhibitory effect of butyrate in the 
colorectal carcinoma cell line Caco-2. Carcinogenesis 22(7):1061-
1067. 
Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S, Xu G. 2005. Plasma 
phospholipid metabolic profiling and biomarkers of type 2 diabetes 
mellitus based on high-performance liquid 
chromatography/electrospray mass spectrometry and multivariate 
statistical analysis. Anal Chem 77(13):4108-4116. 
Wang D, DuBois RN. 2008. Pro-inflammatory prostaglandins and progression 
of colorectal cancer. Cancer Lett 267(2):197-203. 
Wang D, Dubois RN. 2010. The role of COX-2 in intestinal inflammation and 
colorectal cancer. Oncogene 29(6):781-788. 
Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G. 2010. 
Urinary metabolic profiling of colorectal carcinoma based on online 
affinity solid phase extraction-high performance liquid 
chromatography and ultra performance liquid chromatography-mass 
spectrometry. Mol Biosyst 6(10):1947-1955. 
Wang Y, Bollard ME, Keun H, Antti H, Beckonert O, Ebbels TM, Lindon JC, 
Holmes E, Tang H, Nicholson JK. 2003. Spectral editing and pattern 
recognition methods applied to high-resolution magic-angle spinning 
170 
 
1H nuclear magnetic resonance spectroscopy of liver tissues. Anal 
Biochem 323(1):26-32. 
Wang Y, Cloarec O, Tang H, Lindon JC, Holmes E, Kochhar S, Nicholson JK. 
2008. Magic angle spinning NMR and 1H-31P heteronuclear statistical 
total correlation spectroscopy of intact human gut biopsies. Anal Chem 
80:1058-1066. 
Wang Y, Holmes E, Comelli EM, Fotopoulos G, Dorta G, Tang H, 
Rantalainen MJ, Lindon JC, Corthesy-Theulaz IE, Fay LB, Kochhar S, 
Nicholson JK. 2007. Topographical variation in metabolic signatures 
of human gastrointestinal biopsies revealed by high-resolution magic-
angle spinning 1H NMR spectroscopy. J Proteome Res 6:3944-3951. 
Wang Y, Tang H, Holmes E, Lindon JC, Turini ME, Sprenger N, Bergonzelli 
G, Fay LB, Kochhar S, Nicholson JK. 2005. Biochemical 
characterization of rat intestine development using high-resolution 
magic-angle-spinning 1H NMR spectroscopy and multivariate data 
analysis. J Proteome Res 4:1324-1329. 
Warburg O. 1956. On the origin of cancer cells. Science 123(3191):309-314. 
Want EJ, Coen M, Masson P, Keun HC, Pearce JT, Reily MD, Robertson DG, 
Rohde CM, Holmes E, Lindon JC, Plumb RS, Nicholson JK. 2010. 
Ultra performance liquid chromatography-mass spectrometry profiling 
of bile acid metabolites in biofluids: application to experimental 
toxicology studies. Anal Chem 82(12):5282-5289. 
Weiss L. 2000. The morphologic documentation of clinical progression, 
invasion metastasis - staging. Cancer Metast Rev 19:303-313. 
171 
 
Welthagen W, Shellie RA, Spranger J, Ristow M, Zimmermann R. 2005. 
Comprehensive two dimensional gas chromatography - time of flight 
mass spectrometry (GCxGC-TOF) for high resolution metabolomics: 
Biomarker discovery on spleen tissue extracts of obese NZO compared 
to lean C57BL/6 mice. Metabolomics 1:57-65. 
Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, van Velzen E, van 
Duijnhoven J, van Dorsten F. 2008. Assessment of PLSDA cross 
validation. Metabolomics 4, 81-89. 
Wiklund S, Nilsson D, Eriksson L, Sjostrom M, Wold S, Faber K. A 
randomization test for PLS component selection. 2007. J of 
Chemometrics 21, 427-439. 
Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. 2005. 
HPLC-MS-based methods for the study of metabonomics. J 
Chromatogr B Analyt Technol Biomed Life Sci 817(1):67-76. 
Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, 
Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia 
L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang 
L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De 
Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova 
A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I. 2009. HMDB: a 
knowledgebase for the human metabolome. Nucleic Acids Res 
37(Database issue):D603-610. 
Wold S, Ruhe A, Wold H, Dunn WJ. 1984. The collinearity problem in linear 
regression. The partial least squares approach to generalized inverses. 
SIAM J. Sci Stat Comput 5(3):735-743. 
172 
 
Wolmark N, Wieand HS, Rockette HE, Fisher B, Glass A, Lawrence W, 
Lerner H, Cruz AB, Volk H, Shibata H, et al. 1983. The prognostic 
significance of tumor location and bowel obstruction in Dukes B and C 
colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 
198(6):743-752. 
Xin H, Yi-Fei G, Ke Y, Yi-Yu C. 2006. Gas chromatography-mass 
spectrometry based on metabonomic study of carbon tetrachloride-
induced acute liver injury in mice. Chinese J Anal Chem 27:1736-
1740. 
Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, 
Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson 
K, Markowitz SD. 2004. 15-Hydroxyprostaglandin dehydrogenase, a 
COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of 
human gastrointestinal cancers. Proc Natl Acad Sci USA 
101(50):17468-17473. 
Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, Yang Q. 2004. Diagnosis of 
liver cancer using HPLC-based metabonomics avoiding false-positive 
result from hepatitis and hepatocirrhosis diseases. J Chromatogr B 
Analyt Technol Biomed Life Sci 813(1-2):59-65. 
Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, Chen X, 
Dannenberg AJ, Newman RA. 2006. Determination of endogenous 
tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived 




Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind 
LM, Robinson CR, Giardiello FM. 1998. Size-dependent increase in 
prostanoid levels in adenomas of patients with familial adenomatous 
polyposis. Cancer Res 58(8):1750-1753. 
Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, 
Subbaramaiah K, Dannenberg AJ. 2001. Inducible microsomal 
prostaglandin E synthase is overexpressed in colorectal adenomas and 
cancer. Clin Cancer Res 7(12):3971-3976. 
Yue H, Jansen SA, Strauss KI, Borenstein MR, Barbe MF, Rossi LJ, Murphy 
E. 2007. A liquid chromatography/mass spectrometric method for 
simultaneous analysis of arachidonic acid and its endogenous 
eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, 
hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat 
brain tissue. J Pharm Biomed Anal 43(3):1122-1134. 
Yue H, Strauss KI, Borenstein MR, Barbe MF, Rossi LJ, Jansen SA. 2004. 
Determination of bioactive eicosanoids in brain tissue by a sensitive 
reversed-phase liquid chromatographic method with fluorescence 
detection. J Chromatogr B Analyt Technol Biomed Life Sci 
803(2):267-277. 
Zhang GQ, Hirasaki GJ. CPMG relaxation by diﬀusion with constant 
magnetic ﬁeld gradient in a restricted geometry: numerical simulation 
and application. 2003.J Mag Resonance 163, 81-91. 
Zomer S, Guillo C, Brereton RG, Hanna-Brown M. 2004. Toxicological 
classification of urine samples using pattern recognition techniques and 
capillary electrophoresis. Anal Bioanal Chem 378(8):2008-2020. 
174 
 
Zurek G, Schneider B, Zey T, Shockcor J, Spraul M, Baessmann C. 2005. 
Hyphenated LC-NMR/MS for the characterization of complex 
metabolic profiles and biomarker discovery in biofluids. 8th 
Conference of the Israel Analytical Chemistry Society, Jan 11-12. 
i 
 
APPENDIX I: List of Publications 
 
1. Mal M, Koh PK, Cheah PY, Chan EC. 2009. Development and 
validation of a gas chromatography/mass spectrometry method for the 
metabolic profiling of human colon tissue. Rapid Commun Mass 
Spectrom 23(4):487-494. 
 
2. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, 
Nicholson JK, Keun HC. 2009. Metabolic profiling of human 
colorectal cancer using high-resolution magic angle spinning nuclear 
magnetic resonance (HR-MAS NMR) spectroscopy and gas 
chromatography mass spectrometry (GC/MS). J Proteome Res 
8(1):352-361. 
 
3. Mal M, Koh PK, Cheah PY, Chan EC. 2011. Ultra-pressure liquid 
chromatography/tandem mass spectrometry targeted profiling of 
arachidonic acid and eicosanoids in human colorectal cancer. Rapid 
Commun Mass Spectrom 25(6):755-764. 
 
4. Chan EC, Mal M, Pasikanti KK. Book chapter: Metabonomics. In: 
Handbooks of Separation Science: Gas Chromatography. Editor: CF 
Poole. (To be published by Elsevier in 2012). 
 
 
 
